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Introduction
Paracrinicity is the process of short-distance communication
between cells by way of substances released, shed or just ‘presented’
by a cell that affect a speciﬁc target on other cells in the neighbour-
hood. The substance reaches its target by diffusion in the extracellu-
lar space or by direct contact formation. Nowadays, it is recognised
that paracrine communication is essential for body plan organisation
and cell commitment during embryonic development, differentiation
and proliferation of cells during postnatal growth and many func-
tional activities of cells in the adult life of a multicellular organism.
Paracrinicity is distinct from hormonal communication that occurs
via the bloodstream and from neuronal communication that occurs
in specialised synaptic structures. It is also distinct from communi-
cation between cells via gap junctions in the plasma membrane of
neighbouring cells allowing passage of small messenger molecules
(< 1000 Da) from the cytoplasm of one cell to that of another to
co-ordinate the activity of groups of cells (1).
The present review looks into the history of how these con-
cepts were born, how they were introduced in the ﬁeld of
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Living organisms represent, in essence, dynamic interactions of high complexity between mem-
brane-separated compartments that cannot exist on their own, but reach behaviour in co-ordi-
nation. In multicellular organisms, there must be communication and co-ordination between
individual cells and cell groups to achieve appropriate behaviour of the system. Depending on
the mode of signal transportation and the target, intercellular communication is neuronal, hor-
monal, paracrine or juxtacrine. Cell signalling can also be self-targeting or autocrine. Although
the notion of paracrine and autocrine signalling was already suggested more than 100 years
ago, it is only during the last 30 years that these mechanisms have been characterised. In the
anterior pituitary, paracrine communication and autocrine loops that operate during fetal and
postnatal development in mammals and lower vertebrates have been shown in all hormonal cell
types and in folliculo-stellate cells. More than 100 compounds have been identiﬁed that have,
or may have, paracrine or autocrine actions. They include the neurotransmitters acetylcholine
and c-aminobutyric acid, peptides such as vasoactive intestinal peptide, galanin, endothelins,
calcitonin, neuromedin B and melanocortins, growth factors of the epidermal growth factor,
ﬁbroblast growth factor, nerve growth factor and transforming growth factor-b families, cyto-
kines, tissue factors such as annexin-1 and follistatin, hormones, nitric oxide, purines, retinoids
and fatty acid derivatives. In addition, connective tissue cells, endothelial cells and vascular peri-
cytes may inﬂuence paracrinicity by delivering growth factors, cytokines, heparan sulphate pro-
teoglycans and proteases. Basement membranes may inﬂuence paracrine signalling through the
binding of signalling molecules to heparan sulphate proteoglycans. Paracrine⁄autocrine actions
are highly context-dependent. They are turned on⁄off when hormonal outputs need to be
adapted to changing demands of the organism, such as during reproduction, stress, inﬂamma-
tion, starvation and circadian rhythms. Speciﬁcity and selectivity in autocrine⁄paracrine
interactions may rely on microanatomical specialisations, functional compartmentalisation in
receptor–ligand distribution and the non-equilibrium dynamics of the receptor–ligand inter-
actions in the loops.
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is in the context of the integrative functions of the pituitary
gland. From early embryonic development to old age, the micro-
environment surrounding the pituitary cells appears to consist of
an extremely complex and ever growing number of players. We
will focus mainly on the functional aspects of paracrinicity and,
at times, implicate morphological aspects underlying these func-
tions. More specialised aspects of morphogen and growth factor
actions during development will only be reviewed when relevant
for the later functions of the differentiated cells. The reader is
referred to the excellent reviews in this ﬁeld (2–6).
From Cajal and Starling to Feyrter and beyond: walls
segregating hormones, neurotransmitters and tissue factors
broken down
The hypothesis of local humoral action can already be found in the
classical paper of Bayliss and Starling, unequivocally demonstrating
that gastrointestinal secretion is not only nerve-driven, as stated by
the Pavlov doctrine, but also the result of the action of a hormone
(secretin) produced in the duodenal mucosa and released in the
blood in response to acid, stimulating exocrine secretion of the
pancreas (7). At the end of the paper, a side observation is reported
concerning the presence of a vasodilator substance different from
secretin in the experimental duodenal extracts. In the summary sec-
tion of the article, this reads as follows:
‘Acid extracts of the mucous membrane normally contain a body
which causes a fall of blood-pressure. This body is not secretin, and
the latter may be prepared free from the depressor substance by
acting on desquamated epithelial cells with acid. There is some evi-
dence of a speciﬁc localised action of the vasodilator substances
which may be extracted from various tissues’.
Around the same period, Henri Dale had discovered histamine as
a bioactive substance in mould ergot, which caused vasodilatation
(8) and, in 1920, Popielski reported that histamine stimulates exo-
crine secretion from the stomach even after section of the vagal
nerve. He suggested that the active principle with similar activity,
found earlier in tissue extracts, might be histamine (9). The identity
of this tissue factor as histamine was demonstrated in1927 by Best
(10), but whether histamine was a hormone or a locally-acting fac-
tor remained unclear and clariﬁcation of its physiological signiﬁ-
cance in gastrointestinal function came only more than half a
century later after James Black discovered histamine-2 receptor
antagonists (11) and after the cell type producing histamine, the
enterochromafﬁn-like cell, was identiﬁed in 1986 (12).
Another early suggestion for local regulation goes back to
Ramon y Cajal at the end of the 19th century, who discovered a
network of interstitial cells located between the myenteric nerve
plexus and the smooth muscle layers and within these layers in the
stomach and intestine (13). Cajal considered these cells as an inter-
face system in the neurotransmission from the myenteric nerve
perikarya to the muscle cells. Their stellate morphology and associa-
tion in a network also indicated co-ordinating functions. For almost
a century, the true nature of these cells as being neurones, Schw-
ann cells, ﬁbroblasts and macrophages has been debated. However,
they are considered as speciﬁc cell types, sharing only certain stain-
ing characteristics with neurones. They have been shown to func-
tion as pacemaker cells in slow-wave peristaltic propulsion in the
gastrointestinal tract. To this end, they use various chemical media-
tors and their activity is modulated by the innervating enteric ner-
vous system.
In 1914, Masson (14) launched the idea that the solitary cells
dispersed between the intestinal exocrine mucosa cells that fail to
take up conventional stains are the enterochromafﬁn cells
described earlier by Ciaccio. He suggested that they form a func-
tional unit of hormone-secreting cells (15). In 1938, Friedrich Feyr-
ter (16), an Austrian pathologist, described similar unstained cells
(called in german ‘helle Zellen’ ) clear cells) dispersed throughout
pancreatic ducts and growing inwardly in clusters. Feyrter proposed
that these cells form a functional unit of endocrine cells, in addi-
tion to the pancreatic islet cells (17). He included in that system
the enterochromafﬁn cells of the intestine and the enterochromaf-
ﬁn-like cells of the stomach and called them ‘diffuse endocriene
epitheliale Organe’. In 1953, he enriched the concept of the diffuse
endocrine organs by also assigning the cells a paracrine function
in his book, U ¨ber die peripheren endokrinen (parakrinen) Dru ¨sen
des Menschen (18). The merit of Feyrter has been that he consid-
ered dispersed endocrine cells as a novel type of organ, clearly dis-
tinguished from the classical concept of the body as being
composed of compact organs (16), and broadened the sense of
humoral communication over long distance by hormones to local
communication by similar humoral factors acting locally. Feyrter
also noticed the anatomical and functional relationship of the
‘helle Zellen’ with the submucosal part of the enteric nervous sys-
tem, hereby uniting endocrine and neuronal regulation. Unfortu-
nately, since the nature of the hormone-like substances that were
postulated to act locally remained unknown, and since the relation-
ship of them with secretory cells releasing true gastrointestinal
hormones had not been illustrated by direct chemical identiﬁcation,
the notion of paracrinicity remained relatively silent for many
years. A new impetus was given when Erspamer in 1952 identiﬁed
serotonin in enterochromafﬁn cells (19).
In 1968, Pearse incorporated the endocrine⁄paracrine cells of the
gut into a broader family of cells, called amine precursor uptake
and decarboxylation (APUD) cells, on the basis of the neuronal
characteristics that they displayed to manufacture monoamines by
decarboxylating the precursor amino acid (20). In addition, they
were found to produce biologically active peptides. The APUD cell
family rapidly enlarged to some 40 members, including adrenal
medulla and gut chromafﬁn cells, thyroid C cells, endocrine cells of
the anterior pituitary, gut and pancreatic endocrine cells, carotid
body chief cells, Merkel cells, melanocytes, endocrine cells of the
placenta and thymus and sympathetic ganglia cells. However, since
the role of the APUD cell monoamines has not been deﬁned for
each of the APUD cell types and some peptide-producing cells were
found that lacked the typical APUD characteristic, the cell family
was preferentially named the diffuse neuroendocrine system on the
basis of expression of both hormonal and neuronal markers (15).
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came from studies on carcinoid tumours in the gastrointestinal
tract. The latter were ﬁrst deﬁned by Siegfried Oberndorfer (21, 22)
in 1907 and proposed to be endocrine tumours by Gosset and Mas-
son in 1914 (14). The endocrine nature of carcinoid tumours was
suspected from the strong ﬁbrosis that they produce in surrounding
tissue and in remote areas, such as the heart, retroperitoneum and
lungs. Feyrter had already identiﬁed a blood pressure increasing
substance in extracts of carcinoid tumours in 1936 (23), whereas,
in 1941, Selberg found blood pressure lowering material (24). In
1953, carcinoid tumours were shown to produce serotonin and, in
1964, Halle ´n suggested that the ﬁbrosis associated with carcinoids
(25) was probably due to local serotonin (26), although conclusive
evidence still needs to be given today (27).
Growth factors in tumours, salivary glands, serum and
pituitary
Of great impetus in realising the importance of local humoral con-
trol has been the discovery of nerve growth factor (NGF) and epi-
dermal growth factor (EGF) (28). Viktor Hamburger (29) paved the
way to these discoveries by showing that peripheral tissues pro-
mote the growth of sensory and sympathetic neurones (30). In
addition, Bueker demonstrated that implantation of a mouse sar-
coma in the limb ﬁeld of the chicken embryo results in an invasion
of nerve endings from the embryo into the tumour area (31). These
ﬁndings were reinvestigated by Levi-Montalcini who observed that
the tumoural tissue stimulates the growth not only of closely posi-
tioned nerves, but also of many sympathetic and sensory neurones
in the whole embryo. An impressive accidental observation speeded
up the identiﬁcation of the tumour factor. When treating a tumour
extract with a phosphodiesterase preparation from snake venom to
remove nucleic acids, Cohen and Levi-Montalcini (32) found that
the snake venom preparation itself was contaminated by an impu-
rity with the same biological activity as the tumour factor. Further-
more, the ‘activity’ of the snake venom contained amounts several
thousand times greater than the tumour. This led to the isolation
and puriﬁcation by Cohen in 1959 (33) of what is now know as
NGF and to the determination of its structure by Angeletti and
Bradshaw in 1971 (34). A similar enrichment of NGF was found in
extracts of mouse salivary glands. Further exploration of NGF-like
material in the latter source unexpectedly led to the discovery of a
substance that induced precocious eyelid opening and tooth erup-
tion in neonatal mice (35). Cohen named the latter activity EGF
and, together with Savage and Inagami, determined its amino acid
sequence in 1972 (36). Cohen also characterised the EGF receptor
and discovered its autophosphorylating tyrosine kinase activity,
hereby opening an enormous new ﬁeld of research. Interestingly,
shortly thereafter, a factor ﬁrst identiﬁed in 1936, urogastrone,
which inhibits gastric acid secretion, was found to be similar to
EGF (37–39).
A development initially not related to the concepts of local con-
trol, but later on was found to be of enormous importance, was
the demonstration of factors in serum that are required for the
growth, migration or survival of cells in culture. Since puriﬁcation
of these serum factors proved to be very difﬁcult, some investiga-
tors tried to bypass this problem by testing pituitary hormone prep-
arations for growth-promoting activity. In 1973 Armelin and
Gospodarowicz were the ﬁrst to identify a ﬁbroblast growth factor
(FGF) in the pituitary (40). This was subsequently puriﬁed by Gos-
podarowicz (41) and identiﬁed as a 14-kDa basic protein (basic
FGF) (42). A 17-kDa acidic FGF was later isolated from the brain
and shown to be highly angiogenic in the presence of heparin (43).
This growth factor has since been recognised as one member of a
large family of locally-acting factors essential for: (i) positional
determination during embryonic development and (ii) controlling
cell growth, repair, motility and survival during adult life. It also
plays a prominent role in tumour development. Later, the pituitary
also proved to be the source of another very important growth fac-
tor, vascular endothelial growth factor (VEGF) (44).
Somatostatin and the big bang of paracrinicity
With the advent of techniques for high-speed peptide sequencing,
peptide synthesis, immunoassay and immunocytochemistry in the
late 1960s⁄early 1070s, knowledge of the chemical identiﬁcation
and tissue localisation of neuropeptides accelerated rapidly. It was
soon realised that substances originally identiﬁed as hormones or
neuromodulators also were putative paracrine factors. One of the
ﬁrst examples was somatostatin. This peptide was puriﬁed and
identiﬁed by Guillemin’s and Schally’s group (45) in 1973 as the
somatotrophin release-inhibiting factor released from the medioba-
sal hypothalamus into the portal blood vessels in the median emi-
nence. Soon after, it was also identiﬁed by immunostaining in
isolated and clustered cells of the gastrointestinal mucosa and pan-
creatic island D-cells (46). These cells showed peculiar morphological
and topographical arrangements that were suggestive of a local
control function on neighbouring cells. In the pancreatic islets,
D-cells are mainly located between the b-cells, clustered in the
middle of the islet and a-cells clustered in the periphery (47). In
the stomach, mucosal D-cells send long cellular extensions along
the nonluminal side of the mucosa (48).
From the 1980s, the research on local control reached an explo-
sive phase. Several additional modes of local communication were
discovered. In 1980, Sporn and Todaro introduced the concept of
autocrine control, an autocrine factor being a substance released by
the cell and affecting the cell of origin itself. They showed that
cells that had been transformed by an oncogene in culture no
longer required serum supplements because they themselves pro-
duced or overproduced the essential growth factors. The ﬁrst
growth factors identiﬁed on this basis were transforming growth
factor (TGF)-a and TGF-b. This discovery opened an immense ﬁeld
of investigations on the role of autocrine growth factors in tumo-
urigenesis and tumour progression. Several of these growth factors
have been shown to be effective physiologically in the positional
determination of cell fate, in expanding progenitor cell populations
during embryonic development and in preserving cell diffentiation
and survival in adult life (2–6). Many of these autocrine growth
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genesis of tumours (49).
Concepts of local control were also born in the ﬁeld of
Immunology. This year marks the 50th anniversary of the discov-
eries of interferon (IFN) (50). The subsequent ﬁnding that the
supernatants of cultured lymphocytes contain soluble factors
which enhance antibody production, led to the discovery of
several factors affecting B cell growth and differentiation, called
now interleukins (IL) (51). The ﬁrst interleukin being cloned was
IL-2 (52). IL-6, cloned 3 years later (53), was the ﬁrst interleukin
for which biological effects outside the immune system were
described (51). These pleiotrophic factors were also shown to be
local regulators of tissue cell turnover, the inﬂammatory response
and tissue repair (54–56). Cytokines were also identiﬁed in
speciﬁc cells in endocrine glands (57, 58) and neural tissue (59),
as well as in hormone (57) target cells, and shown to modulate
hormone or neurotransmitter action and help maintain tissue
homeostasis and plasticity (60). Through the latter research the
notion of a diffuse neuro-immuno-endocrine network in the
body was born (59).
In parallel with these studies, a vast number of neuropeptides
were discovered within the central and peripheral nervous systems
and in the solitary cells in the diffuse neuroendocrine system (61).
One of the ﬁrst to be identiﬁed was Substance P in 1931 (62, 63).
Substance P was described as a substance present in brain and gut
that stimulated smooth muscle contraction in a way not blockable
by atropine and which also lowered blood pressure. The peptide
was sequenced by Susan Leeman in 1970. An enormous repertoire
of neuropeptides which also act in non-neuronal tissues have since
been discovered (64).
On the other hand, classical neurotransmitters, such as acetyl-
choline and noradrenaline, which were initially thought to be
neurone-speciﬁc, were also discovered in discrete cells in several
peripheral tissues (65–71). Serotonin, ﬁrst identiﬁed in entero-
chromafﬁn cells, was later also found in many other tissues
(72–75). In addition, purines (76), fatty acids and fatty acid
derivatives (77), and nitric oxide (NO) (78) are synthesised and
released locally to affect neighbouring cells. Importantly, the
classical endocrine organs (ductless glands), pituitary, gonads,
ovaries, the adrenal cortex and the thyroid gland, all contain
cells which, in addition to hormones, produce certain of these
messenger molecules which affect diverse functions within the
gland. Today, more than 100 different bioactive substances have
been identiﬁed in the anterior pituitary gland (Table 1) and most
have been localised in speciﬁc cell types (Table 2). Considerable
evidence suggests that these messengers effectively exert a local
function during particular physiological changes. Thus, treatment
with substances either blocking synthesis or release, or the
action of these factors, results in obliteration of the changed
functional response.
Another mode of local humoral control of cells is by so-called
juxtacrine factors. This mode of control was discovered by Massag-
ue ´ who observed that the TGF-a precursor can be expressed as a
plasma membrane-anchored polypeptide on the surface of cells and
bind to EGF receptors on adjacent cells, in this way inducing both
Table 1. Signalling molecules identiﬁed in the adenohypohysis.
Signalling molecules
Neurotransmitters
Acetylcholine
GABA
Purines
ATP, ADP
Arginine derivatives
Nitric oxide
Agmatine
Fatty acid derivatives
Prostanoids
Anandamide
2-arachidonoylglycerol
Retinoic acid
Neuropeptides
Vasoactive intestinal peptide
Galanin
Gastrin-releasing peptide
Neuromedin B
a-melanocyte-stimulating hormone
c-melanocyte-stimulating hormone
b-endorphin
N-pro-opiomelanocortin
Enkephalins
Dynorphin
Nueropeptide Y
Substance P
Neurokinin B
Neuromedin U
Neurotensin
Vasopressin
Oxytocin
Delta-sleep-inducing peptide
Vascular growth factor peptides
Calcitonin
Calcitonin-R-stimulating peptide
Calcitonin gene-related peptide
Intermedin
Adrenomedullin, proadrenomedullin N-terminal 20 peptide
Atrial natriuretic peptide
B-type natriuretic peptide
C-type natriuretic peptide
Angiotensin II
Gastrin
Endothelins
Thyroid-releasing hormone
Gonadotrophin-releasing hormone
Growth hormone-releasing hormone
Somatostatin
Corticotrophin-releasing hormone
Urocortin
Urocortin II
Prolactin-releasing peptide
Ghrelin
Cocaine and amphetamine-regulated transcript
Orexin A
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ples of juxtacrine communication have been observed with media-
tors including several members of the EGF family, tumour necrosis
factor (TNF)-a, colony-stimulating factor, platelet-activating factor
and annexin-1. Juxtacrine communication provides a mechanism of
strict spatial control of activation of one cell type by another, in
contrast with paracrine control where the factor acts in the ﬂuid
phase within an action radius determined by its diffusion gradient.
The active domain of a juxtacrine polypeptide can be cleaved from
the cell surface by regulated proteolysis which will, if needed, abol-
ish spatial speciﬁcity and which, in turn, will optimise diversity of
communication but, by spreading, the signal could also be the start
of disregulation.
Finally, some regulatory factors do not need ﬁrst to be released by
the cell and then activate a plasma membrane receptor, but they can
also be active inside the cell of production after moving to another
compartment and binding and activating receptors inside the cell. The
latter mode of local control is called intracrine action (80).
Early suggestions for local control in the anterior
pituitary gland
Until 1970, the anterior pituitary gland did not attract attention
in terms of local control systems. It was considered as a classical
endocrine organ in which each hormone was produced by a spe-
ciﬁc cell type (one hormone–one cell type theory) with no obvious
anatomical subdivision according to cell types except, in most
mammalian species, for the intermediate lobe. Histochemical stain-
ing procedures were used to distinguish the different cell types
(81). However, a proportion of the cells were considered hor-
mone-free as they failed to be stained by these histochemical
procedures and were named ‘chromophobes’. A peculiar group of
cells that did not contain secretory granules was discovered by
electron-microscopic examination by Rinehart and Farquhar in
1953 and called follicular cells (subsequently folliculo-stellate cells)
(FS cells) (82). These were the ﬁrst cells for which a local function
was suspected, although the proposals for such function remained
little deﬁned. As FS cells engage in phagocytosis of hormonal
cells, they were thought to have a local house-keeping role in
removing dying cells and waste products. Moreover, FS cells show
a stellate shape with long cytoplasmic extensions between the
granulated hormonal cells and often associate among each other
to form tiny follicles ﬁlled with ﬂuid or colloid material. On these
grounds, the cells were thought to have some role in local trans-
port of material.
The path to experimental evidence for local control of and by
the hormonal cells was found by two other endeavors. One was
morphological, the other functional. The classical one cell type-
one hormone theory stated that each pituitary hormone was
produced by a speciﬁc cell type but the theory was based on
histochemical procedures used to discriminate one cell type from
another. Final proof could only be given when the hormone
itself was identiﬁed in the cell. In 1970, Nakane (83) was the
ﬁrst to report that, indeed, growth hormone (GH), prolactin
(PRL), adrenocorticotrophic hormone (ACTH) and thyroid-stimulat-
ing hormone (TSH) were stored in separate cell types but that
many gonadotrophs showed immunoreactivity for both luteinising
hormone (LH) and follicle-stimulating hormone (FSH). Another
important morphological feature observed by Nakane (83) was
that, although at ﬁrst glance the different pituitary cell types
were intermingled, they did not appear distributed homoge-
neously over different areas of the gland and within a particular
cell cord. Nakane also observed close associations between
somatotrophs and corticotrophs and between gonadotrophs and
lactotrophs. Some of the PRL cells embraced the oval-shaped
gonadotrophs with long cellular processes and were therefore
named ‘cup-shaped’ PRL cells (83). Nakane suggested that the
gonadotroph–lactotroph association might have functional conse-
quences, although he only proposed that the cup exerted some
kind of hindrance for secreted material to diffuse to the blood
vessels.
A second path that led to exploring local control systems
stemmed from efforts made to purify the cell types of the pitui-
tary. The ﬁrst success of enrichment of somatotrophs and lacto-
Table 1. Continued.
Signalling molecules
Orexin B
Neuropeptide B
Neuropeptide W
Apelin
26Rfa
Hormones and derivatives
Growth hormone
Prolactin
Cleaved prolactin
Glycoprotein hormone a-subunit
Growth factors
Fibroblast growth factor (FGF)-2, FGF-4, FGF-8
Epidermal growth factor, transforming growth factor-a, neuregulins,
Insulin growth factor (IGF)-I, IGFII
Nerve growth factor, glial cell line-derived neurotrophic factor
Transforming growth factor (TGF)-b1, TGF-b3, Activins, Inhibin,
Bone morphogenetic protein (BMP)-2, BMP-4
Pancreatitis-associated protein
Dll1, Dll3, Dlk1
Cytokines
Interleukin (IL)-1, IL-2, IL-6, IL-10, IL-11, IL-12
Leukaemia-inhibitory factor, interferon-c, tumour necrosis factor-a, vascu-
lar endothelial growth factor,
Angiopoietins
Migration inhibitory protein, ciliary neurotropic factor, oncostatin M,
Leptin
Tissue factors
Insluin frowth factor-binding proteins
Follistatin, Noggin,
Interleukin-1 antagonist
Annexin 1
Adiponectin
Adiponutrin
Resistin
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mentation of dispersed rat pituitary cells at unit gravity through
a serum albumin gradient (84, 85). Large cells sediment faster
than smaller cells and, as not all pituitary cell types are of the
same average size, they enrich according to type. When the dis-
persed cells in the enriched populations were established in
Table 2. Cellular Distribution of Signalling Molecules in the Anterior Pituitary.
Signalling molecule
Cell types (L, lactotrophs; S, somatotrophs; G, gonadotrophs; T, thyrotrophs; C, corti-
cotrophs; FS, folliculo-stellate cells)
LSGTCF S
Acetylcholine n
GABA n
Nitric oxide nn
Vasoactive intestinal peptide n
Pituitary adenylate cyclase-activating peptide n
Galanin nn nn
Gastrin-releasing peptide nn n
Neuromedin B n
Neuromedin U n
Corticotrophin-releasing hormone n
Urocortin nn n
Urocortin II n
Neuropeptide Y nnnnn
Atrial natriuretic peptide nnn
C-type natriuretic peptide nn
Neurotensin nn
Dynorphin n
Enkephalins nnnn
Pro-opiomelanocortin nnn
Angiotensin(ogen) n
Calcitonin n
Calcitonin gene-related peptide n
Adrenomedullin, proadrenomedullin N-terminal 20 peptide n
Intermedin n
Substance P nn
Endothelin-1 nn
Endothelin-3 nn
Vasopressin n
Oxytocin n
Ghrelin nn n
Cocaine and amphetamine-regulated transcript nnn
Orexin A n
Orexin B n
ﬁbroblast growth factor-2 nn
Transforming growth factor-a nn
Transforming growth factor-b1 n n
Transforming growth factor-b3 n
Activin n
Inhibin n
Leukaemia-inhibitory factor n
Migration inhibitory protein n
Interleukin-1 n
Interleukin-6 n
Vascular endothelial growth factor nnnnnn
Angiopoietins n
Leptin nnnnn
Follistatin nn
Annexin-1 n
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became evident that their responses were functionally different
(86). In 1976, we succeeded in highly enriching gonadotrophs by
the latter technique (87). The success was owed to the choice of
the animal model: instead of adult, 14-day-old female rat pitui-
taries were used, from the knowledge that female rat pituitary
at that age contains more gonadotrophs and secretes more FSH
than at any other time in life (88–90), and that, due to this
high functional activity, gonadotrophs were expected to be
hypertrophic or at least advanced in development compared to
other cell types and would therefore sediment faster and, in this
way, separate from other cell types. Indeed, the fastest-sediment-
ing cells were large gonadotrophs and they were enriched to a
purity of approximately 75%. Most of these gonadotrophs con-
tained FSH and LH. When we challenged these gonadotrophs
with gonadotrophin-releasing hormone (GnRH) in culture, they
released unexpectedly high amounts of FSH compared to adult
animals (87). Another unexpected observation we made was that
the magnitude of the FSH response to GnRH was different
between these gonadotrophs and smaller gonadotrophs isolated
in other fractions from the sedimentation gradient (91, 92). Also
the FSH : LH ratio showed marked differences among fractions
and these differences also were sex-dependent, males showing
more heterogeneity than females (91, 92). These ﬁndings clearly
suggested functional heterogeneity among the gonadotrophs,
which raised the next question: what is the mechanism of func-
tional heterogeneity? Do these differences represent differences
between true gonadotroph subtypes or differences in hormone
synthesis⁄secretion caused by alterations of the microenviron-
ment due to sorting out certain cell types. We tested the latter
hypothesis by comparing separated with recombined cell popula-
tions and found that recombination of the puriﬁed gonadotroph
population with the gonadotroph-poor population again altered
the FSH : LH ratio in the response to GnRH (93). These data
suggested that signals from nongonadotroph cells contribute
directly or indirectly to the mechanism of differential control of
FSH and LH secretion. This observation was of particular impor-
tance since, up to now, all GnRHs stimulate both LH and FSH
release, implying that a local mechanism in the pituitary must
exist that is capable of controlling FSH independently of LH
secretion. The cell separation and recombination experiments sug-
gested to us that such a local mechanism might rely on inter-
cellular communication with other pituitary cell types. Some
years later, we showed that this gonadotroph-poor population
consists mainly of PRL cells, some GH cell and nonhormonal
cells, most of which are FS cells (94) and, as will be discussed
below, all these cell types appear to be involved in cross-talk
with gonadotrophs. FS cells are an important source of follistatin
and follistatin attenuates the action of activin on FSHb synthesis
and secretion in a paracrine manner (95).
The next natural question was: do gonadotrophs also affect
the function of PRL, GH and FS cells? Indeed, they appear to do
so. When puriﬁed gonadotrophs were mixed with the PRL cell
population, we found that GnRH unexpectedly evoked PRL
release.
Gonadotrophs signal to lactotrophs, somatotrophs and
corticotrophs
Gonadotrophs acutely affect PRL and GH secretion in early
postnatal rat pituitary
In the 14-day-old rat model, we examined PRL secretion in the
PRL cell population from which gonadotrophs had been removed
by unit gravity sedimentation. GnRH had no effect on PRL
release, as expected. However, when the 75% pure gonadotroph
population was mixed with the PRL cell population in a 1 : 3
ratio and established in monolayer culture, at high cell density
in order to optimise cell–cell contact, GnRH did evoke PRL
release. These data were not published at that time as we had
started to culture cells as three-dimensional aggregates, which
were felt to be superior in terms of their tissue-like organisation
(96). We were very lucky that this culture system was brought
to our attention by Dr J. J. Cassiman, a colleague in our insti-
tute, who used it for studying cell adhesion mechanisms of
ﬁbroblasts. He and his PhD student, B. Vanderschueren, found
that ﬁbroblasts do not proliferate in an aggregate conﬁguration
and even are auto-digestive (97). Since pituitary cell monolayer
cultures are usually over-grown with nonhormonal cells, which
at that time were considered as ﬁbroblasts, particularly when
plated at low density and when culture medium was supple-
mented with serum, we felt the aggregate system was physio-
logically more reliable than the monolayer cultures. Moreover,
aggregates can easily be used in a perifusion system, allowing
the examination of rapid secretory responses as a function of
time. In perifused aggregates, both the magnitude of secretory
responses and the sensitivity to secretagogues were considerably
greater than those of static incubations of monolayer cultures
(98). With this technology and the background information from
our previous studies on 14-day-old rat gonadotrophs, we clearly
demonstrated the ﬁrst evidence for communication between
gonadotrophs and lactotrophs (99). When perifused pituitary cell
aggregates from 14-day-old female rats were exposed to a GnRH
pulse, an acute and dose-dependent stimulation of PRL release
was seen from doses as low as 10 pM. The PRL response
occurred in dopamine-free condition and also during coperifusion
with 10 nM dopamine that on its own suppressed basal PRL
secretion to more than 85%. No such response was seen in the
gonadotroph-poor PRL cell-enriched aggregates. However, when a
small percentage of a population consisting of 75% gonado-
trophs was coaggregated with the lactotroph preparation, GnRH
elicited a clear-cut acute stimulation of PRL release, the magni-
tude of which increased with the proportional number of
gonadotrophs added to the lactotrophs. Thus, the GnRH effect
on PRL release appeared to be mediated by gonadotrophs or
required the presence of these cells in the vicinity of the lacto-
trophs. Also, aggregates from 14-day-old male rats showed this
response. In aggregates from adult rats, however, no PRL
response to GnRH could be elicited, at least not at day 4 in cul-
ture. When gonadotrophs from the 14-day-old rat were coaggre-
gated with an enriched PRL cell population of adult males,
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nal is produced only by immature gonadotrophs, but that lacto-
trophs remain responsive to it up to adult age. A curious
phenomenon was that, when aggregates from adult rats were
maintained for 3 weeks in culture, they acquired some PRL
responsiveness to GnRH (99). In the coaggregates, thyroid-releas-
ing hormone (TRH) stimulated PRL release, as expected, but did
not affect LH or FSH release, indicating that the gonadotroph-
lactotroph communication is not a random bidirectional commu-
nication. We also obtained evidence that the signal from
gonadotrophs is a secreted molecule. A large number of puriﬁed
gonadotrophs was incubated for 3 h in the absence and pres-
ence of GnRH and, subsequently, the spent media was perifused
over the lactotroph population; we found that the spent medium
obtained without GnRH stimulated PRL release, but that the
spent medium, obtained in the presence of GnRH, and perifused
together with an excess GnRH antagonist, induced a considerably
higher PRL release.
We also looked at GH secretion in these 14-day-old rat aggre-
gates and found an impressive GH response to GnRH as well.
However, the secretory response was dual (100). During the
GnRH pulse, GH release was rapidly inhibited, whereas, after
stopping the application, a rapid rebound secretion of GH was
observed that only slowly returned to initial basal release values.
The total amount of GH released after the exposure to GnRH
was considerably higher than that inhibited during GnRH
exposure, suggesting that GnRH had both inhibitory and
stimulatory actions on GH release. The latter conclusion was
conﬁrmed by the ﬁnding that pertussis toxin pretreatment turned
the initial GnRH-induced inhibition of GH secretion into a stimu-
lation.
The paracrine cross-talk with lactotrophs and somatotrophs
was also conﬁrmed by coaggregation of a lactotrophs⁄somato-
troph population from 14-day-old rats with cells of the gonado-
trophic cell line aT3-1 (101). It was found that GnRH induced a
stimulation of PRL release and a dual effect on GH
release, although the magnitude of the response was smaller
than in normal pituitary. Furthermore, medium conditioned by
aT3-1 cells contained PRL secretory and GH-inhibitory sub-
stance(s) (101).
We found out that, in vivo, the gonadotroph–lactotroph and
gonadotroph–somatotroph secretory cross talk may be a process
typical for the early postnatal period (102). No PRL or GH secre-
tory response to GnRH was seen in freshly isolated intact pitui-
taries from day 1 (P1) rats; some response was seen on P3, rose
in magnitude on P5 and decreased thereafter to be almost absent
at the age of 14 days. As to GH secretion, some stimulation was
seen at P1, followed by a rebound upon withdrawal of GnRH;
both stimulation and rebound augmented in magnitude until P5
and became low again at P14. Apparently, establishing the 14-
day-old rat pituitary cells in culture rejuvenates the cells to an
earlier developmental phenotype. The signiﬁcance of this observa-
tion remains unknown, but the ﬁndings inspired us to also inves-
tigate developmental actions of GnRH on lactotrophs and
somatotrophs.
Gonadotrophs manage lactotroph and somatotroph
development
Independently, Be ´geot et al. (103) reported that GnRH stimulates
the development of lactotrophs in rat Rathke’s pouch explants.
Since the latter effect could be mimicked by treatment with the
free glycoprotein hormone a-subunit (aGSU) and blocked by an
LH antiserum cross-reactive with aGSU, the authors proposed
that, during fetal development, GnRH exerts a paracrine
action within the pituitary anlagen. GnRH is present in the rat
embryonic pituitary as soon as embryonic day (E) 14 (104)
and in amniotic ﬂuid as soon as E12 (105) and the GnRH
receptor is present in Rathke’s pouch as early as E12 as well
(104).
We have shown that GnRH mRNA is expressed in Rathke’s
pouch explants (106). Furthermore, treatment of Rathke’s pouch
explants with a GnRH antagonist depressed the development of
lactotrophs, consistent with a paracrine action of GnRH in the
explants. Importantly, the endogenous GnRH appeared only active
(or present) provided some adjacent mesenchym was retained
within the explant (106), suggesting a much broader paracrine
system is operating during lactotroph development. Although
GnRH is not essential for the development of gonadotrophs and
lactotrophs, since these cells still develop in the hypogonadal
mouse (that lacks GnRH) (107), it may have a trophic action at
E11–E12, which is long before the terminal differentiation of
these cells at E17–E18 (108, 109). The mechanism of that early
action, however, remains unknown, but other factors seem to
compensate the absence of GnRH, indicating the robustness of
the lactotroph developmental track.
A gonadotroph-lactotroph axis is also supported by in vivo
experiments in a transgenic mouse model (110, 111). By targeting
the diphtheria toxin A gene selectively to the gonadotrophs with
the bovine aGSU promoter fragment, the great majority of
gonadotrophs is destroyed as examined in newborn mice (P1–3),
at a time that oestrogens are not produced or are not active yet.
The number and size of PRL cells and the size of the clusters
they make, as well as PRL mRNA level, were signiﬁcantly reduced
in the DTA mouse pituitary compared to the wild-type mice, with
no alterations seen in thyrotrophs and ACTH cells. However, there
was no change seen in the number and size of GH cells or GH
mRNA level. Other studies also revealed no changes in somato-
troph number in adult transgenic mice with targeted ablation of
gonadotrophs, nor did they ﬁnd a change in late fetal life (112,
113). It is possible that the inhibitory action of gonadotrophs on
GH cell proliferation is compensated by other factors or is not
operational at P1–3 or that inhibition of somatotrophs is down-
stream of the stimulatory effect on lactotrophs. In that case,
there would be barely an effect seen when lactotrophs are
depressed.
A trophic action of GnRH on PRL production has also been
noticed in the sheep fetal pituitary (114). Consistent with the
trophic action of gonadotrophs on lactotrophs is that, in the
hypogonadal gonadectomised mouse, treatment with GnRH slightly
increases PRL synthesis even in adult life (115).
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As far as tested in the 14-day-old rat pituitary aggregate cell
culture system, treatment with GnRH for 40 h was found to
enhance cell cycle entrance of lactotrophs and to lower that of
somatotrophs (116). GnRH also inhibited the mitogenic effect of
GH-releasing hormone (GHRH) on somatotrophs (117). GnRH also
increased the total number of cells containing PRL mRNA within
40 h (118), suggesting that new lactotrophs are recruited by differ-
entiation of a progenitor cell type into PRL-expressing cells, rather
than to a mitogenic action on pre-existing lactotrophs alone.
Conversely, the total number of cells expressing GH mRNA was
signiﬁcantly reduced by GnRH (117). Also, prolonged treatment of
aggregates with GnRH was found to expand the population of cells
expressing PRL mRNA as well as of cells expressing aGSU mRNA
(119).
By means of cell separation and recombination experiments, we
again showed that the developmental actions of GnRH depend on
the presence of gonadotrophs (116). Mediation by paracrine fac-
tor(s) was indicated by the ﬁnding that medium conditioned by a
highly enriched population of gonadotrophs cultured in the pres-
ence of GnRH, mimicked the effects of GnRH (120, 121). Also, med-
ium conditioned by the gonadotroph precursor cell line aT3-1
contained material stimulating development of lactotrophs and
inhibiting development of somatotrophs (101). Four substances with
a selective mitogenic effect on lactotrophs were partially puriﬁed
by high-performance liquid chromatography fractionation, whereas
two other substances were isolated with antisomatotroph action
(120, 121). These data clearly indicated that separate factors deter-
mine reciprocal development of lactotrophs and somatotrophs.
Gonadotroph–lactotroph axis in adult life, a context-
dependent system?
It has repeatedly been shown that peripheral injection of GnRH
increases plasma PRL concentrations in adult rats (122–124), mice,
hamsters (125), monkeys (126) and humans (127–133). Endogenous
GnRH seems to exert a similar effect since treatment of castrated
female monkeys with a GnRH antagonist causes PRL plasma con-
centrations to drop (126, 134) and hyperprolactinemia induced by
oestrogen⁄progesterone treatment is attenuated by administration
of a GnRH antagonist (135). Also in female rats, blockade of endog-
enous GnRH by injection of anti-GnRH antiserum causes hypoprol-
actinemia (136). The ﬁnding of a PRL response to GnRH is,
however, not always consistent and may depend on hormonal sta-
tus, sex, circadian rhythms and other physiological and pathological
conditions. Some investigators found GnRH to increase plasma PRL
concentrations in normal women during the follicular (127) and
luteal phase (133) of the cycle and in postmenopausal women
(131), whereas others found that the response was signiﬁcantly
greater in the luteal phase and in progesterone-treated menopausal
women compared to women in early follicular phase (132). During
the luteal phase, LH and PRL pulses are synchronous (133). Other
studies only found a PRL response to GnRH in women during the
periovulatory period and not during the late follicular or the mid-
luteal phase (128–130). Pretreatment with testosterone 6 h prior to
GnRH administration allowed such a response to occur in the follic-
ular phase (137). A clear-cut rise in plasma PRL level was also seen
in girls (average age 10 years) with Klinefelter syndrome (primary
gonadal failure) (138). In the latter study, oestrogen treatment was
found to decrease the PRL response to GnRH. Interestingly, the lat-
ter study is probably better comparable to the PRL response we
have observed in immature rat pituitary since we found that addi-
tion of a low physiological dose of oestradiol (30 pM) in the culture
medium facilitated the PRL response to GnRH but that a high dose
attenuated it (Denef et al., unpublished observations). In men, a
PRL response to GnRH was only seen after oestrogen treatment
(139, 140). In untreated men, the PRL response to TRH was larger
after prolonged GnRH pretreatment (141).
PRL responses are not always observed in normal people but can
be seen under certain pathological conditions, such as anorexia
nervosa and bulimia (142, 143), in hypergonadotrophic hypogonadal
women (144, 145) and women with functional hypothalamic amen-
orrhea (145), in polycystic ovary syndrome (146) and in women
treated with benzodiazepines (147). In human pituitary cell cultures,
GnRH stimulated PRL secretion in an oestrogen-free environment
and was inhibited by pretreating the cells with oestradiol (148).
It should be noticed that all these data only show that there is a
PRL response to GnRH in vivo but it cannot be distinguished where
these effects are established by a paracrine mode of action or by
an indirect action at the median eminence or by a direct action at
the level of the lactotrophs. Paracrine and direct actions of GnRH
on lactotrophs are not mutually exclusive. It is known that GnRH is
taken up in gonadotrophs, as expected, but also in lactotrophs,
most likely by receptor-mediated endocytosis (149). Furthermore, it
should be noticed that GnRH has been reported to stimulate PRL
release from a clonal cell line derived from embryonic pituitary cells
(150). Also in teleost ﬁsh, GnRH stimulates PRL release in culture
and this must be a direct effect on PRL cells since the rostral pars
distalis is a nearly homogeneous population of PRL cells without
gonadotrophs (151).
Whatever the mechanism, it seems that the effect of GnRH on
PRL release in vivo is complex due to the fact that it may be part
of a communication network of which some components can com-
pensate for each other and the behaviour of that system seems
context-dependent. It may also be difﬁcult to disrupt by interfer-
ence with exogenous GnRH. Moreover, PRL responses to GnRH dur-
ing fetal and immature life could be based on different
mechanisms than that observed in adult life or in certain pathologi-
cal states. Consistent with this line of thinking are the observations
that a PRL response to GnRH is not elicited immediately following
a bolus injection, but does occur after some time during an infu-
sion (140). Injection of a single dose of anti-GnRH antiserum into
female rats is followed immediately by blockade of LH and ovula-
tion but the pre-ovulatory PRL peak is normal, but only after
several days hypoprolactinemia is seen (136). Another important
parameter that might explain some controversies in ﬁndings may
be the interaction between the hormonal status and the day–night
cycle, since GnRH failed to elicit a PRL response in women in the
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so when given at night and even more so when given during sleep
(152).
Several investigators have shown experimentally that gonado-
trophs are important for a normal activity of lactotrophs during
adult life, and the data conﬁrm that the system may be context-
dependent. Infusion with a high dose of a GnRH agonist is known
to down-regulate gonadotroph secretion. Torres-Aleman et al.
(153) showed that, during the ﬁrst 30 min of such an infusion,
LH release rises but that plasma levels return to normal level
within the next 2 h and that, during this time, interval PRL
plasma levels also decrease signiﬁcantly. When pituitary tissue
was tested in vitro at that time point, they also released signiﬁ-
cantly less PRL than the controls. Furthermore, long-term in vivo
treatment with a GnRH agonist was also shown to reduce basal
PRL secretion strongly when examined in vitro, but this was only
observed in female rats and not in males (154). Agonist treatment
also blocked the increase in serum PRL concentration induced by
the dopamine receptor antagonist haloperidol as well as hyperp-
rolactinemia obtained by transplantation of the pituitary under
the kidney capsule (155). In perifused pituitary cells, basal LH and
PRL release is pulsatile and administration of a GnRH agonist at
more than two pulses per hour was reported to cause desensitisa-
tion of the LH response simultaneously with a disappearance of
pulsatile PRL release (156).
Identiﬁcation of paracrine factors involved in lactotroph
development
aGSU
The ﬁrst candidate paracrine factor from gonadotrophs proposed
to be involved in the development of lactotrophs was aGSU. In
fetal rat pituitary explants, Be ´geot showed that the stimulation of
lactotroph development by GnRH could be mimicked by addition
of aGSU to the explants and blocked by an LH antiserum cross-
reactive with aGSU (103). We found large amounts of aGSU in
conditioned medium from gonadotrophs and a semipuriﬁed frac-
tion containing aGSU immunoreactivity stimulated PRL mRNA
expression and lactotrophs mitogenesis, clearly suggesting that
aGSU may be implicated in a paracrine gonadotroph network.
Chronic (8 days) treatment with aGSU also stimulates PRL produc-
tion in ovine fetal pituitary explants taken at gestational day 50
(114), only the acidic variant of the natural (free) aGSU and not
the aGSU dissociated from LH showing this activity (157). These
data are of substantial interest because, until now, a speciﬁc
receptor for aGSU has not been identiﬁed. A stimulatory action of
aGSU on PRL secretion has also been reported in frogs (158)
where aGSU is coexpressed with PRL in and released from some
lactotrophs (158, 159).
It should be realised, however, that aGSU may also be derived
from other cell types. Recently, we showed that prolonged treat-
ment of aggregates from 14-day-old rat pituitary with GnRH
expands the population of cells expressing PRL mRNA as well as of
cells expressing aGSU mRNA, but that a population of cells devel-
oped (approximately 20%) that expresses both PRL and aGSU
mRNA (119).
N-pro-opiomelanocortin (POMC)
We have identiﬁed one of the trophic factors in gonadotroph-con-
ditioned medium mediating lactotroph recruitment and PRL mRNA
expression. This factor was puriﬁed from that medium and found
to be the glycosylated N-terminal fragment of POMC, POMC1-74
(N-POMC) (120, 121). We also showed that N-glycosylation is
essential for bioactivity and that certain glycosylated isoforms stim-
ulate PRL mRNA level whereas others have a mitogenic action in
lactotrophs (160). That a subpopulation of gonadotrophs is capable
of synthesising N-POMC was shown at the mRNA level by means
of single cell reverse transcription-polymerase chain reaction (RT-
PCR) (161, 162), and some cells also show immunoreactive N-POMC
and aGSU colocalisation (161). Nonglycosylated N-POMC, prepared
by recombinant synthesis, keeps a speciﬁc mitogenic action on lac-
totrophs (and no other cell types) but its efﬁcacy is weaker and,
importantly, the effect is mediated via the c3-melanocyte-stimulat-
ing hormone (MSH) moiety in its C-terminal domain by the mela-
nocortin-3 receptor, whereas glycosylated N-POMC has no action
through the melanocortin-3 receptor (163). Moreover, c3-MSH is
mitogenic for somatotrophs and thyrotrophs, in addition to lacto-
trophs (164). These data suggest that paracrinicity can be tuned to
highly speciﬁc targets by differential post-translational modiﬁca-
tions of the paracrine pro-peptide.
We also presented evidence that endogenous N-POMC is toni-
cally involved in lactotroph mitotic activity and PRL gene expres-
sion, as treatment of pituitary aggregates with polyclonal or
monoclonal antibodies raised against N-POMC signiﬁcantly
decreased the lactotroph mitotic rate (164). Other investigators also
found N-POMC increases PRL and GH mRNA expression and stimu-
lates PRL and GH secretion (after 12 h of treatment) in frog pitui-
tary cell cultures (165). A crucial experiment still lacking is to
determine whether N-POMC is a mediator of the action of GnRH
on lactotrophs by investigating whether the GnRH effect can be
blocked by treatment with an anti-N-POMC antiserum. In this
respect, it should be realised that gonadotrophs may not necessarily
use GnRH as their physiological agonist and that different agonists
may elicit different paracrine contacts with lactotrophs. For exam-
ple, neuropeptide Y (NPY) can mimic the action of GnRH on lacto-
troph mitosis in pituitary cell aggregates (116) but it inhibits the
stimulation of PRL mRNA by GnRH (118).
The paracrine action of N-POMC in the pituitary has not yet
been studied in vivo. However, some indirect data are available
from mice in which the POMC gene was disrupted. These mice
develop a profound phenotype, characterised by obesity, extreme
adrenal hypoplasia (166), a more active hypothalamic-pituitary-thy-
roid (HPT) axis (167) and development of nonfunctional adenomas
in the pituitary intermediate lobe (168). As to the status of the lac-
totrophs axis in these animals, no data are available yet. However,
it has been reported that selective transgenic ablation of cortico-
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arcuate nucleus remain intact) does not result in a manifest change
in the proportions of lactotrophs, somatotrophs and thyrotrophs
(169), suggesting that paracrine actions of N-POMC are not essen-
tial and that other factors can compensate for its loss. However,
the absence of a change in pituitary cell type distribution in the
latter transgenic mice may also be explained by the fact that not
all POMC cells are destroyed in these transgenic mice (170), and
that the promoter fragment used to drive speciﬁc expression of the
toxigene in classical POMC cells may not be the same as that used
for activation of POMC expression in gonadotrophs, which would
preserve POMC-expressing gonadotrophs from being destroyed.
Link with EGF-like molecules
A peculiar characteristic of the gonadotroph–lactotroph–somato-
troph axis, which further supports the complexity and context-
dependency of that system, is that the mitogenic effect of GnRH,
as well as the mitogenic action of the substances in gonadotroph-
conditioned medium, can be blocked by an inhibitor of the EGF-
receptor (-R) tyrosine kinase (171). Since EGF or TGF-a are
expressed in the pituitary of different species including human
(172–175), more precisely in gonadotrophs (176), somatotrophs and
lactotrophs (173, 174, 176), and since these growth factors are
mitogenic for these cell types (171, 173, 175, 177, 178) and stimu-
late PRL gene expression and production (179, 180), these growth
factors may have a permissive function in the paracrine action of
gonadotrophs. This is supported by other ﬁndings. Treatment of
cultures with antisense oligodeoxynucleotide to TGF-a (but not
antisense to EGF) inhibited lactotroph cell proliferation induced by
oestradiol (177). The mechanism may be direct or may rely on
transactivation of an EGF-R present on lactotrophs and somato-
trophs. It is well established that the EGF-R can be transactivated
by agonists of numerous G protein-coupled receptors (GPCRs)
(181). It is therefore plausible that various peptides from gonado-
trophs act on the target PRL and GH cells via transactivation of the
EGF-R expressed on lactotrophs and somatotrophs. Interestingly,
expression of TGF-a is inhibited by TGF-b1 (182), which itself inhib-
its PRL gene expression and lactotroph proliferation, creating in this
way a feedforward ampliﬁcation of a negative control.
Many other peptides in gonadotrophs may stimulate
lactotroph function, but none have been shown to be
involved yet
An impressive number of peptides have been identiﬁed in gonado-
trophs and, as they are secreted (183), they are potential candidates
for a paracrine action on lactotrophs (Fig. 1), namely angiotensin II
(184), neurotensin (185, 186), pituitary adenylate cyclase-activating
peptide (PACAP) (187, 188), calcitonin (189), calcitonin gene-related
peptide (CGRP) (190), atrial natriuretic peptide (ANP) (191), C-type
natriuretic peptide (CNP) (192), proenkephalin A and B-derived
PACAP
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Fig. 1. Schematic representation of the paracrine systems acting between gonadotrophs and lactotrophs. Full lines indicate pathways for which experimental
criteria for paracrine action have been largely met. Interrupted lines are hypothetical interactions proposed on the basis of the presence of the indicated fac-
tors in the cell and their pharmacological effects on the other cell. ﬁ , Stimulatory effect; ^, inhibitory effect; Cl-PRL, cleaved prolactin; aGSU, glycoprotein
hormone a-subunit; FSH, follicle-stimulating hormone; GnRH, gonadotophin-releasing hormone; LH, luteinising hormone; NPY, neuropeptide Y; PACAP, pituitary
adenylate cyclase-activating peptide; POMC, pro-opiomelanocortin; PRL, prolactin; TGF, transforming growth factor.
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(CART) (196), NPY (197), endothelins (ET) (198, 199) and leptin (200,
201). TRH has been located in gonadotrophs maintained in culture,
although this observation was not conﬁrmed yet (202). Among
these peptides, angiotensin II (184) and neurotensin (203–206) have
well documented PRL-releasing activity in in vitro pituitary cell
systems from adult rats. However, expression of neurotensin in
gonadotrophs in vivo coincides with the prepubertal rise in plasma
oestradiol throughout the second and third weeks in both sexes
(185, 186) whereas, in the intact pituitary, the PRL response to
GnRH is already decreasing by that time (see above). PACAP effects
on PRL release are controversial and depend on the test system
used (207–211). Whereas PACAP inhibits PRL release in monolayer
cell cultures, it stimulates release in aggregate cell cultures and
in vivo (207, 212). In studies where a stimulation of PRL release by
PACAP was found in monolayer culture, the effect is probably on
PRL gene expression and translation as it was only found after sev-
eral hours of treatment (213). PACAP activates PRL gene expression
(209, 214, 215) and is therefore a candidate peptide to participate
in gonadotroph-mediated increase in PRL mRNA levels. ANP has no
PRL-releasing action in mammals (216, 217) and whether CNP has
such an effect seems unknown for mammals. In ﬁsh, ANP was
reported to have PRL-releasing activity, although only after hours
of exposure and not acutely as seen in our experiments (217).
Leptin may be involved as it has been found to strongly stimulate
PRL release (218). NPY is also reported to be stimulatory for basal
PRL release by some investigators but others found it to inhibit
basal and TRH-stimulated PRL release (219). CART has been
reported to stimulate PRL release by some investigators but others
found it to be inhibitory (196, 220). As to angiotensin II, a debate
has going on for many years on whether or not there is an
independent renin–angiotensin system expressed in the pituitary
and in which cell types the different components are located (184).
According to recent studies, there are two different renin-angioten-
sin systems (221): one is fully expressed within the gonadotrophs,
with both renin and angiotensin II detectable in the regulated
secretory pathway, but angiotensinogen appears to sort into the
constitutive secretory pathway, raising a puzzling question how
angiotensin II can then be formed within the regulated pathway.
The second system seems to be extracellular with angiotensinogen
located in perisinusoidal cells and angiotensin produced by circulat-
ing renin in the sinusoid lumen after release of angiotensinogen
(221). Angiotensin II could then affect various other cell types
downstream in the gland. Several investigators have reported
PRL-releasing activity in response to GnRH in pituitary monolayer
cultures, although only upon using a very high dose of GnRH (222).
In reaggregate cell cultures kept in serum-free medium, we found
that physiological doses of GnRH stimulate PRL release and, at
these doses, neither an angiotensin-converting enzyme inhibitor,
nor angiotensin receptor-1 antagonists were capable of inhibiting
the GnRH-stimulated PRL release (222). Only at 100 nM GnRH could
a partial inhibition of the PRL response by angiotensin receptor-1
antagonists be detected (222). Thus, angiotensin II may be involved
in GnRH-stimulation of PRL release, but it seems to play only an
accessory role at high concentration of GnRH. Possibly, the more
physiologically relevant effect of GnRH is not involving the local
renin–angiotensin system at all and gonadotroph-mediated stimula-
tion of PRL release is mediated by another molecule or by a combi-
nation of substances.
A novel candidate may be PRL-releasing peptide (PrRP) (223) that
does stimulate PRL release in aggregate cell cultures (224). In both
intact pituitary and aggregates, we recently found PrRP mRNA and
PrRP-like immunoreactivity, particularly in gonadotrophs associated
with cup-shaped lactotrophs (Swinnen and Denef, unpublished
observations). The peptide was also found in the culture medium by
radioimmunoassay (Swinnen and Denef, unpublished observations).
Gonadotrophs contain peptides that can affect somatotroph
function
Several peptides in gonadotrophs are also candidates for mediating
the gonadotroph-induced effects on somatotrophs, although none
of them have been shown to be implicated yet (Fig. 2). PACAP stim-
ulates GH release and GH gene expression in several species (197,
207–211, 225, 226). CNP stimulates GH secretion in GH3 cells
(227). ANP inhibits basal and GHRH-stimulated GH secretion in rat
(228) but other studies have found it to be ineffective (216). We
found that angiotensin II is a peptide displaying both inhibition and
stimulation of GH release (229). However, angiotensin II antagonists
were inactive in opposing the GH response to GnRH (100). Endoth-
elins have a short-lasting stimulatory effect on GH release followed
by a sustained inhibitory one (230). NPY stimulates basal and inhib-
its GHRH-stimulated GH release in swine pituitary in vitro (231).
Also, TRH has dual effects on GH secretion, with a stimulatory
component more pronounced in neonatal rats (232) and an inhibi-
tory component prevailing at later age (233). TRH appears to have
an inhibitory effect on GH gene expression (234). CGRP stimulates
GH release (235). Another valid candidate is leptin as it has been
shown to stimulate GH secretion and to inhibit GH cell proliferation
(GH3 cells) (236). NPY stimulates basal GH secretion in rat pituitary
cells loaded on a Bio-Gel P-2 column (237), in porcine monolayer
cultures (238) and in gold ﬁsh pituitary fragments (239), but inhib-
its GHRH-stimulated GH release in porcine pituitary cultures (238).
Calcitonin-like peptides, ET and NPY as inhibitory paracrine
signals from gonadotrophs
Gonadotrophs have also been shown to interact with PRL cells in a
negative fashion (Fig. 1), a phenomenon that makes sense in view
that most stimulatory systems need an attenuating feedback mech-
anism for equilibrated functionality. Well-studied players here are
calcitonin-like peptides and ETs.
Calcitonin
Calcitonin-like immunoreactive material has been detected, is syn-
thesised and released by rat and chicken pituitary cells (240–242),
is present in rat gonadotrophs (189) and in an aGSU expressing cell
line (243), and the pituitary also expresses the calcitonin receptor
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basal and TRH-stimulated PRL release (245, 246), lactotroph mitosis
and PRL mRNA expression (247), but not TRH-induced TSH release
or GnRH-induced LH release (245). Conversely, treatment of the
cultures with an anticalcitonin antibody enhances PRL mRNA
expression and PRL release (241), as well as lactotroph mitosis
(247), suggesting that endogenous calcitonin is tonically active in a
paracrine manner. Calcitonin has a similar antimitogenic action
in vivo and passive immunisation with anticalcitonin antibody
increases the mitotic index in lactotrophs (248) as well as serum
PRL levels (249). Targeted overexpression of calcitonin in gonado-
trophs of mice leads to long-term hypoprolactinemia, decreased
PRL gene expression, female subfertility and a selective underdevel-
opment of lactotrophs (250). A calcitonin-like substance is also
expressed in the chicken pituitary, although there it colocalises with
PRL, but, as in the rat, its level ﬂuctuates inversely with PRL mRNA
level (251). In both rat and chicken, oestradiol is a negative regula-
tor of calcitonin mRNA level (251, 252). In the rat, progesterone is
a positive regulator. Most interestingly, calcitonin immunoreactivity
is found mainly in gonadotrophs that are associated with cup-
shaped lactotrophs (253), a clear-cut morphological characteristic
supporting a paracrine role. Rat calcitonin produced in the anterior
pituitary was shown to have the same amino acid sequence as
calcitonin from the thyroid C cells, but, recently, another peptide,
named calcitonin receptor-stimulating peptide, has been discovered
that shows sequence homology with CGRP and has also been
found to be expressed in the pituitary (254).
The paracrine action of calcitonin appears to be indirect, and at
least in part, mediated by endogenous TGF-b1. TGF-b1 is expressed
in lactotrophs (255, 256), its expression is enhanced by calcitonin
and TGF-b1 in turn inhibits lactotrophs mitosis (256), PRL mRNA
expression and secretion (257, 258). TGF-b1 acts as a paracrine and
not as an autocrine factor on lactotrophs. In single cell experiments
where PRL expression was followed in ‘real-time’ by quantiﬁcation
of photons emitted by the living cells by means of a luciferase
reporter (injected in individual cells) under the control of the PRL
promoter (259), PRL gene expression decreased upon exposure to
TGF-b1 and treatment of the cells with a TGF-b1 antibody
increased PRL gene expression. The latter, however, was only seen
in lactotrophs that were adjacent to another lactotroph, suggesting
that TGF-b1 acts in a paracrine and not in an autocrine manner.
However, these experiments cannot exclude that TGF-b1 is acting
in an autocrine manner and needs the context with other lacto-
trophs (i.e. that an intimate contact between lactotrophs is a prere-
quisite for the response to autocrine TGF-b1). We have found
several examples of secretory responses that needed close associa-
tion between cells, such as the GH response to angiotensin II (229)
and the inhibitory PRL response to acetylcholine (260). Again, these
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Fig. 2. Schematic representation of the putative paracrine systems acting between gonadotrophs and somatotrophs. Full lines indicate pathways for which
experimental criteria for paracrine action have been largely met. Interrupted lines are hypothetical interactions proposed on the basis of the presence of the
indicated factors in the cell and their pharmacological effects on the other cell. ﬁ , Stimulatory effect; ^, inhibitory effect; CGRP, calcitonin gene-related
peptide; FSH, follicle-stimulating hormone; GH, growth hormone; GHRH, growth hormone-releasing hormone; LH, luteinising hormone; NPY, neuropeptide Y;
PACAP, pituitary adenylate cyclase-activating peptide; TGF, transforming growth factor; TRH, thyroid-releasing hormone.
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autocrine regulation.
Endothelins
Another inhibitory paracrine signal from gonadotrophs to lacto-
trophs may be mediated by ETs. ET1 and 3 are present in the mam-
malian anterior pituitary (261–263), more precisely in gonadotrophs
of humans (264) and rats (199), although it as also expressed in
subpopulations of somatotrophs and lactotrophs (199) and in
gonadotrophs of frogs, particularly in female frogs (198). Treatment
with ET1 or ET3 in culture profoundly inhibits basal PRL release
(265–267), but, initially, there is a short-lived stimulatory action as
well (268) or higher doses may be stimulatory (267). It remains to
be shown whether the endogenous peptides exert such an action.
As will be discussed below, ETs make an inhibitory autocrine loop in
lactotrophs, which is well documented.
NPY
NPY has been found in gonadotrophs but whether it acts in an
autocrine or paracrine fashion is not experimentally illustrated yet.
Nevertheless, NPY has been reported to inhibit basal and TRH-stim-
ulated PRL release and to be additive with dopamine in inhibiting
PRL release (219). NPY also blocks the action of GnRH on PRL gene
expression and mitosis and on GHRH-stimulated mitosis of GH cells
in aggregate cell cultures.
Gonadotrophs may positively and negatively interact with
corticotrophs.
Several peptides located in gonadotrophs modulate corticotroph
activity when added exogenously to pituitary cell preparations and
it is striking that most of these peptides are involved in volume
homeostasis in other parts of the body. Among them are the calci-
tonin-like peptides adrenomedullin and CGRP and the natriuretic
peptides (NP) ANP (191) and CNP (192, 269–272) (Fig. 3). The
importance of these peptides is also emphasised by their similar
distribution in gonadotrophs in other species, even nonmammalian
(273) and by the observation that, during a 50% reduction in
maternal adrenomedullin, gene expression in mice lacking one allele
of the gene leads to profound defects in implantation, placentation
and fetal growth (274).
NP
The NPs ANP, brain natriuretic peptide (BNP) and CNP have been
shown to inhibit corticotrophin-releasing hormone (CRH)-stimulated
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Fig. 3. Schematic representation of paracrine systems acting between gonadotrophs and corticotrophs. Full lines indicate pathways for which experimental cri-
teria for paracrine action have been largely met. Interrupted lines are hypothetical interactions proposed on the basis of the presence of the indicated factors in
the cell and their pharmacological effects on the other cell. ﬁ , Stimulatory effect; ^, inhibitory effect; ACTH, adrenocorticotrophic hormone; ANP, atrial natri-
uretic peptide; AVP, arginine-vasopressin; CART, cocaine and amphetamine-regulated transcript; CGRP, calcitonin gene-related peptide; CNP, C-type natriuretic
peptide; CRH, corticotrophin-releasing hormone; FSH, follicle-stimulating hormone; LH, luteinising hormone; NMU, neuromedin U; POMC, pro-opiomelanocortin.
14 C. Denef
ª 2008 The Author. Journal Compilation ª 2008 Blackwell Publishing Ltd, Journal of Neuroendocrinology, 20, 1–70ACTH release from mouse pituitary fragments (275) and isolated
E21 fetal pituitary (276). Moreover, these peptides also reduced
POMC mRNA levels (276). Receptors for NPs (NPR-A and NPR-B),
both membrane guanylyl cyclases that generate cGMP as second
messenger, have also been identiﬁed at the mRNA level in the
anterior pituitary (277). That the effect is of physiological signiﬁ-
cance in vivo has also been shown (278).
Adrenomedullin (AM)
AM, a 52 amino-acid peptide, and proadrenomedullin N-terminal
20 peptide (PAMP), are peptides derived from the same precursor
with important roles in the physiologic regulation of volume and
electrolyte homeostasis (279). The peptides belong to the calcitonin
peptide family together with CGRP, calcitonin, and amylin (280). In
cell culture AM and PAMP inhibit ACTH secretion (269) and blunt
CRH- and oxytocin-stimulated ACTH secretion (281–284). Intrave-
nous administration of AM in sheep also lowered the plasma level
of ACTH (285).
CGRP
A positive paracrine regulator of corticotrophs released from
gonadotrophs may be CGRP as this peptide stimulates basal and
CRH-stimulated ACTH secretion (286). These observations are inter-
esting as intracerebroventricular administration of CGRP activates
the hypothalamic-pituitary-adrenal (HPA) axis as well (287). It
remains to be seen whether all these peptides act similarly as
their pharmacology predicts and under which conditions they are
important.
Gonadotrophs as paracrine targets
There is substantial evidence for paracrine communication in the
direction of the gonadotrophs. Cell separation experiments have
shown a positive inﬂuence of nongonadotrophs on gonadotroph
FSHb expression (288) and the secretory FSH : LH ratio (93). The
best characterised signalling systems in rats are from lactotrophs to
gonadotrophs through galanin and from corticotrophs to gonado-
trophs by opioid peptides (Figs 1–3).
Galanin
This oestrogen-dependent peptide is found mainly in lactotrophs
in female rats (289) and exposure of pituitary monolayer cell cul-
tures or pituitary tissue fragments to galanin results in an acute
inhibition of GnRH-stimulated LH and FSH release. Conversely,
treatment with galanin antiserum augments the LH and FSH
response to GnRH (290). Although these data support a paracrine
inhibitory role in the rat, galanin was found to stimulate LH
secretion in the porcine pituitary, whereas the use of antigalanin
antiserum weakened GnRH-stimulated LH release (291). This may
suggest an opposite regulation in porcine pituitary but the data
were obscured by the ﬁnding that an anti-NPY antiserum had the
same weakening effect on GnRH- as well as galanin-stimulated
LH release (291).
b-endorphin
It was found that b-endorphin inhibits basal as well as GnRH-stim-
ulated LH release in pituitary cell culture (292, 293). This apparently
also occurs in the tissue in situ, as treatment of cultured pituitary
cells with naltrexone, an opioid receptor antagonist, or with
b-endorphin antibodies, increased basal LH release (292). Moreover,
CRH depresses basal LH release by cultured pituitary cells, and this
was also blocked by naltrexone (292).
Cart
CART is expressed in the pituitary (294) and it is striking to ﬁnd
the peptide in several cell types that can exert paracrine inhibitory
feedbacks on GnRH-stimulated LH release. It is found in gonado-
trophs (196, 295), lactotrophs (295, 296) and corticotrophs (297).
CART release is increased by GnRH and TRH (295) and production
is up-regulated by CRH (297). CRH is known to be a negative regu-
lator of gonadotrophin secretion. Pituitary CART expression and
secretion is up-regulated during lactation and down-regulated by
dopamine, and ﬂuctuates up and down during the oestrous cycle
(lowest at dioestrous) (295), suggesting a broad role for the peptide
in reproduction (296). Also leptin increases CART release (196).
These regulatory ﬁndings are consistent with the localisation of the
peptide in the different cell types. CART inhibits K
+- (295) and
GnRH-stimulated (220) but not basal (295) LH release in culture.
CART also inhibits PRL release (196). These ﬁndings point towards a
signiﬁcant paracrine inhibitory action of CART on gonadotrophs,
which can occur during different physiological changes via different
cell types or in an autocrine manner when released from gonado-
trophs. However, the paracrinicity potential remains still to be con-
ﬁrmed by immunoneutralisation studies and by examining release
from identiﬁed cells.
PRL and cleaved PRL
Lactotrophs may also signal to gonadotrophs through PRL and
certain cleaved forms of PRL. Hyperpolactinemia is well known to
inhibit LH secretion and to depress the hypothalamic GnRH pulse
generator (298). The PRL receptor is already expressed in the rat
anterior pituitary during fetal life (299) and has been found in sub-
populations of different hormonal cell types, including gonado-
trophs in rats (300) and sheep (301) but not in the horse (302).
PRL has been shown not to tonically inhibit GnRH-stimulated LH
release in rat monolayer cell culture (303). However, either intrave-
nous administration of PRL or raising plasma PRL levels by immo-
bilisation stress, reduced the LH response to GnRH pulses and
GnRH-stimulated increase in GnRH-R density, whereas addition of
antiserum against PRL lowered the responsiveness of LH cells to
GnRH, consistent with a paracrine inhibitory tone of PRL on LH
secretion (304). In sheep, PRL on its own was found to inhibit (305)
Paracrinicity 15
ª 2008 The Author. Journal Compilation ª 2008 Blackwell Publishing Ltd, Journal of Neuroendocrinology, 20, 1–70or not affect (306) GnRH-induced LH release in culture but, in the
presence of a dopamine agonist, it completely blocked it, at least
when cells are taken in the nonbreeding season (306). Dopamine
agonists were also reported to improve the LH response to GnRH
when no exogenous PRL is present (305), which led the authors to
speculate that this was the consequence of inhibiting endogenous
PRL secretion. Whether immunoneutralisation of PRL also results in
opposite effects needs to be studied.
We have reported that the large disulphide loop of PRL can be
cleaved between Tyr145 and Leu146 with preservation of the disul-
phide bridges (307). The compound was isolated from spent culture
medium of pituitary cell aggregates from 14-day-old rat pituitary
and represented 0.6–1% of total bulk PRL. This cleaved PRL stimu-
lates mitotic activity of LH and TSH cells but of no other cell types
in rat pituitary aggregates (307), whereas treatment with polyclonal
antibodies, raised against the new N- or C-terminals of cleaved PRL
and not recognising native PRL, inhibits mitosis in these cells (308).
Although these experiments show a paracrine tone by cleaved PRL
on gonadotrophs, the physiological signiﬁcance remains unknown.
The compound is stereoselective as neither PRL, nor another some-
what larger cleaved PRL showed the latter bioactivity. Interestingly,
in a recent study it has been shown that a 16-kDa cleaved PRL
may be responsible for the postpartum cardiomyopathy syndrome
(309), suggesting that cleaved PRL variants can be pathophysiologi-
cal mediators in certain conditions of enhanced PRL output.
Oxytocin
Another peptide synthesised within the anterior pituitary of which
receptors are found in gonadotrophs is oxytocin (310). The cell type
expressing oxytocin appears to be the lactotroph and not any other
cell type (311). Oxytocin has been shown to stimulate basal LH
release in culture as well as to potentiate GnRH-stimulated LH
release (312), an effect only seen when pituitaries were tested at
pro-oestrous (313). The peptide did not have to be present for the
latter potentiation as it also occurred when oxytocin was adminis-
tered to the perifusion for 2 h prior to GnRH (314). Thus, a para-
crine function of oxytocin on LH release seems possible but
remains to be experimentally demonstrated.
Close association between cup-shaped lactotrophs and
gonadotrophs in mammals and frogs and between
gonadotrophs and somatotrophs in ﬁsh
Paracrine interactions with gonadotrophs may be rendered selective
by microanatomical associations between cell types. Association
between certain gonadotrophs and lactotrophs (often cup-shaped)
and between certain somatotrophs and corticotrophs was already
reported more than three decades ago in the rat pituitary by
Nakane (83). These observations were conﬁrmed by Siperstein and
Miller (315) and Yoshimura and Nogami (316, 317). The lactotroph–
gonadotroph associations were also reported in horse (302, 318),
sheep (301), chicken (319) and frog pituitary (304). Associations
between lactotrophs and gonadotrophs reconstitute in monolayer
cultures of densely plated cells (320) and in reaggregate pituitary
cell cultures (321), indicating that the afﬁnity between cell types is
locally regulated. In aggregate cultures, oestradiol signiﬁcantly
decreases the occurrence of cup-shaped lactotrophs embracing
gonadotrophs (321). A functional correlate of the morphological
association is the observation that the cup-shaped lactotrophs are
always associated with gonadotrophs that contain calcitonin
immunoreactivity and that the changes in PRL output in vivo
evoked by ovariectomy, pregnancy and lactation in rats were
opposite in direction to that of the PRL change (253), which is
consistent with the inhibitory paracrine action of gonadotroph
calcitonin on PRL gene expression (see above).
Another peculiar characteristic of anterior pituitary gonadotroph
and lactotroph distribution is that these cells are densely repre-
sented near the intermediate lobe in several species such as rats
and horse (83, 318, 322). In this way, these cells are well exposed
to substances made by the neurointermediate lobe, such as the
PRL-releasing factor intermedin (see below) and, at the same time,
receive modulatory paracrine signals from the adjacent gonado-
trophs. The higher incidence of gonadotrophs near the intermediate
lobe has also been observed in the monkey pituitary and this is
even a selective location in juvenile monkeys (323).
In teleost ﬁsh, gonadotrophs distribute in close association with
somatotrophs. Unlike mammals, ﬁsh pituitary shows a zonation
according to cell types (324). Lactotrophs are located in the rostral
pars distalis, whereas somatotrophs reside in the proximal pars dis-
talis, but there they distribute together with the gonadotrophs.
Most interestingly, gonadotrophs always show a distribution as
central cell clusters surrounded by a matrix of somatotrophs. This
cellular association may form a microanatomical basis of local
functional interactions and many data are consistent with this view.
In salmonids, the population size of the somatotrophs ﬂuctuates in
parallel with that of the gonadotrophs expressing the gonadotro-
phic hormone GTH-II (LH in ﬁsh) during sexual maturation (325). In
goldﬁsh, the rise in GH level during sexual recrudescence and
spawning and during the pre-ovulatory GTH-II surge always occurs
together with that of GTH-II (326). GH has an important permissive
role in reproductive functions in ﬁsh (327). Moreover, in ﬁsh, GnRH
stimulates both GH and GTH-II secretion (328–330). Recently, direct
evidence for paracrine interaction between the cell types has been
reported. In experiments on carp pituitary cells, the effect of exoge-
nous GTH and GH and of immunoneutralisations of endogenous
GH or GTH indicated that GTH released from gonadotrophs stimu-
lates GH release and synthesis in somatotrophs, whereas secreted
GH maintains somatotroph sensitive to stimulation by GTH, and
inhibits basal GTH release from gonadotrophs (331).
Possible physiological signiﬁcance of gonadotroph
paracrinicity
Gonadotrophs play the central executive role in the orchestration of
reproduction. However, these cells do not work alone. Homeostasis
and adaptation of the pituitary to reproductive needs also requires
adaptation to metabolic needs by a co-ordinated action between the
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axis. Both PRL and GH have essential roles to play in reproduction
and growth (332–335). A proper co-ordination of gonadotrophin,
GH and PRL release by the pituitary and the relative representation
of the respective hormone-producing cell types are therefore
mandatory. This is already the case during development as shown
by the accelerated lactotroph development from the second week
after birth in the rat (336) that coincides with the rapid expansion
of gonadotrophs (88–90), particularly in the females. Somatotrophs,
by contrast, are already well developed at birth, and are well prolif-
erating already during the ﬁrst week of life (336). It therefore makes
sense that gonadotrophs stimulate PRL cells during the second week
after birth in the rat but that they release an inhibitory paracrine
signal to somatotrophs. Since high FSH levels during the second
postnatal week are thought to be an important stimulus for ovarian
follicle development, and since ovarian maturation also requires GH,
it is conceivable that GH output is also under a certain trophic con-
trol by gonadotrophs as well, hence, a dual effect of gonadotrophs
on somatotrophs is not surprising. Attenuation of postnatal somato-
troph expansion is also seen at the level of GHRH-R expression.
GHRH-R mRNA is highly expressed just before birth and declines
during the perinatal period to reach a nadir at 12 days of age and
increases again at 30 days of age (337).
On the other hand, it is well known that stress-induced activa-
tion of the HPA axis inhibits the HPG axis, such as during stress
and undernutrition, during which conditions for reproduction are
not optimal, reproduction is even contraindicated and saving energy
is important (338). At the pituitary level, the negative interrelation
of the HPA and HPG axis may be mediated by the paracrine nega-
tive signals of b-endorphin on GnRH-induced LH release. In addi-
tion, CART, being located in several cell types involved in the stress
response, can exert paracrine inhibitory feedbacks on GnRH-stimu-
lated LH release.
On the other hand, in a different context, it may be mandatory
that the reproductive system attenuates the stress response.
Gonadotrophs may contribute to this goal by releasing NPs that in
turn attenuate CRH-activated ACTH release. NPs inhibit the HPA
axis at a hypothalamic level (339), which makes sense in view of
the sodium and water retention properties of glucocorticoids during
enhanced HPA axis activity. Stress responses need to be attenuated
in certain physiological states, such as lactation and in situations
that lead to low levels of visceral adipose tissue (340). It has
been shown that, in such cases, responsiveness of the pituitary to
hypothalamic CRH⁄vasopressin appears depressed (340). The cellular
mechanisms still need to be explored, but one hypothesis is that
the pituitary NPs located in gonadotrophs are involved through
their paracrine actions, together with mechanisms located at the
level of CRH production in the hypothalamus (340). The NPs are
functional opponents of the renin–angiotensin system that is a
positive component of the stress response in the control of ﬂuid
volume regulation at both central and peripheral level. A question
in this respect is whether NPs are up-regulated by oestrogen in
gonadotrophs. In heart tissue oestrogens and progesterone are
known to up-regulate NP expression (341). An increased inhibitory
tone by NP on corticotroph function during increased oestrogen
exposure during pregnancy is therefore not unlikely in the pituitary
as well.
Another contextual paracrine regulation is the inhibition of ovu-
lation during lactation. The primary factor responsible is at the level
of the GnRH pulse generator in the hypothalamus, where suckling-
induced increase of endorphinergic input leads to inhibition of the
GnRH pulses (298). The local lactotroph–gonadotroph association
in the pituitary may contribute to this suckling-induced negative
inﬂuence on ovulation via an inhibitory input of b-endorphin from
corticotrophs. Since the HPA axis is activated during pregnancy
and energy normally consumed for ovulation is senseless during
pregnancy, the raised pituitary b-endorphin and galanin tone may
contribute to silencing of the pre-ovulatory LH release. In addition,
pregnancy may antagonise the HPG axis via the growing activity of
the lactotrophs that make higher amounts of galanin under the
inﬂuence of oestrogen, which in turn not only will increase lacto-
troph activity, but also weaken LH release at the same time in
response to GnRH. As will be discussed below, another important
local negative regulator of the HPG axis activated during lactation
is the NO system in gonadotrophs and FS cells.
Although we have not been able to show a primary role of
angiotensin II from gonadotrophs in paracrine regulation of GH
and PRL release under basal conditions, such a role could exist in
other contexts. For example, we found that angiotensin II is much
more effective in releasing GH in pituitary aggregate cell cultures
from hypertensive and prehypertensive spontaneously hypertensive
rats (SHR) than in cultures from normal littermates (342) and,
recently, it has been reported that, whereas normal rat anterior
pituitary expresses the angiotensin AT1B-R, the SHR down-regu-
lates AT1B-R and induces expression of the AT1A-R (343). It would
be worthwhile to explore whether paracrine angiotensin II acts pri-
marily through the AT1A-R. The SHR is also much more responsive
to angiotensin II in terms of ACTH secretion (343). Since there is no
evidence for delivery of angiotensin II into the hypophyseal portal
blood (344, 345), it seems plausible that either circulating angioten-
sin II and⁄or the local renin–angiotensin system in the anterior
pituitary is involved in the exaggerated stress response of the pitui-
tary gland under pathological conditions but that, during preg-
nancy, this system is used to generate a normal increase in HPA
axis activity. In addition, CGRP and adrenomedullin in gonadotrophs
may help in modulating the HPA output during pregnancy as these
peptides stimulate and inhibit, respectively, CRH-induced ACTH
secretion at the level of the pituitary.
During recent years, considerable information was obtained in
support of a cross-talk between body energy reserves and fertility
(346–348). Metabolic demands increase substantially during preg-
nancy and lactation. Body weight and appetite increase. The mecha-
nisms involved in the regulation of these homeostatic changes are
still largely unknown (349). No data are available to associate one of
the above discussed peptides with that homeostatic system. However,
several orexigenic peptides that are involved in the up-regulation of
the energy balance and feeding in the hypothalamus have also been
detected in the anterior pituitary, such as ghrelin and orexins and
both stimulate GH release (350). Orexins also enhance LH (351) and
ACTH (352) secretion. Orexin-A is mostly found in lactotrophs and a
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and orexin-B only in corticotrophs (350). Orexin-1-R is found in
GH cells and orexin-2-R in ACTH cells (353). Thus, orexins are located
to enable cross-talk at the pituitary level for achieving appropriate
adaptations in energy homeostasis during pregnancy, but this area
remains to be fully explored.
Autocrine regulation of lactotrophs
An autocrine regulatory system is a stimulus–response system in
which the cell releasing the stimulus is also the target. Various
autocrine systems have been claimed in the anterior pituitary on
the basis of the following criteria: (i) the cell produces and secretes
the stimulus; (ii) the same cell type expresses the receptor for the
stimulus; (iii) the cell type under study responds to the exogenously
added stimulus; and (iv) addition of a receptor blocker or of an
antibody immunoneutralising the endogenous ligand or its receptor
has effects opposite to that of the exogenous ligand. Strictly, it
should also be demonstrated that single cells plated on a large dis-
tance from other cells meet the same criteria. However, under the
latter conditions, the context in which the autocrine system oper-
ates may be altered or even be destroyed and this may jeopardise
the functioning of the system. Evaluation of autocrine loops in sin-
gle cells has often been performed by means of the reverse haemo-
lytic plaque assay. In this assay, PRL secretion is measured from
individual cells that cannot interact by direct contact between each
other and paracrine action is avoided if, at least, the distance
between the cells is kept substantial (354).
There is ﬁrm experimental evidence for autocrine control of
lactotroph secretion, PRL gene expression and growth of the lacto-
trophs cell population in terms of the ﬁrst four criteria, but demon-
stration that the signalling cell is also the responding cell is only
rarely provided. Therefore, autocrine systems can not always be dis-
tinguished from paracrine systems among cells of the same type. It
is important to distinguish between both, and several theoretical
models have recently been presented that show the biological
importance of this distinction (see below under ‘The dynamics of
autocrine and paracrine systems’). Nevertheless, on the basis of the
above four criteria, the most important autocrine loops reported
today are made by vasoactive intestinal peptide (VIP), galanin, ET,
several growth factors (i.e. TGF-a, TGF-b1, TGF-b3 and FGF-2) and
PRL itself. These autocrine loops can be interconnected, resulting in
an activation of positive feedforward mechanisms that enable
strong auto-activation (Fig. 4). As will be discussed in detail below,
the activity of these autocrine loops is strongly context-dependent
and the direction of the functional change seen in one condition is
sometimes opposite to that in another condition.
VIP
As repeatedly shown, VIP mRNA and peptide and VIP receptors are
expressed in anterior pituitary of several species, including human
(355, 356). The peptide is releasable and its expression is regulated
by thyroid, gonadal and adrenocortical hormones (183). Moreover,
the number of VIP immunoreactive cells in pituitary cell cultures
decreases upon dopamine treatment (357), suggesting a link to the
protagonist regulatory signal of PRL release. The peptide is located
in lactotrophs (358) and in a non-identiﬁed cell type with stellate
shape (359). After oestrogen treatment, VIP expression is increased
and is present in a subpopulation of lactotrophs also containing
galanin (289). It is well established that VIP is a PRL secretagogue
and the ﬁnding that addition of anti-VIP antiserum to cultured
anterior pituitary cells decreases PRL release is consistent with a
paracrine or autocrine role of the peptide (358–362). There is evi-
dence that the action is at least in part autocrine and not paracrine
because the phenomenon is seen in a reverse haemolytic plaque
assay set-up (358). The relevance of this in vivo is supported by the
ﬁnding that lactotroph hyperplasia and associated angiogenesis
induced by oestrogen in vivo can be reduced by treatment with a
VIP antagonist (362), indicating that VIP mediates in part the action
of oestradiol on lactotrophs. Serotonin-induced PRL release is asso-
ciated with VIP release and is also blunted in the presence of a VIP
antagonist (363). TRH-stimulation of PRL release is associated with
VIP release and, when this stimulation occurs in the presence of a
VIP receptor antagonist, TRH-induced PRL release is blunted, sug-
gesting an autocrine potentiating role of VIP in TRH action (361).
Insulin growth factor (IGF)-I-stimulated PRL release (but not IGF-I-
inhibition of GH release) could also be blunted by anti-VIP antibody
FS cell
Oestradiol
Oestradiol
Oestradiol
Oestradiol
Dopamine
5-HT
IGF-I
IGF-I
Galanin
VIP
ET-1
ET-3
PRL
TGF-α
TGF-β3
TGF-β1
Mitosis
FGF
NGF
PRL mRNA
TRH
+ progesterone
Fig. 4. Schematic representation of the autocrine loops acting in lacto-
trophs. Full lines indicate pathways for which experimental criteria for auto-
crine action have been largely met. Interrupted lines are hypothetical
interactions proposed on the basis of the presence of the indicated factors
in the lactotroph and their pharmacological effects on the same cell. ﬁ ,
Stimulatory effect; ^, inhibitory effect; ET, endothelin; FGF, ﬁbroblast growth
factor; IGF, insulin-like growth factor; NGF, nerve growth factor; PRL, pro-
lactin; TGF, transforming growth factor; VIP, vasoactive intestinal peptide.
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drawal of dopamine (364) is blunted by anti-VIP antibody (365).
Interestingly, the effect of VIP on PRL release itself appears to be
mediated by galanin released from a subpopulation of lactotrophs
that itself does not secrete PRL in response to VIP (366). Thus, VIP,
galanin and IGF-I appear to be linked to each other in a complex
autocrine⁄paracrine network in which VIP is a feedforward system
in the local regulation of lactotroph activity by galanin.
Galanin
This peptide is a well-studied autocrine regulator of PRL gene
expression and secretion in a gender-speciﬁc manner. It is located
mainly in a subpopulation of lactotrophs in female rats, in contrast
to its main location in somatotrophs and thyrotrophs in male rats
(367). The production of pituitary galanin ﬂuctuates with oestrogen
levels during the oestrous cycle, pregnancy and lactation (367,
368), with oestradiol increasing its mRNA level with several orders
of magnitude. Oestradiol also increases the number of galanin-posi-
tive lactotrophs (366). It is in fact galanin that mediates the stimu-
latory action of oestradiol on lactotroph proliferation and PRL gene
expression. Galanin is releasable and antigalanin antiserum prevents
the action of oestradiol on lactotrophs (366). Direct evidence that
galanin is acting in an autocrine and not in a paracrine fashion on
lactotrophs comes from experiments using the reversed haemolytic
plaque assay. Galanin-positive lactotrophs (identiﬁed by in situ
hybridisation) release more PRL than galanin-negative lactotrophs,
whereas galanin antiserum signiﬁcantly blunts PRL secretion from
galanin-positive cells. The oestrogen-dependent autocrine action of
galanin has been conﬁrmed in vivo in transgenic mice with a gala-
nin gene null mutation (369). In female transgenic mice, PRL mRNA
levels and hormone content were signiﬁcantly reduced compared to
wild-type controls, leading to a failure in lactation and reduced
plasma PRL levels. In the null mice, the proliferative response of
the lactotrophs to oestrogen was lost and oestrogen failed to stim-
ulate PRL release. Conversely, in transgenic mice overexpressing
galanin in lactotrophs, PRL release and synthesis was increased but
only in the presence of oestrogen (370).
TGF-a, TGF-b1, TGF-b3 and FGF-2
Galanin appears to be linked to another autocrine network that is
also recruited by oestrogen for lactotroph mitosis and differentia-
tion. That network includes, besides VIP, as discussed earlier, TGF-a,
TGF-b1, TGF-b3 and FGF-2. In rats and mice, lactotrophs produce
TGF-a and express the EGF-R (176). Exogenous TGF-a and its
homolog EGF have a mitogenic action on lactotrophs (171, 173,
177). Treatment of mouse pituitary cells cultured in serum-free
medium with an inhibitor of the EGF-R tyrosine kinase or with
antisense TGF-a oligonucleotides reduces the mitogenic effect of
oestradiol on lactotrophs (177). As already mentioned earlier, the
paracrine gonadotroph–lactotroph connection can only work in
context with the TGF-a–EGF-R system for functioning (171). More-
over, oestradiol has a positive feedforward effect as it stimulates
TGF-a expression (371). A positive feedforward effect of oestradiol
has also been noticed on TGF-b3-producing lactotrophs, as the oes-
trogen increases both the number of the latter cells and their pro-
duction of TGF-b3 (372). As immunoneutralisation of endogenously
secreted TGF-b3 or blocking endogenous TGF-b3 generation by
antisense TGF-b3 oligodeoxynucleotide treatment of cultures
reduces the mitogenic action of oestrogen, it is believed that
endogenous TGF-b3 mediates the proliferative effect of oestrogen
(373, 374). It appears that TGF-b3 does not act directly on lacto-
trophs because TGF-b3 stimulates lactotroph proliferation in a
mixed pituitary cell culture but not in cultures of enriched lacto-
trophs nor in the RC-4B⁄C cell line, a pituitary cell line representing
all cell types of the pituitary except FS cells (372). The addition of
FS cells to this cell line restores the response to TGF-b3 (372). The
factor mediating the effect of TGF-b3 appears to be FGF-2 pro-
duced by FS cells, because immunoneutralisation of FGF-2 abolishes
the effect of TGF-b3 (372). Moreover, oestradiol also favours lacto-
troph cell proliferation by attenuating an autocrine inhibitory loop.
It decreases expression of TGF-b1 and its receptor in a subpopula-
tion of lactotrophs, the number of TGF-b1-containing lactotrophs
and PRL secretion (255, 256, 375–377).
The relevance of the TGF-a system has also been evaluated
in vivo in transgenic mice. Targeting TGF-a overexpression in lacto-
trophs leads to lactotroph hyperplasia and adenoma formation
(378), with no effect on corticotrophs, despite EGF being able to
stimulate corticotroph proliferation (175). In another more powerful
approach, EGF-R signalling was blocked by overexpressing a domi-
nant negative EGF-R, lacking the intracellular protein kinase
domain, into GH and PRL cells. The mutant receptor was targeted
by GH and PRL promoters combined with a tetracycline-inducible
expression system, that allows expression at a precise age (379).
When the dominant mutant gene was overexpressed in GH cells
during embryonic life, both somatotroph and lactotroph numbers
were strongly depressed in adult life. However, when the dominant
negative mutant gene was expressed in the GH cells during the
early postnatal period, no change in the adult appearance of the
cells was observed. Moreover, when expression of the mutant
receptor was started during pregnancy, the typical hyperplastic
lactotroph response of pregnancy was maintained (379). These data
suggest that EGF-R signalling is only essential for the embryonic
expansion or maintenance of the lactosomatotroph lineage and
that, later in life, other mechanisms can compensate for the lack of
the TGF-a–EGF-R signalling. It should be noticed that initial differ-
entiation into GH cells is not dependent on EGF-R signalling
because the expression of the dominant negative EGF-R gene needs
an active GH promoter in order to be functional. Thus, TGF-a is
required for the expansion of the somatotrophs and lactotrophs
and not for their initial differentiation.
TGF-a is ﬁrst synthesised as an integral transmembrane protein,
with the TGF-a sequence present in the extracellular domain. TGF-a
and other EGF-like molecules can be enzymatically cleaved and
shed into the extracellular space by a metalloproteinase-disintegrin,
also expressed as a transmembrane protein and known as ‘TGF-a
converting enzyme’ (380) and this processing is usually required in
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for several other EGF-like molecules, the TGF-a precursor may also
function as an EGF-R agonist in an autocrine manner while still
bound to the membrane, and there is evidence that the obtained
effect can be different from that of the shed form (382). This may
be related to the fact that the EGF-R and the TGF-a precursor are
sorted to the same area on the plasma membrane to ensure rapid
and efﬁcient recapturing of the shed TGF-a by the EGF-R (381,
383, 384). Exposing the cells randomly to free TGF-a, which occurs
when TGF-a is added exogenously, obviously leads to cellular
responses that may not be representative of the physiological
response to the endogenous ligand.
There is evidence that TGF-a acts in a strict autocrine way
because its endogenous action was demonstrated in a reverse hae-
molytic plaque assay (385). It has even been suggested that the
transmembrane form, and not the cleaved form, of TGF-a at the
surface of the lactotrophs is the effective form in the pituitary
gland (385), but this proposal could be criticised because the
method used may have failed to detect small amounts of released
TGF-a. It has been shown in other systems that normally processed
and cleaved TGF-a may be completely captured by the EGF-R pres-
ent in the immediate molecular vicinity and become undetectable
in the interstitium (386).
Autocrine loops may be essential for preserving speciﬁc auto-
stimulation of the expressing cell without neighbouring cells are
affected. This positional speciﬁcity has been assessed by Kudlow’s
group by comparing mice overexpressing wild-type TGF-a in lacto-
trophs with mice overexpressing an obligately soluble form of
TGF-a in lactotrophs (i.e. a TGF-a molecule lacking the transmem-
brane region of the gene) (387). Mice overexpressing the soluble
form of TGF-a did not display lactotroph hyperplasia, but the
pituitary became very large due to proliferation of nonhormonal
interstitial cells. These ﬁndings led the authors to propose that
the speciﬁc autocrine mechanism of lactotroph growth requires a
membrane bound TGF-a precursor that is shed in a strictly con-
trolled manner, whereas TGF-a shed in large amounts can diffuse
widely and act in a paracrine, but nonphysiological manner to
stimulate growth of interstitial cells all over the tissue. In the lat-
ter studies, however, it is strange that no growth of other glan-
dular cells was seen as these cells also express EGF-R (176) and
EGF can stimulate corticotroph proliferation (175). An additional
observation by the Kudlow’s group, however, was that mice over-
expressing the mutant TGFa lacking the intracellular kinase
domain developed a normal pituitary, which led the authors to
propose that the normal TGF-a precursor may be signalling
through its own intracellular domain instead of via the EGF-R
autocrine loop (387).
An autocrine EGF-R-implicating loop has also been demonstrated
in lactotroph cell lines. Treatment of these cells with the receptor
tyrosine kinase inhibitor herbimycin A, markedly reduced basal PRL
mRNA levels in a reversible manner, as well as Tyr phosphorylation,
and inhibited PRL mRNA gene expression induced by bFGF and TRH
(388).
It is important to emphasise here that the VIP-galanin-TGFa–
TGF-b1–TGF-b3–FGF-2 system provides a nice example of how an
autocrine system functions. It consists of several components that
can be recruited by the same factor (oestradiol) in a feedforward
manner in order to establish an efﬁcient response. At the same
time, stability in the system is preserved by interaction with para-
crine substances such as signals from gonadotrophs. Stability and
ﬁne-tuning is also reinforced by the existence of an autocrine neg-
ative feedback loop by ETs, as explained below, and by redundancy,
which can allow compensation in case one of the constituents in
the network would be lacking.
NGF
Another growth factor that may be implicated in autocrine growth
of lactotrophs is NGF. According to Missale, NGF is produced in
the rat pituitary and selectively expressed in lactotrophs already in
early postnatal life and is released by these cells when established
in culture (389), although others found NGF also in subpopula-
tions of other cell types (390). Exogenous NGF increased PRL
mRNA expression (391, 392) and augmented the number of cells
expressing PRL in monolayer cell cultures from newborn rats
(391). Immunoneutralisation of secreted NGF completely prevented
the generation of lactotrophs (391). Whether the action is strictly
autocrine or paracrine on lactotrophs remains unsettled. In reag-
gregated cell cultures from 14-day-old rats, we also found that
exogenous NGF increased mitotic activity in cells identiﬁed as lac-
totrophs and augmented the total number of cells expressing PRL
mRNA (393). However, addition of the same antibody that Missale
used in her monolayer cultures did not result in a decrease in
basal lactotroph expansion in our aggregates, despite it clearly an-
tagonising the action of exogenous NGF (393). A possible explana-
tion of the discrepancy in the ﬁndings is that autocrine action of
endogenous NGF may be restricted to the neonatal period and
that later spontaneous NGF release no longer affects lactotroph
cell renewal unless NGF release is speciﬁcally activated. Another
possible explanation is that, in three-dimensional cultures, the
antibody is not efﬁcient enough to capture the released NGF due
to a much more restricted and locally aggregated NGF-R–NGF
complex, which would require a very high antibody concentration
to be broken. NGF secretion has been shown to be activated by
IL-1 (394) and VIP (389), whereas GHRH, TNF-a and FGF-2 inhibit
it and dopamine completely blocks the VIP-stimulated secretion.
Thus, the NGF autocrine loop may be switched on and off accord-
ing to the context in the microenvironment. Both IL-1 and VIP are
molecules that are important during the pituitary response to
immune stress. Another possibility is that endogenous NGF can
only function in a contextual setting when there is a three-
dimensional cellular organisation, and that the contextual setting
is not reached in the aggregate culture medium used, leading to
a silencing of endogenous NGF. In monolayer culture, NGF could
be secreted in an uncontrolled manner due to the loss of intimate
cell–cell contact in the latter culture system and, hence, immuno-
neutralisation would ‘show’ an endogenous NGF activity. We also
found that at least part of the action of NGF on lactotroph
expansion was through a proliferative effect on lactotroph pro-
genitor cells already expressing Pit-1 but not yet PRL (393). NGF
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dopamine receptor D2 (395).
Endothelins
ET-1 and ET-3-like immunoreactivity and ET-R are expressed in the
anterior pituitary (261–263), more precisely in lactotrophs (396,
397). The peptides are secreted as shown in a reverse haemolytic
plaque assay (398). The functioning of endogenous ET is highly
context-dependent with time, with steroid hormones and dopamine
determining the direction of the secretory response to ET. The
prominent action of exogenous ET is profound inhibition of PRL
secretion (268, 399–401) but, when studied in a perifused cell col-
umn, ET-1 initially induces a prompt and short-lasting increase in
PRL release, which is followed by a profound sustained inhibition
(402). A similar response was seen for GH release (230). The auto-
crine action of ET via the ET(A)-R has clearly been documented in a
reverse haemolytic plaque assay (398). The ET(A)-R antagonists
BQ123 and BQ610, and the ET convertase enzyme inhibitory pep-
tide, [22Val]big ET1(16)38), increase basal PRL secretion, whereas the
ET(B)-R antagonist BQ788 was ineffective. A peculiar phenomenon
in ET action is that, after long-term (48 h) exposure to dopamine in
culture, the inhibitory component of ET-1 on PRL secretion reverses
into a stimulatory one (403). The stimulatory versus inhibitory com-
ponent also appears to depend on gender and oestrogen status.
Blocking the ET-mediated autocrine loop with the ET(A)-R antago-
nist resulted in an increase in PRL secretion when pituitary cells
were obtained at pro-oestrous, oestrous, and dioestrous-1, whereas
PRL secretion was decreased by the antagonist at dioestrous-2
(404). Importantly, the authors found that the concentration–
response curves of the stimulatory effect of the ET(A) antagonist
were bell-shaped at pro-oestrous and dioestrous-1 but that, at
oestrous, the dose–response was monophasic, indicating that
endogenous ET at pro-oestrous and dioestrous-1 is both stimula-
tory and inhibitory depending on receptor occupancy and that, at
dioestrous-2, endogenous ET is predominantly stimulatory. These
ﬁndings led the authors to propose that, at oestrous, the autocrine
negative feedback by ET may play a role in restraining PRL secretion
following the oestradiol-induced pro-oestrous PRL surge. The gona-
dal steroid modulation of the lactotrophs ET system is further illus-
trated by the ﬁnding that ET(A)-R antagonism did not affect PRL
secretion in cultured cells obtained from progesterone-implanted
ovariectomised animals but increased PRL secretion in the cells
from oestradiol and oestradiol + progesterone-treated groups (405).
Once released, ETs may also target other autocrine networks or
may be itself a target of other networks. ETs release Substance P
(406) and ET-3 release is augmented by IGF-I and inhibited by
TGF-b, whereas ET-1 secretion is augmented by TGF-b (262). Thus,
through altering the availability of ET, these interactions may
trigger feedforward inhibition or, depending on the interacting
substance, exert negative feedbacks.
As already discussed earlier, ET peptides are also present in
gonadotrophs and somatotrophs and could therefore affect
lactotrophs in a paracrine manner (199). Moreover, ovarian steroid
hormones have a differential effect on the distribution of ET over
these cell types (199): the number of ET-1 immunoreactive pituitary
cells in ovariectomised rats was unaffected by prior in vivo treatment
with progesterone alone whereas treatment with oestradiol slightly
decreased the number of ET-1-positive lactotrophs and somatotrophs
but increased the occurrence of ET-1-positive gonadotrophs. Com-
bined treatment with oestradiol and progesterone robustly increased
the proportion of ET-1 immunoreactive lactotrophs and gonado-
trophs but had no effect on somatotrophs. Thus, the ovarian oestro-
gen signal augments the paracrine action of gonadotrophs on
lactotrophs whereas oestrogen and progesterone in combination
augment autocrine signalling in lactotrophs.
Autocrine regulation of somatotrophs
Whereas autocrine regulation of lactotroph function is a target of
oestrogen and related to reproductive functions, it can be expected
that autocrine regulation of somatotrophs may be related to energy
homeostasis because GH is one of the protagonist players in energy
expenditure, an action performed in concert with TSH and also PRL.
Molecules playing a central role in food intake regulation at the
hypothalamic level, such as ghrelin, leptin, NPY and TRH, are also
expressed in somatotrophs and operate directly in the pituitary
(Fig. 5). However, to date, there is only indirect evidence for auto-
crine regulation by these peptides.
Ghrelin
Ghrelin, a 28-amino-acid acylated peptide originally isolated from
the rat stomach, displays manifest orexigenic activity (407). In the
rat pituitary, it is expressed in somatotrophs, lactotrophs and
Fasting
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Fig. 5. Schematic representation of autocrine loops acting in somatotrophs.
Full lines indicate pathways for which experimental criteria for autocrine
action have been largely met. Interrupted lines are hypothetical interactions
proposed on the basis of the presence of the indicated factors in the
somatotroph and their pharmacological effects on the same cell. ﬁ , Stimu-
latory effect; ^, inhibitory effect; ET, endothelin; GH, growth hormone;
GHRH, growth hormone-releasing hormone; NPY, neuropeptide Y; TGF, trans-
forming growth factor; TRH, thyroid-releasing hormone; VIP, vasoactive
intestinal peptide.
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Ghrelin and GH secretagogue receptor GHS-R1a mRNA expression
were also detected in GH3 cells (409) and in human pituitary (410).
Ghrelin strongly stimulates GH release (407). Endogenous pituitary
ghrelin appears to play a physiological role in GH release because
the GHS-R-speciﬁc antagonist [d-Lys-3]-GHRP-6 signiﬁcantly
reduces GHRH-stimulated GH release in vitro (411). Thus, local
ghrelin is a positive feedforward system for GHRH action by sensi-
tising the somatotroph to GHRH. Local regulation is also adapted
for such a role because ghrelin mRNA and peptide content change
in the same direction as GHRH content in the hypothalamus under
various conditions. For example, GH treatment, glucocorticoid
excess, hyperthyroidism and food deprivation decrease hypotha-
lamic GHRH and pituitary ghrelin mRNA and peptide levels,
whereas the opposite was found in dwarf rats, and during gluco-
corticoid deﬁciency and hypothyroidism (408, 411). GHRH treatment
increases ghrelin expression in the pituitary (408, 412).
Of note, pituitary ghrelin expression ﬂuctuates developmentally
(408), being highest at E18 in rats and then declining with age
(412). GHS-R expression is also high in fetal and neonatal life,
decreases postnatally and increases again just before puberty to
decrease again later (413). Moreover, at early postnatal age,
somatotrophs are more sensitive to GHRH (414–417). These high
early postnatal levels of ghrelin and ghrelin receptor correlate
with higher GH levels at late embryonic and early postnatal ages
(418, 419), when hypothalamic GHRH is still low, suggesting a
more important local role of pituitary ghrelin system in releasing
GH at that young age and possibly also at puberty. Ghrelin is also
able to increase Pit-1 gene transcription in neonatal rat anterior
pituitary cells (420), suggesting a role in pituitary somatotroph
development.
It is interesting to relate these ﬁndings to the age-dependent
differences in sensitivity of GH secretion in vitro in response not
only to GHRH, but also to angiotensin II and TRH. We found that
all these peptides have dual effects on GH release in aggregate
pituitary cell cultures, with the response being predominantly stim-
ulation in neonatal life and inhibitory after puberty (229, 232, 233).
Glucocorticoids enhanced the stimulatory component but only in
aggregates from prepubertal rats; at adult age, glucocorticoids
increased the inhibitory effect (229). It is tempting to speculate
that the occurrence of a strong GH response to angiotensin II in
the presence of glucocorticoids in neonatal life may be related to
the high level of ghrelin at that age, and the increased level of
GHS-R1a known to be induced by glucocorticoids (421). In favour
of the implication of a paracrine system in establishing the GH
releasing effect of angiotensin II is the ﬁnding that the GH
response to angiotensin II disappears when pituitary cells are used
dispersed in a cytodex bead cell column, whereas the PRL response
is preserved (229). The stimulation of GH release by VIP in the
presence of glucocorticoids (233) is perhaps also related to the
ghrelin system.
It is interesting to relate pituitary ghrelin function to pathophysi-
ological phenomena occurring during protracted critical illness in
humans. In these patients, the synchrony among pulsatile GH, PRL
and TSH secretion is lost and pulse height is depressed. Upon infu-
sion, GHRP-2, a synthetic GH secretagogue acting through the
ghrelin receptor, restores these pulses and synchronisation to some
extent (422). As ghrelin is expressed not only in somatotrophs, but
also in a subpopulation of lactotrophs and thyrotrophs (at least as
studied in the rat), it would be worthwhile to test the hypothesis
that the local pituitary ghrelin system is depressed in these
patients, leading to a depression of pulses and hormone peak mag-
nitude. It is also noteworthy that, in anorexia nervosa, there is a
decreased sensitivity to the GH releasing action of ghrelin even
though ghrelin plasma levels are increased (423).
TRH
Whereas thyroid hormone increases appetite, TRH has central
effects reducing food intake (424). TRH has also been detected
within the anterior pituitary. Gwen Childs was the ﬁrst to notice
the presence of TRH immunoreactivity in the intact rat anterior
pituitary in secretory granules of thyrotrophs and PRL cells (202).
The presence of the proTRH mRNA was later shown in a subpopu-
lation of somatotrophs by Bruhn et al. (425). In culture (from
2-week-old rats), TRH expression was stimulated by thyroid hor-
mone and potentiated by glucocorticoids (426), whereas TRH gene
expression was undetectable in cultures deprived of glucocorticoid
(427). Cultures from female rats contained and secreted higher
amounts of TRH than those from males (428).
Although there is ample evidence for a secretagogue action of
TRH in GH, TSH and PRL release, an autocrine action on somato-
trophs remains to be demonstrated. Exogenous TRH is capable of
stimulating GH secretion in vivo, but this is only under particular
developmental, experimental or pathological conditions (429, 430).
TRH stimulates GH release in neonatal rat pituitary in vivo (431)
and in cell culture (232, 417) whereas, in adults, it inhibits GH
release stimulated by VIP in vitro (233). Stimulation in vitro has also
been observed in pituitary tissue from adult hypothyroid rats (as is
the case in hypothyroid humans) (432) or in pituitary tissue from
euthyroid rats after pre-exposure to GHRH (433). The TRH-1-R has
been detected by in situ hybridisation in approximately 50% of the
GH cells (434) as well as in human GH adenomas (429). In lower
vertebrates (birds and amphibians), TRH is a prominent GH secreta-
gogue, particularly in immature chicken (435). In adult chicken, the
GH releasing action of TRH depends on the feeding status of the
animal (435) and can also be evoked in vitro in the presence of
GHRH (436).
Although there is no experimental evidence that TRH is an auto-
crine GH secretagogue, there is circumstantial evidence for a para-
crine action on TSH secretion (437). The latter may be important for
TSH release in concert with GH release for the control of energy
expenditure. When cultures are treated with disulﬁram, an inhibitor
of the C-terminal amidation of glycine-extended TRH precursor, the
accumulation of TRH is drastically lowered, as is TSH release (437).
However, release of GH was not affected, suggesting that no auto-
crine loop of TRH on GH secretion is operative under conditions
where it was acting in a paracrine manner. The latter observation
again emphasises the importance of contextual conditioning of
autocrine and paracrine interactions.
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Leptin is a hormone secreted by adipocytes that signals the energy
reserve status stored in fat to hypothalamic centres regulating sati-
ety and energy expenditure. It negatively affects food intake and
body mass and increases metabolic rate, psychomotor activity and
body temperature (438, 439). A sufﬁcient leptin signal is also essen-
tial for normal activity at all levels of the HPG axis (439). Leptin
(440, 441) and leptin receptor (440) have also been located in the
pituitary gland in several species including humans (442–444). In
the rat, leptin is found in subpopulations of somatotrophs, gonado-
trophs, thyrotrophs, corticotrophs and FS cells but very little in PRL
cells (200), whereas other studies found it only in somatotrophs
and gonadotrophs (201), and still others in thyrotrophs (440) or in
gonadotrophs and less in thyrotrophs (445). In humans, leptin was
found in somatotrophs, gonadotrophs, thyrotrophs and cortico-
trophs but, again, not in lactotrophs (446). Thus, it appears that
leptin is expressed in all hormonal cell types, except lactotrophs. By
contrast, the leptin receptor is distributed more restrictively. In the
rat, most somatotrophs express leptin receptor, whereas only 1% of
the other cell types is leptin receptor-positive (445). It therefore
appears that local leptin signals converge the needs of the different
hypothalamic-pituitary-peripheral axes to the somatotrophs. Such a
convergence is of particular importance whenever there is a need
for adaptation in energy homeostasis. Indeed, during starvation,
there is a concerted adaptation in the GH axis, the HPT axis and
the HPA axis. Leptin plasma levels fall during starvation and this is
the physiological stimulus for suppression of pro-TRH mRNA
expression in the paraventricular nucleus within the hypothalamus,
which in turn will result in decreased activity in the HPT axis in
order to save energy (447). During starvation, the TSH response to
TRH is diminished and, in most species, there is an increase in GH
secretion with a decrease in IGF-1 levels and a rise in GH respon-
siveness to GHRH (448).
A contribution of the pituitary leptin system for the sake of
decreasing metabolic rate but, at the same time, favouring GH out-
put during starvation would require that starvation would lead to
less leptin action in somatotrophs, which in turn would lead to an
increase in the sensitivity to GHRH. However, to date, no studies
have demonstrated a fall in pituitary leptin levels during starvation.
Nevertheless, studies with leptin treatment in sheep and swine
already revealed actions of leptin that are compatible with a pitui-
tary leptin contribution in the right direction. In sheep, treatment
with leptin for 1–3 days reduces mRNA levels of GH and GHRH-R
in the pituitary, and decreases the GH secretory response to GHRH
(449). In pig pituitary in vitro, leptin acutely increases GH secretion
and, as in sheep, inhibits GHRH-stimulated GH release (450, 451).
Thus, in case leptin levels decrease, such as during starvation, the
opposite is expected to occur: a rise in GH output and sensitivity to
GHRH. Whether endogenous leptin acts in a similar manner in an
autocrine or paracrine way on somatotrophs still remains to be
demonstrated.
Nevertheless, pituitary leptin reserves appear to adapt to changes
in the HPG axis in a cell type-speciﬁc manner. The proportion of
leptin-positive somatotrophs increases from dioestrous to pro-
oestrous (442) and the number of leptin-positive cells increases
after short-time treatment in vitro with GHRH and oestrogen (452).
Another potential role of pituitary leptin may be related to the
GH axis during development because leptin can stimulate GH secre-
tion at the level of the pituitary in human fetal pituitary in vitro
(442). By contrast, no such effect was seen in adult rat pituitary
when the GH axis is no longer necessary for growth (453).
Other peptides
Various other peptides have been shown to be present in somato-
trophs such as enkephalin (454), NPY and Substance P (particularly
in male rats) (183, 455).
NPY has been reported to stimulate basal GH release (197) but
to block the GH response to GHRH in porcine pituitary cells (231).
Based on the prominent action of NPY at the hypothalamic level in
regulating feeding and energy consumption (456) and the role of
GH in energy homeostasis, the question can be raised as to
whether NPY may participate in such actions by modulating GH
secretion at the pituitary somatotroph level.
No effect of Substance P on GH release has been found but sev-
eral Substance P antagonists reduced the stimulation of GH release
by GH-releasing peptides (ghrelin receptor agonists) but not GHRH
(457). An inhibitory effect of Substance P antagonists on basal GH
release was also reported by us in aggregate cell cultures (458).
However, the latter study also showed nonspeciﬁc actions of these
antagonists. The presence of Substance P in somatotrophs has also
been detected in the porcine pituitary (459). Importantly, food
restriction during pregnancy increases the activity of the GH axis in
the fetus, including an increased somatotroph cell size and the
appearance of a higher proportion of somatotrophs expressing Sub-
stance P (459). GHRH is known to increase Substance P in the pitu-
itary (460). The signiﬁcance of these ﬁndings is unknown but is
intriguing considering that Substance P was found to be ineffective
with respect to in vitro GH secretion (457, 461).
Autocrine regulation of gonadotrophs
Evidence for autocrine control of gonadotroph function is substan-
tial, particularly with respect to the differential regulation of FSH
and LH secretion. Various signalling molecules participate, forming
a complex network (Fig. 6). Importantly, there is evidence for cross-
talk between at least certain autocrine substances, such as between
NO, CNP and leptin and between PACAP and the activin–follistatin
system.
The activin–inhibin–follistatin system
Activin and inhibin are growth and differentiation factors belonging
to the TGF-b family. Members of this family are involved in many
developmental and functional processes of many cell types in nor-
mal as well as tumoural state. The system plays an important role
at all levels of the HPG axis (462). Inhibin consists of an a-subunit
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form (inhibin A and inhibin B). Activins are dimers consisting only
of the inhibin b-subunits [i.e. either two identical bA isoforms (acti-
vin A), two identical bB isoforms (activin B) or a hetero bA⁄bB
complex (activin AB)]. Activin bA and bB as well as the activin
receptor and coreceptors are expressed in the anterior pituitary and
anterior pituitary cells secrete activin A and B (463). In mammals,
the main site of synthesis is within the gonadotrophs (462). Also
inhibin-a is expressed together with the b-subunits in rat gonado-
trophs (464), although secretion of native inhibin B from these cells
has not been demonstrated yet. In frogs, activin subunits are
located in thyrotrophs, gonadotrophs and somatotrophs (465, 466).
In ﬁsh both bA and bB subunits have been located in somatotrophs
and not in gonadotrophs and inhibin-a is located mainly in nerve
endings (467), suggesting that in ﬁsh pituitary mainly native activ-
ins are operative. In mammals, activin A and B stimulate FSH syn-
thesis and secretion in pituitary cell cultures (468) and there is
essentially no effect on LH release except under particular condi-
tions (469). In frogs, activins stimulate FSH as well as LH produc-
tion and inhibin blocks both these effects (466). In ﬁsh, activin A
and B as well as inhibin stimulate GH secretion (467), which is
interesting in view of the protagonist role of GH in gonadal func-
tion in that animal class. Moreover, in cultured gold ﬁsh pituitary
cells, activin B stimulates the gonadotrophin GTH-Ib but suppresses
GTH-IIb mRNA levels (470). As shown in mammals, inhibin dimin-
ishes FSH production by obliterating the action of endogenous acti-
vin at its receptor, for which the coreceptor b-glycan is obligate
(471, 472). When activin and inhibin are added to pituitary cell cul-
tures simultaneously, FSHb mRNA becomes undetectable (473),
suggesting that inhibin is dominant over activin in regulating FSHb
expression.
Autocrine activin
Activin is acting in an autocrine loop in both basal and speciﬁed
physiological situations and represents one of the fundamental
mechanisms for selective regulation of FSH expression and secre-
tion under the governance of a single GnRH. By using a speciﬁc
anti-activin B (not cross-reacting with activin A or inhibin) mono-
clonal antibody, it has been shown that activin B from gonado-
trophs in culture exerts a tonic stimulatory inﬂuence on FSHb
mRNA levels and FSH secretion, because adding this antibody to
cultures resulted in a decrease in basal FSHb mRNA levels and FSH
secretion without affecting secretion of LH (468). The same anti-
body fully blocked the stimulation of FSHb expression elicited by
added activin B but not the inhibition by added inhibin (albeit it
was smaller in magnitude) (468). Similarly, in castrated mice in
which the gene for activin receptor type II (Act-R-II) was disrupted,
FSHb expression in the pituitary is lower than in castrated wild-
type mice (474).
Several known effects of steroids on FSHb expression appear to
be mediated at least in part by activin B released from the gonado-
trophs after application of these hormones. Testosterone, progester-
one or glucocorticoid treatment increased FSHb levels in cell
cultures and, again, this effect can be blocked with the monoclonal
antibody against activin B (463, 475–478). Immunoneutralisation
studies also showed that activin B mediates the rise in FSH after
ovariectomy in vivo in the rat (479–481) and that, in sheep, oestra-
diol depresses pituitary FSHb expression, at least partly via inhibi-
tion of activin B expression (482). The latter ﬁndings are
particularly relevant as the ovine FSHb promoter has an oestrogen
responsive region, but not an oestrogen response element, suggest-
ing that oestrogen regulates FSH expression indirectly (483) via
repression by the latter of the activin bB subunit gene.
Even though the above experiments provide strong evidence for
a local control of FSHb expression and FSH secretion by activin B,
they leave the question open whether activin B acts in a strict
autocrine manner or diffuses to neighbouring gonadotrophs to
exert its effect in a paracrine fashion. Some indirect evidence has
been found, however, that the action of activin is at least in part
autocrine. Using a cell blot assay test system, in which the secre-
tion of single cells can be separately explored and in which no
cell–cell contact exists, it was found that testosterone, known to
increase FSH production via activin B, does not increase the number
of FSH-secreting cells but signiﬁcantly augments the amount of
FSH secreted from the FSH-positive cells (484). Interestingly, the
largest secretors did not increase their output upon testosterone
application.
Several physiological events appear to operate through altera-
tions of activin B expression. Whereas the pro-oestrous rise in FSH
and LH secretion is dependent on the GnRH pre-ovulatory peak, the
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Fig. 6. Schematic representation of autocrine loops acting in gonadotrophs.
Full lines indicate pathways for which experimental criteria for autocrine
action have been largely met. Interrupted lines are hypothetical interactions
proposed on the basis of the presence of the indicated factors in the
gonadotroph and their pharmacological effects on the same cell. ﬁ , Stim-
ulatory effect; ^, inhibitory effect; Act-R, activin receptor; CNP, C-type
natriuretic peptide; FS, folliculo-stellate; FSH, follicle-stimulating hormone;
GnRH, gonadotophin-releasing hormone; IL, interleukin; iNOS, inducible nitric
oxide synthase; LH, luteinising hormone; LPS, lipopolysaccharide; nNOS, neu-
ronal nitric oxide synthase; NO, nitric oxide; PACAP, pituitary adenylate
cyclase-activating peptide.
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follicles, is independent on hypothalamic GnRH input (485, 486). It
is the latter selective FSH rise that is dependent on activin, as
treatment with the activin B monoclonal antibody on the evening
of pro-oestrous attenuated the rise of serum FSH on early oestrous
(480). The second FSH peak is intrinsic to the pituitary because it
persists in culture when pituitaries are isolated at the time that the
second FSH peak would have occurred (487). Another argument in
support for activin-controlled FSH secretion is the ﬁnding of FSH
hypersecretion after ovariectomy in hypophysectomised rats receiv-
ing a pituitary graft under the kidney capsule and of inhibition of
this secretion by quenching the action of activin by follistatin (479).
Activins are also permissive for the stimulation of FSH production
by GnRH (488, 489).
Activin appears to be involved in the juvenile FSH rise in the
female rat. As already mentioned, it is well documented that FSH
plasma levels in rats increase to very high levels between the end of
the ﬁrst and second postnatal week, particularly in females (88–90),
and that the gonadotroph cell population expands rapidly to propor-
tions never obtained in later life (91, 490), raising the intriguing
question of whether this developmental change is also mediated by
activin B. Some answers to this question were given by Wilson and
coworkers (491, 492). They showed that activin bA subunit mRNA
reaches a peak level at 10 days of age and then falls gradually to an
adult level at day 21, whereas bB subunit mRNA level displays a
marked peak value at day 10 and has already fallen to normal adult
level by day 12. Moreover, Act-R-II mRNA was found to be
expressed diffusely over the entire anterior pituitary whereas mRNA
of Act-R-IIB, which is the preferred receptor for activin B, was
almost exclusively found in gonadotrophs, but there was no appar-
ent change in the level of Act-R-IIB during the second and third
week of life. These data suggest at least the possibility that activin B
can have an autocrine⁄paracrine role for up-regulation of FSHb
expression during the second week of postnatal life. Furthermore,
experiments with androgen and oestrogen antagonists in vivo and
with androgen agonists in pituitary cell culture have clearly shown
that oestradiol and testosterone are responsible for the rise in FSH
production at 2 weeks of life (492). Moreover, plasma levels of oes-
tradiol (493) and binding of oestradiol to its receptors (494) in the
anterior pituitary increase dramatically around postnatal day 10,
declining slightly thereafter, and the expression level of oestradiol
receptor-b mRNA is much greater in the gonadotrophs of immature
than of adult female rats (495). An additional sensitisation mecha-
nism for FSH production at 1–2 weeks of life is that the conversion
of testosterone to 5a-dihydrotestosterone, which is the preferred
form for binding to the androgen receptor and the preferential
androgen to stimulate FSH production (496), also increases dramati-
cally between days 10 and 15 of life (497), with this conversion
occurring mainly in the gonadotrophs (498).
Autocrine inhibin
The question whether there is also a negative tone of pituitary inhi-
bin on FSH secretion has not been deﬁnitely answered, but there
are data supporting this view. Kumar et al. (474) compared Act-R-II
null mice, which are unable to respond to endogenous pituitary
activin, with inhibin-a null mice, which cannot make inhibins; these
mice were also castrated to eliminate circulating inhibins from
gonadal origin. The inhibin-a null mice showed enhanced levels of
FSH plasma levels but the level of FSHb mRNA in the pituitary was
unchanged. Furthermore, in mice that lacked both inhibin-a and
the Act-R-II genes (474), FSHb mRNA levels were as low as in the
mice with only the Act-R-II gene disrupted and the absence of
inhibin increased serum FSH levels both in the presence and
absence of the Act-R-II (474).
Paracrine⁄autocrine follistatin
An important paracrine⁄autocrine modulator of activin-regulated
FSHb gene expression and FSH secretion is follistatin. This glycopro-
tein binds activin and in this way masks the binding domain of the
activin molecule, preventing it from binding to the Act-R-II; conse-
quently, activation of Act-R-I does not occur (472), resulting in bio-
neutralisation of activin. Follistatin has been shown to be present
in and secreted by pituitary FS cells (499). It was later found that
several pituitary cell types, including gonadotrophs, also express
follistatin (500–503). At midcycle, follistatin is expressed mainly by
LH gonadotrophs, but it is expressed by all other hormonal cell
types earlier in the cycle (503). The local availability of follistatin
appears to be important in orchestrating the efﬁcacy of locally
secreted activin B to drive basal FSH secretion (502, 504). GnRH,
gonadal steroids and plasma all decrease the expression of follista-
tin (481, 505, 506), as shown by GnRH immunoneutralisation and
GnRH antagonist treatments and by gonadectomy experiments,
providing evidence that these substances are physiological regula-
tors of follistatin. Activin and PACAP stimulate follistatin expression
(507).
Another level of differential FSH and LH regulation is via changes
in GnRH pulse patterns. At least in part, these patterns are trans-
lated in changes in inhibin, activin bB and follistatin expression
that in turn change the FSH : LH ratio (508). During the oestrous
cycle in the rat, pituitary follistatin levels are high before the pri-
mary gonadotrophin surge, decrease on pro-oestrous evening, and
rise again at midnight on pro-oestrous before returning to basal
levels on oestrous morning when the second FSH peak occurs (509,
510). The peak in follistatin mRNA levels precedes the peak in FSHb
gene expression by 6 h (510). The fall in serum inhibins, together
with pituitary follistatin following the primary surge, is thought to
facilitate the generation and bioavailability of the secondary surge
of FSH on oestrous morning, necessary for new follicle recruitment
for the next cycle (511, 512).
The NO system
NO is a gaseous transmitter that is produced intracellularly from
L-arginine through the enzyme NO synthase (NOS). NO plays an
important regulatory role in many tissues including the neuroendo-
crine system (513). There are three forms of NOS: type 1 (neuronal)
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and Ca
2+-calmodulin-dependent, whereas type 2 is inducible (iNOS)
and Ca
2+-independent. All three types are expressed in the anterior
pituitary (514, 515).
Distribution and regulation
nNOS is expressed primarily in gonadotrophs and FS cells (516,
517). There are important gender differences in cellular distribution,
and expression changes according to reproductive status. In male
rats, nNOS resides mainly in FS cells, whereas, in females, it is
mainly in LH cells (518). Gonadectomy causes nNOS up-regulation
in LH cells and down-regulation in FS cells and this can be reversed
by testosterone or oestradiol treatment (517–519). The effect of
gonadectomy is mediated by endogenous GnRH, as it was abolished
by treatment with a GnRH antagonist and the GnRH antagonist
also decreased basal NOS expression (519). A GnRH agonist
increased nNOS expression but only in gonadotrophs and not in FS
cells (519). nNOS activity ﬂuctuates with the oestrous cycle and
pregnancy⁄lactation. A steep rise in nNOS expression in gonado-
trophs (but not FS cells) occurs during the afternoon of pro-
oestrous and, again, this effect is abolished by treatment with a
GnRH antagonist (520). In lactating rats, LH cells overexpress nNOS,
whereas LH cell size decreases and serum LH levels become low
(518).
Actions of NO
The change in nNOS expression and the concomitant depression of
LH cell activity during lactation both suggest a role of the NO
system in down-regulating the HPG axis. At the hypothalamic
level, however, NO stimulates GnRH secretion whereas, in isolated
rat pituitary or dispersed cells, NO stimulates basal LH and FSH
secretion, with both actions being through a cGMP-independent
mechanism (517). By contrast, NO appears to inhibit GnRH-stimu-
lated LH release at the pituitary level. Several workers found that
the NO donor SNP signiﬁcantly reduced GnRH-induced LH secre-
tion, whereas the NOS inhibitor Me-Arg potentiated it (516, 517,
521). These data support an intracrine or autocrine negative feed-
back loop on GnRH stimulation of LH release (but not basal LH
release). However, anterior pituitary of pro-oestrous rats made
NO-deﬁcient by chronic treatment with a NOS inhibitor showed a
lower LH response to GnRH than that of normal controls (522). The
effect of an NO donor and a NOS inhibitor had clear effects on the
LH response but they depended on whether the pituitaries were
from normal or NO-deﬁcient rats, indicating the complexity of
the local NO actions (522). Possibly, NO can be inhibitory and
stimulatory, and it has been suggested that this may depend on
the cellular source of NO (518). NO from FS cells may inhibit
GnRH-stimulated LH release as, in cocultures of gonadotroph-
enriched populations with FS cell enriched populations, the LH
response to GnRH is blunted (94). Another aspect suggesting the
complexity of the NO system in the gonadotrophs was revealed by
looking at the mechanism of action of NO. Most NO actions are
established by activation of soluble guanylate cyclase by NO, result-
ing in a rise of cGMP (523). However, in isolated rat pituitary cells,
the stimulatory action of NO on basal LH and FSH secretion is
through a cGMP-independent mechanism (517). Moreover, cGMP
does not affect LH release (524). It is known that GnRH stimulates
cGMP levels in pituitary in vitro (blockable by a NOS inhibitor) (520)
and that treatment of pituitary slices with NO donors results in the
appearance of cells expressing cGMP, mostly gonadotrophs but not
FS cells (525). Together, these data support a cross-talk between
GnRH and the gonadotroph NO system on cGMP-dependent pro-
cesses. Below, whether another autocrine cross-talk via cGMP could
be established by the natriuretic peptide CNP in the gonadotrophs
is discussed.
The importance of the pituitary nNOS system has also been
illustrated by the ﬁnding that the nNOS promoter contains the
transactivation domain AF-2 of steroidogenic factor-1 (SF-1), an
essential transcription factor for gonadotroph differentiation. Dele-
tion of this promoter fragment strongly inhibits nNOS promoter
activity (526). The importance of nNOS has also been assessed in
vivo in mice with targeted disruption of the nNOS gene. Although
serious hypofertility was found (fewer oocytes in the oviducts),
pituitary responsiveness to GnRH was intact, suggesting that
compensatory mechanisms can take over control at the pituitary
level (841).
In humans, an interesting interaction of the NO system activated
by GnRH has been observed. In vivo treatment with a NOS inhibitor
attenuated the LH and FSH response to GnRH but this characteris-
tic was lost when simultaneously treated with oxytocin whereas, by
itself, oxytocin did not affect the response to GnRH (527)
Interestingly, in frog pituitary, NO increases both basal and
GnRH-stimulated LH release (528) and, in goldﬁsh, in which GH is
even more essential than in mammals for gonadal function, GnRH
stimulates GH secretion and this effect also is attenuated by
endogenous pituitary NO (529).
CNP
CNP is the third member of the NP family, comprising ANP, BNP
and CNP. As all NPs, it acts via a one-pass transmembrane receptor
with intrinsic guanylyl cyclase (GC) activity, located in the intracel-
lular domain (339). The highest tissue concentration of CNP is
found in the anterior pituitary where CNP is synthesised in a sub-
population of gonadotrophs (192). The A-type (GC-A) and B-type
(GC-B) receptors are selectively activated by ANP and CNP, respec-
tively, and are both expressed in the pituitary as well (192, 530,
531). Since the GC-B mRNA is detectable in gonadotrophs, CNP is a
candidate autocrine regulator of gonadotrophs (192). Such an auto-
crine action remains to be experimentally demonstrated. However,
the actions of exogenous CNP have been explored in primary pitui-
tary cell cultures and in the gonadotrophic cell line aT3-1 (192,
532), and these observations indeed support a putative autocrine
role. Strikingly, CNP robustly increases cGMP levels and the intra-
cellular free Ca
2+ concentration, but does not affect GnRH-stimu-
lated LH release. Nevertheless, GnRH reduced CNP-stimulated cGMP
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ing that there is cross-talk between the GnRH signal transduction
pathways and the CNP-activated pathways. Secondarily, a cross-talk
via cGMP may also be generated with the gonadotroph NO system.
Interestingly, ANP is also expressed in gonadotrophs and does stim-
ulate LH and FSH release (216).
Leptin
Since leptin is present in gonadotrophs (200, 201, 445, 446) and
the number of gonadotrophs that contain leptin increases at pro-
oestrous and during pregnancy, and since GnRH stimulates leptin
secretion in cultured pituitary cells (201), an autocrine function
may exist. Leptin has been shown to stimulate basal and to mag-
nify GnRH-stimulated LH and FSH release from rat pituitary in vitro
and from rat (218, 533, 534) and sheep (535) pituitary cell cultures.
However, in rats, the leptin receptor has been detected mainly on
somatotrophs (236), a ﬁnding pleading against an autocrine action
of leptin in gonadotrophs, unless leptin receptors on gonadotrophs
fell below detection limits in the respective study. In sheep, leptin
receptors have indeed also been located in gonadotrophs (536).
Interestingly, there may be a connection between leptin and the
NO system, described above, as leptin-induced LH release from iso-
lated pituitary appears to be mediated by NO, with the effect being
most pronounced in pituitary from pro-oestrous female rats (537,
538).
Final proof of leptin autocrine⁄paracrine action by immunoneu-
tralisation experiments still needs to be given.
NPY
Although NPY is secreted in portal blood (539), it is also synthesi-
sed in the pituitary gonadotrophs and released from this source, as
mentioned earlier. Several research groups have shown that NPY is
essential for ovulation. At pro-oestrous, its synthesis in the arcuate
nucleus and its release into portal blood is increased (540). At the
pituitary level, NPY augments the magnitude of the LH response to
GnRH during the pre-ovulatory LH surge (541). For this purpose,
NPY appears to act only when the appropriate endocrine milieu
that exists just before ovulation is present. In vitro, NPY augments
GnRH-stimulated LH secretion from anterior pituitary removed
from pro-oestrous, but not metoestrous, rats (542). When NPY
action is blocked by infusion of anti-NPY antiserum (539) or by
deleting the NPY gene in transgenic mice (543), the ovulatory LH
surge is signiﬁcantly attenuated. In pentobarbital-blocked rats,
ovulation can only be restored by combined treatment with GnRH
and NPY (544). One mechanism of sensitisation of the response to
NPY is enhancement of the expression of the NPY receptor Y1
under the inﬂuence of the pre-ovulatory increase in oestrogen
secretion (541, 545). Thus, the well known positive feedback of
oestrogen is realised partly via augmentation of NPY action. NPY
also acts as a facilitatory stimulus for the onset of puberty, as
shown by the effect of immunoneutralisation of NPY on the
release of LH and LHRH (546).
Before we can establish NPY as an autocrine factor, it remains
to be demonstrated whether immunoneutralisation of NPY in pitui-
tary cell cultures or selective deletion of NPY expression in the
pituitary decreases the LH response to GnRH.
PACAP
Although PACAP is present in portal blood, it may also have an
autocrine action on gonadotrophs, as already above. PACAP is tran-
siently present in the gonadotrophs during pro-oestrous (187, 188,
547). The peptide stimulates LH release in pro-oestrous pituitary
(548). Treatment with oestradiol or oestradiol + progesterone rap-
idly enhanced basal and GnRH- or PACAP-stimulated LH secretion,
whereas prolonged treatment with oestradiol and progesterone
reduced the response to GnRH (549). The peptide was also reported
to increase expression of aGSU but to depress FSHb (550). The lat-
ter appears to be brought about by stimulating follistatin gene
transcription in the FS cells that bear PACAP receptors (550, 551).
Thus, PACAP may set the balance between LH and FSH secretion in
favour of LH.
It is noteworthy that PACAP interacts with the NO system by
increasing nNOS expression and potentiating the cGMP rise in
response to GnRH (552); NADPH diaphorase staining revealed that
these changes occurred in gonadotrophs (552).
Endothelins
As already mentioned, ETs have been located in gonadotrophs and
are releasable as far as tested in monolayer cell cultures. ET recep-
tors are found on aT3-1 cells and ET1 has been shown to acutely
stimulate intracellular Ca
2+ and LH secretion in cultured pituitary
cells (553). These data should prompt studies investigating whether
the immunoneutralisation of ET would lead to attenuated LH
release.
ATP
The purine ATP, and the derivatives ADP and adenosine, are known
to induce various responses in a number of biological systems
(554). ATP is coreleased with neurotransmitters and hormones dur-
ing exocytosis and is believed to augment the exocytotic process
through an autocrine positive feedback. Also in the anterior pitui-
tary, ATP is costored with hormones in secretory granules and cose-
creted (555, 556). The gland has been shown to express different
subtypes of purinergic receptors: P1-R, P2Y-R and P2X-R, in a cell
type-speciﬁc manner (557) and their activation leads to ampliﬁca-
tion of intracellular free Ca
2+ responses to secretagogues (558). The
pituitary is also equipped with enzymes (ectonucleotidases) that
degrade extracellular ATP (559). The enzymatic cascade generates
ADP, the primary agonist for some P2Y-Rs, and adenosine, the ago-
nist for purinergic P1-R (560).
GnRH enhances ATP release from dispersed pituitary cells (555,
556). Addition of ATP to cultured pituitary cells produces a rapid
increase in intracellular free Ca
2+, blockable by a P2Y-R antagonist
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gonadotrophic cell line aT3-1. In perifused pituitary cells ATP
promptly caused a more than ten-fold rise of basal LH release
(556), with an agonist-order of potency typical for the P2Y-R.
Gonadotrophs were also reported to express functional P2X-Rs,
which are ion-channel receptors (562), that may have a role as
pace-making channels (563). Through these receptor channels, ATP
induces non-oscillatory, depolarising, slowly desensitising, and
rapidly deactivating Ca
2+ currents, leading to initiation of ﬁring in
quiescent cells, an increase in the frequency of action potentials in
spontaneously active cells, and a transient stimulation of LH
release. The ATP signalling is contextual, because inositol-1,4,5-tri-
phosphate-dependent oscillations were found to be facilitated,
slowed, or stopped, depending on ATP concentration.
The available data clearly suggest a putative autocrine role for
ATP in gonadotroph function, although it cannot be excluded that
ATP also acts in a paracrine way on other gonadotrophs in the
neighbourhood. The physiological conditions under which ATP
action takes place also remains to be studied.
Corticotrophs as autocrine⁄paracrine cells and targets
Corticotrophs transduce the stress response registered in the brain
towards peripheral organs. They do this directly by releasing ACTH
in response to CRH and vasopressin but also by transmitting this
response to other hormonal cell types in the pituitary. Again, tuning
of the corticotrophs via autocrine loops can be anticipated due to
the complexity and context of the stress phenomenon (Fig. 3).
Vasopressin and paracrine communication among
corticotrophs
It is well known that arginine-vasopressin (AVP) is one of the corti-
cotroph secretagogues. It releases ACTH via the V1b-R (564). In
addition, AVP enhances the responsiveness of corticotrophs to CRH
in terms of ACTH secretion (565) but not in terms of POMC gene
transcription (566). AVP plays an important role in chronic stress
(564) and appears to compensate for the lack of CRH drive on
ACTH secretion in CRH-R1 knockout mice (567). The main source of
AVP is the hypothalamic paraventricular nucleus but the anterior
pituitary itself contains AVP (568–570) and pro-AVP mRNA (569).
Pro-AVP mRNA is located mainly in corticotrophs, although AVP
immunoreactivity has been detected in all hormone-secreting cell
types except somatotrophs (571). Approximately 45% of the ante-
rior pituitary cells are AVP-immunoreactive (569). AVP is secreted
by cultured pituitary cells but this is not augmented by CRH (569)
and remains elevated during exposure to glucocorticoids, which is
consistent with its role in chronic stress situations. Glucocorticoids
even increase the coupling efﬁciency and signal transduction of the
V1b receptor (564).
To what extent pituitary AVP contributes to the output of pitui-
tary ACTH under basal conditions or during enhanced input of CRH
and AVP from the hypothalamus, however, remains unexplored. This
is surprising because highly selective antagonists of the different
AVP receptors are available that would allow experiments to dem-
onstrate an autocrine action of endogenous AVP.
Nevertheless, there are data supporting inhibitory and stimula-
tory paracrine control of corticotrophs amongst each other in rela-
tion to the actions of AVP in the pituitary. Not all corticotrophs are
responsive to CRH or AVP and a remarkable observation is that AVP
augments the number of corticotrophs that are responsive to CRH.
CRH also increases the percentage of corticotrophs that bind AVP
(572–574). The latter regulation is modulated by paracrine interac-
tions.
Inhibitory paracrinicity
Schwartz and Cherny (574) have demonstrated a peculiar auto-con-
trol system among corticotrophs in the rat that regulates the pro-
portion of AVP- and CRH-responsive corticotrophs, and this may
obviously modulate the overall responsiveness of the pituitary HPA
axis at the pituitary level. The authors showed that elimination in
culture of CRH target cells, by treatment with a CRH-toxin conju-
gate (taken up by receptor-mediated endocytosis, the toxin being
released intracellularly), did not result in a fall of basal ACTH secre-
tion, which was even elevated, despite the number of corticotrophs
and overall ACTH content being decreased by the treatment, sug-
gesting that CRH-responsive corticotrophs inhibit the secretion of
the other corticotrophs. A similar observation was later made using
sheep pituitary cells (575). This inhibitory paracrine mechanism was
conﬁrmed by means of the reverse haemolytic plaque assay (576).
By comparing the ACTH response of cells seeded at different densi-
ties, it was observed that the number of CRH-responsive cortico-
trophs increased to almost double when a certain distance between
the cells was exceeded, presumably because the paracrine factor
depressing responsiveness dilutes out and becomes ineffective
when distances between cell become too large. That factor appears
to be delivered by the CRH-responsive cells themselves because
selective laser-ablation of the CRH-responsive cells allowed ACTH
secretion in response to CRH by cells that before were not secreting
ACTH. The latter mechanism was proposed to have a role in holding
corticotrophs in reserve.
Stimulatory paracrinicity
There is also evidence for the existence of a stimulatory paracrine
factor released from non-CRH-responsive cells, as medium condi-
tioned by exposure to a pituitary cell population, in which CRH-
target cells were destroyed by a CRH-toxin conjugate, was found to
increase ACTH secretion in naive pituitary cells (574).
AVP also appears to be implicated in the local control of the
total size of the corticotroph cell population (577, 578). This popu-
lation expands after adrenalectomy and chronic stress and involutes
by glucocorticoid treatment. Adrenalectomy also increases cell mito-
sis in the pituitary but the bulk of mitotic cells do not express
ACTH. They may be progenitor cells or stem cells. AVP appears to
mediate the effect of adrenalectomy because, in V1b receptor null
mice and in mice treated with a V1b antagonist, this mitotic
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increment of corticotroph number after long-term adrenalectomy.
The question remains as to whether this population growth is
induced by the risen output of hypothalamic or of pituitary AVP or
both. Since destruction of the AVP neurones in the hypothalamus
did not affect basal ACTH levels, although it strongly reduced
stress-induced ACTH release (580) but was unable to prevent corti-
cotroph proliferation after adrenalectomy (581), it is possible that
adrenalectomy induces pituitary AVP to support basal ACTH secre-
tion and to mediate a trophic effect on the corticotroph population.
In support for the latter hypothesis is the ﬁnding that adrenalec-
tomy increases pituitary AVP content (568) and exogenous AVP
increases cell proliferation in the anterior pituitary (578, 582, 582).
Very interestingly, the same population of progenitor cells that
develops after adrenalectomy also proliferates after gonadectomy
(578). We also found enhanced cell mitosis in pituitary aggregate
cell cultures during the ﬁrst week of culture (116) and this mitotic
activity was for a large part in nonhormonal cells (393). Other
investigators found a three-fold increase in pituitary AVP secretion
after a 3-day culture period (570). Thus, there may be a relationship
between pituitary AVP and progenitor cell mitosis.
CRH and urocortin peptides
Pecori et al. (583) have provided evidence for an autocrine or at
least paracrine activity of CRH on corticotrophs in the anterior
pituitary. Combined in situ RT-PCR and immunocytochemistry dem-
onstrated the presence of CRH in corticotrophs and CRH was found
in the medium of anterior pituitary cell cultures. Incubation of
anterior pituitary cells with an anti-CRH antibody reduced basal
ACTH secretion compared to non-immune serum-treated controls.
The antibody as well as a-helical CRH(9)41), a CRH antagonist, also
blunted the ACTH response to K
+ and forskolin.
The recently identiﬁed urocortin peptides play an important role
in the HPA axis, in part by attenuating various functions activated
by CRH. The urocortin gene is highly expressed in the anterior pitu-
itary of the rat and human (584, 585). An autocrine or paracrine
action of urocortin is feasible because urocortin was localised in
corticotrophs in fetal sheep pituitary and transfection of sheep
pituitary cells in culture with urocortin antisense oligonucleotides
depressed ACTH secretion, whereas exogenous urocortin stimulated
ACTH release (586). In human, the great majority (75%) of urocor-
tin-immunoreactive cells were shown to be somatotrophs, whereas
20% were lactotrophs and only a few were corticotrophs, suggest-
ing that urocortin is a paracrine rather than an autocrine peptide
on corticotrophs. Urocortin II is also expressed in the anterior pitui-
tary (587), in the rat more speciﬁcally in the corticotrophs, where
its expression is increased by CRH and inhibited by glucocorticoids
(588). To date, no evidence for the expression of urocortin III in the
pituitary has been found (589).
CRH and the different urocortin peptides bind with similar afﬁn-
ity to the CRH1-R, but the afﬁnity of urocortin for the CRH2-R is
much higher than that of CRH, whereas urocortin II has no afﬁnity
for CRH1-R (590). Since CRH1-R is mainly expressed on cortico-
trophs and CRH2-R mainly on gonadotrophs (591), it can be
expected that urocortins have an autocrine and paracrine function
on both the HPA and HPG axis but this needs still to be demon-
strated experimentally.
The physiological signiﬁcance of CRH and urocortins within the
anterior pituitary needs to be further investigated but it can be
proposed that the presence of CRH and urocortins in the pituitary
may explain why POMC mRNA levels are not decreased during
hypothalamic-pituitary disconnection (584) and why humans with
panhypopituitarism due to agenesis or transsection of the pituitary
stalk still have ACTH secretion (592). Division of labour between the
hypothalamus and anterior pituitary for providing basal ACTH
secretion would make sense for a system that has been of crucial
importance for survival and evolution.
An interesting observation is that in lower vertebrates CRH stim-
ulates the release of TSH, and hence of aGSU, via the CRH2-R
(593). This phenomenon may pave the way to explore whether uro-
cortins inﬂuence the release of aGSU in mammals as well, particu-
larly because cells exist in rat as well as chicken pituitary that
express both POMC and aGSU (161).
Acetylcholine
A neurotransmitter in non-neuronal tissue
The anterior pituitary has been one of the ﬁrst non-neuronal tis-
sues in which a cholinergic system has been identiﬁed. Today, it
has become clear that extra-neuronal cholinergic systems are pres-
ent in many tissues (65–71). Anterior pituitary acetylcholine has
been established as a paracrine factor by Carmeliet and Denef (65,
66, 260, 594). Choline acetyltransferase (ChAT) has been demon-
strated in the cytoplasm of rat pituitary corticotrophs by means of
different polyclonal and monoclonal antibodies. Production and
release of acetylcholine was demonstrated in cultured rat anterior
pituitary cell aggregates using [
3H]choline as precursor. Acetylcho-
line synthesis was blocked by classical inhibitors of neuronal acetyl-
choline production. Both synthesis and release of acetylcholine are
increased by glucocorticoids. Also, the corticotroph cell line AtT20
expresses a functional cholinergic system.
The pituitary cholinergic system appears to be highly
context-dependent
Perifusion of anterior pituitary cell aggregates or organ-cultured
anterior pituitaries with the muscarinic agonist carbachol can stim-
ulate or inhibit basal PRL and GH release, depending on the hor-
monal environment. PRL release is stimulated in the presence of T3
but inhibited in the presence of T3 and glucocorticoid simulta-
neously; GH release is stimulated in the presence of T3 but inhib-
ited in the presence of glucocorticoid. A paracrine action of
endogenous acetylcholine could only be demonstrated for the
inhibitory component of acetylcholine on secretion. Indeed, in
perifused pituitary aggregates, muscarinic receptor antagonists
evoked a dose-dependent (0.1–100 nM) increase in basal PRL and
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ture medium. No effect of the antagonists was seen under condi-
tions in which carbachol showed a stimulatory effect on secretion,
indicating a stimulatory paracrine action is not active or desensi-
tised under basal conditions. Muscarinic antagonists also potenti-
ated the stimulation of GH release by the b-adrenergic agonist
isoproterenol and of PRL release by VIP in glucocorticoid-supple-
mented aggregates.
As shown in frogs, acetylcholine is a putative autocrine factor in
melanotrophs in the intermediate lobe of the pituitary. These cells
also express ChAT, and acetylcholine stimulates a-MSH release via
an M1-R (595–597). Whether endogenous acetylcholine has a simi-
lar action and when it is recruited physiologically, remains to be
studied.
Cross-talk with the NO system?
There are highly suggestive data that the cholinergic system cross-
talks with the NO system (1). FS cells express nNOS (2, 517, 518).
Carbachol inhibition of GH release in aggregates can be blocked by
the calcium channel blockers cadmium and verapamil (594), consis-
tent with the activation of nNOS by intracellular free calcium (3,
598). FS cells express muscarinic receptors, probably of the M1 type,
that mediate activation of phospholipase C and intracellular free
Ca
2+ rises (4, 599). Carbachol does not inhibit GH secretion in the
GH3 cell line cultured as aggregates (5, 594). The muscarinic inhibi-
tion of PRL release is abrogated by the NO synthase inhibitor
L-NAME (6, 600). Muscarinic inhibition of PRL release is more
prominent in pituitary cell aggregates from male rats than in those
from females (260), which is consistent with the knowledge that, in
male rats, nNOS resides mainly in FS cells whereas, in females, it
resides mainly in LH cells (7, 518). The inhibition of PRL release by
acetylcholine found in aggregates is lost when cells are attached to
cytodex beads, which precludes a tight contact with FS cells (260).
Putative functions of pituitary acetylcholine
The role of pituitary acetylcholine remains to be identiﬁed but sev-
eral data at least suggest some putative links. The glucocorticoid
dependency of paracrine inhibition of GH and PRL release suggests
a relationship of the pituitary cholinergic system with the modula-
tion of these hormone secretions during stress. The suggested
implication of the FS cell NO system (see above) in the inhibitory
response points towards a role of the pituitary cholinergic system
during immune or inﬂammatory stress. The FS cells are important
targets for inﬂammatory molecules in the pituitary and during
inﬂammatory events GH and PRL secretion change (see below).
Moreover, the pro-inﬂammatory molecule IL-1 was found to down-
regulate ChAT (601). IL-1 is known to activate the HPA axis and to
alter GH and PRL secretion via hypothalamic and pituitary sites
of action (see below). The inhibition of acetylcholine production by
IL-1 has biological sense as, during immune stress, GH and PRL
secretion increase, and inhibiting ChAT would result in less tonic
inhibition of these secretions by paracrine acetylcholine.
The pituitary cholinergic system might also be related to the
HPG axis. Inhibition of PRL release by acetylcholine is not uniquely
dependent on glucocorticoids and can be seen in the combined
presence of T3 and oestradiol (600). Here, a possible link may exist
with the NO system in gonadotrophs. Moreover, there is ChAT
expression also in some lactotrophs (65, 66, 260, 594) and this
expression may be affected by oestrogens, although this remains to
be demonstrated.
It is also interesting to relate the well-known rise in PRL plasma
levels during ageing to the pituitary cholinergic system, since basal
and TRH-induced PRL release become less sensitive to inhibition by
acetylcholine with age (602).
It is noteworthy that a subpopulation of POMC neurones in the
arcuate nucleus of the basal hypothalamus also expresses the ele-
ments of a cholinergic system (603, 604). POMC neurones in the
arcuate nucleus also coexpress CART and are central regulators of
energy homeostasis by suppressing food intake (456). Cholinergic
mechanisms are known to interfere in energy homeostasis. Nicotine
reduces appetite and body weight (605, 606) and a M3-R-mediated
cholinergic pathway operates downstream of the hypothalamic
POMC system, facilitating food intake (607). Just like POMC cells in
the arcuate nucleus (456), pituitary corticotrophs express CART and
a cholinergic system. Thus, it appears that the coexpression pattern
in POMC cells of the pituitary and hypothalamus are very similar to
each other, suggesting a concerted action of the expressed mole-
cules for a common aim. It would be worthwhile to evaluate
whether ACh co-operates with POMC-derived a-MSH and CART to
increase energy expenditure via a pituitary-located effect on GH
and PRL secretion. GH is catabolic in terms of promoting lipid and
carbohydrate breakdown (448). During periods of fasting, lipid util-
isation is promoted in part via GH secretion. Fasting increases
plasma GH levels in all species although, in the rat, the amplitude
of GH pulses is decreased but basal levels may be increased (608,
609). During fasting, pituitary GHRH receptor and ghrelin receptor
mRNA level and sensitivity to GHRH and ghrelin is increased (610,
611). Since acetylcholine is inhibitory on GH release in the presence
of glucocorticoids (594), it could be assumed that GH release in
response to a GHRH pulse will be smaller in the rat when the HPA
axis is activated. Since, during fasting, the HPA axis is activated
(612), the pituitary cholinergic system may contribute to the
decrease in GH pulse height during fasting in the rat.
Neuromedin U (NMU) and apelin
Several other peptides are located in corticotrophs and are putative
autocrine factors, namely NMU) (613, 614) and apelin (615). NMU
is anatomically and functionally linked to the HPA axis at several
levels. It ampliﬁes the stress response and reduces food intake
(616). In the rat, the pituitary is the tissue with highest expression
level of NMU mRNA. Signiﬁcant expression is also found in the
pars tuberalis (617). The pituitary does not appear to express the
NMU receptor NMU-R1 (618, 619) (which, until recently, was an
orphan receptor called FM-3 or GPR66) (620), but low level expres-
sion of the NMU-R2 (previously called TGR-1) was found (621,
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have not been reported. However, in obese (fa⁄fa) Zucker rats,
NMU expression in the anterior pituitary (and pars tuberalis) is
decreased, whereas fasting in rats lowers the anterior pituitary
NMU mRNA level, suggesting a role for NMU in adapting ACTH
secretion to lower energy expenditure during fasting (617). Another
interesting observation is that anterior pituitary NMU content
increases several-fold upon administration of TRH (623), an effect
established via increased T3 secretion, suggesting a link between
the HPT and HPA axes via NMU in the pituitary.
Apelin, the endogenous ligand of the human orphan GPCR APJ,
as well as the apelin receptor, are located in corticotrophs and mel-
anotrophs, although, in part, also in other unidentiﬁed cells (624).
Since apelin is capable of stimulating basal ACTH secretion (624), it
is a putative autocrine ACTH secretagogue but the secretion of ape-
lin still needs to be shown. Interestingly, apelin inhibits cAMP levels
(625, 626). The negative coupling to adenynyl cyclase also suggests
an inhibitory component in apelin action, which may be unmasked
in the presence of CRH.
Intermedin⁄adrenomedullin-2, the PRL-releasing factor
(PRF) from the neurointermediate lobe (NIL)?
It is known for many years from the work of Nira Ben-Jonathan
and Georges Nagy that the NIL produces PRL releasing factors that
appear to be important for the suckling-induced PRL release (627).
This factor may reach the anterior pituitary lactotrophs, particularly
those that are concentrated near the NIL (83), by diffusion or via
the small portal vessels. One of these PRFs may be oxytocin (628)
and another salsolinol (629), a dopamine-derived compound. There
are still other PRFs that can be distinguished from b-endorphin,
a-MSH, b-MSH, ACTH, TRH, angiotensin II, VIP and corticotrophin-
like intermediate peptide (630).
Recently, a novel peptide belonging to the calcitonin⁄
CGRP⁄amylin⁄adrenomedullin family has been discovered. It was
named intermedin (IMD), also known as adrenomedullin-2 (631,
632). The peptide is located in both central and peripheral tissues
and in the anterior and intermediate lobe of the pituitary (626,
631), more precisely in corticotrophs and melanotrophs, but not in
other cell types (631). IMD has a selective PRL-releasing activity in
pituitary cells of female (631), but not male rats (633), and inhibits
GHRH-stimulated (but not basal) GH secretion and cAMP levels in
the latter (633). A physiological role of IMD in lactation is sup-
ported by the ﬁnding that, during lactation, the expression of IMD
doubles. Conversely, ovariectomy causes a 90% reduction of IMD
expression in the pituitary whereas oestrogen treatment is stimula-
tory (631). On the basis of these data, IMD has been proposed to
represent the PRF from the NIL (631).
It is important to realise that the speciﬁcity in the action of the
individual calcitonin-like peptides is dependent on interaction with
coreceptors. Calcitonin classically acts through the calcitonin recep-
tor (CR), a GPCR, but the other calcitonin-like peptides act through
a heterodimer consisting of the CR or the calcitonin receptor-like
receptor (CLR), also a GPCR, and either one of the recently discov-
ered ‘receptor activity-modifying proteins’ (RAMP-1, -2 and )3)
(634). RAMPS are one-span transmembrane proteins that enable
CLR delivery to the cell surface and determine the selectivity of the
heterodimer for the individual calcitonin peptide. Thus, the
CR⁄RAMP-1 and CR⁄RAMP-3 heterodimer form amylin receptors,
the CLR⁄RAMP-1 heterodimer functions as the CGRP receptor, and
both CLR⁄RAMP-2 and CLR⁄RAMP-3 are functional adrenomedullin
receptors. Heterodimerisation of CLR with any of the three RAMPs
is sufﬁcient to generate an IMD receptor (631, 632).
The machinery for assembling selective receptors for the calcito-
nin peptides exists in the pituitary, and regulation ﬁts with a role
of IMD during reproduction. The mRNAs coding for RAMP-1 and -3
are detected in the anterior and intermediate lobes (631) and, dur-
ing lactation, the expression of RAMP-3 doubles whereas levels of
CLR and RAMP-1 do not change (631). Changes in RAMP-3 expres-
sion are also seen during the oestrous cycle and pregnancy in other
parts of the reproductive axis (274). As discussed in the latter
review, in most tissues under basal conditions, expression of
RAMP-3 is relatively low and mainly RAMP-2 is expressed. During
pregnancy, the expression of RAMP-3 is strongly increased whereas
RAMP-2 and CLR expression are depressed. Furthermore, regulatory
regions of the RAMP-3 gene contain oestrogen response elements.
Increased RAMP-3 expression has been suggested to switch the cell
from a state of high responsiveness to adrenomedullin (high
RAMP-2 expression under basal conditions) to a blunted respon-
siveness.
To further assess the putative function of IMD, further work is
needed to study the consequence of pharmacological IMD receptor
blockade or immunoneutralisation of IMD on suckling-induced PRL
release. Most interesting in this respect is the compound
BIBN4096BS, a nonpeptide CGRP antagonist that acts at the extra-
cellular interface of the RAMP-1–CLR protein interaction (635),
already indicating a proof of principle.
It is also most important to realise that calcitonin, adrenomedul-
lin and CGRP are made by gonadotrophs (see above) and IMD is
made by corticotrophs and melanotrophs. In this way, the
CLR⁄RAMP-3 could be an interface integrating signalling between
gonadotrophs, corticotroph⁄melanotrophs and lactotrophs, particu-
larly during pregnancy and lactation, when the entire pituitary
function is homeostatically adapted.
Thyrotrophs as autocrine⁄paracrine cells and targets
Thyrotrophs have attracted relatively less attention with respect to
their role as autocrine⁄paracrine cells or as paracrine targets. Yet,
to meet particular physiological needs in the body, the function of
these cells also needs to be co-ordinated with that of other pitui-
tary cell types. For example, during cold stress, the HPA axis is acti-
vated and there is a need for increased metabolic rate in order to
maintain body temperature. This is brought about by activation of
the HPT axis (636). During pregnancy and lactation, energy con-
sumption has to be adapted to the needs of the growing fetus and
newborn and, during starvation, energy expenditure needs to be
minimised. Under these conditions, the metabolic rate needs to be
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expected that corticotrophs and gonadotrophs may signal to thyro-
trophs. Furthermore, thyrotroph function may be adapted to chang-
ing needs through alterations in putative thyrotroph autocrine
factors, the synthesis and⁄or release of which may be affected by
peripheral or hypothalamic hormones.
Neuromedin B (NMB)
This peptide belongs to the bombesin peptide family, in mammals
together with gastrin-releasing peptide (neuromedin C) (183). The
anterior pituitary appears to be the tissue with the highest concen-
tration of NMB in the body (637). In rat, mouse and human, it is
mainly found in thyrotrophs (614). There is ample evidence for an
autocrine negative feedback of NMB on thyrotroph activity. In iso-
lated pituitary or cultures, exogenous NMB inhibits TSH secretion
whereas an anti-NMB antibody has the opposite effect (638, 639).
This can be explained by an autocrine action of endogenous NMB,
because thyrotrophs are not numerous and can occur rather isolated
in the tissue, so that paracrine actions on other thyrotrophs appear
unlikely. NMB also attenuates TRH-stimulated TSH release in vitro
(640). Consistent with the characteristics of an autocrine system,
NMB content in thyrotrophs increases with physiological changes
that have a negative impact on TSH secretion, such as fasting and
diabetes when TSH secretion is decreased (641). The pituitary con-
tent of NMB increases in hyperthyroidism and decreases in hypothy-
roidism. In hypothyroid pituitaries, thyroxine or T3 increases NMB
content within 30 min and this is associated with suppression of
TSH secretion (642). Somatostatin treatment, which inhibits TSH
secretion, also raises NMB content (643). The NMB autocrine loop is
physiologically related to energy homeostasis, as TRH and leptin rap-
idly decrease pituitary NMB levels, which, in turn, might increase the
efﬁcacy of TRH on TSH release (644). Mice with a disrupted NMB
gene display slightly enhanced TSH plasma levels, reduced T3 levels,
increased TRH receptor mRNA level in the pituitary and an enhanced
TSH response to TRH compared to wild-type mice, demonstrating
that the autocrine action of NMB may also operate in vivo (645).
Leptin
As already mentioned earlier, leptin is found in various cell types in
the anterior pituitary, including thyrotrophs. Leptin decreases pitui-
tary NMB levels (644). These data may point towards an inter-rela-
tionship between leptin and NMB in the control of TSH secretion at
the pituitary level during adaptation to nutritional status. When fat
stores are high, circulating leptin is high and TSH secretion should
not be restrained. However, during starvation, when circulating lep-
tin is low, NMB would rise, which, in turn, would result in less TSH
release, and this would help saving energy stores. This reasoning is
conﬁrmed by in vivo observations that, in normal fed rats, serum
TSH levels increased and pituitary NMB content decreased 2 h after
subcutaneous injection of leptin (644). There is direct evidence for
an autocrine or paracrine action of endogenous pituitary leptin
(646). In isolated pituitaries from hyperthyroid rats (in which NMB
is high), leptin reduced TSH release whereas antileptin antiserum
increased TSH secretion. In pituitaries from hypothyroid rats (in
which NMB is low), however, there was no effect of leptin nor of
leptin antiserum on TSH secretion. These data suggest that the lep-
tin–NMB–TSH axis is affected by thyroid negative feedback.
AVP
This peptide is known to render more cells responsive to CRH (see
previous section). The identity of these target cells has not been
established (647) but one candidate is the thyrotroph. It has been
shown that almost as many thyrotrophs as corticotrophs bind AVP
and part of these thyrotrophs starts expressing POMC rapidly when
the animals had been subjected to cold stress in vivo, an effect that
could be simulated by AVP treatment in vitro (572).
Paracrine control by nonhormonal cells
The nonhormonal cell population of the anterior pituitary represents
a substantial proportion of the pituitary cell population. Based on
estimates by means of single-cell RT-PCR, we count approximately
30% in 14-day-old rats and approximately 10–20% in adult rats
and mice as being nonhormonal (648, 649). Part of the nonhor-
monal cells may be degranulated hormonal cells in a quiescent
phase of their secretory cycle but they remain poorly deﬁned as a
population due to lack of a biochemical marker. Their proportional
number appears to depend on the hormonal status since reciprocal
changes in the number of nonhormonal cells and of GH cells or
PRL cells have been observed after treatment with glucocorticoids
(increasing the number of GH expressing cells) (Pals and Denef
unpublished observations) or T3 (increasing the number of PRL
expressing cells) (648). The other nonhormonal cells include FS cells
(5–10%), dendritic cells (650, 651), macrophages (650), endothelial
cells, pericytes (see below), ﬁbroblasts, transferrin-positive cells
(652) and, as recently identiﬁed, ‘colony-forming cells’ (653–655),
nestin-positive cells (656) and cells displaying the peculiar capacity
of exporting the dye Hoechst-33342 (657). The latter cells are called
‘side population’ (SP) cells on the basis of their sorting behaviour in
a ﬂow cytometry system, and amount to approximately 2% of the
cells in mouse pituitary (657).
The nonhormonal cells are small- to medium-sized and display
low granularity. When dispersed and sedimented at unit gravity,
they remain in the upper layers of the sedimentation gradient sys-
tem (656). As examined by ﬂow cytometry, most FS cells do not
sort within the SP but between the SP population and the bulk of
hormonal cells (657). Thus, with appropriate machinery, it is possi-
ble to study subpopulations of nonhormonal cells with respect to
their putative paracrine actions.
‘Side population’ cells may have local activities in cell
renewal
The SP cells include nestin-positive cells (656) and cells expressing
stem cell antigen-1 (sca-1) and markers typical for stem cells in
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as Lhx4 and molecules belonging to the Notch, Sonic hedgehog
and Wnt signalling pathways (657). On the basis of the latter
expression proﬁle, SP cells are suspected to include pituitary stem
cells or early progenitor cells. However, whether these are
stem⁄progenitor cells of hormonal or nonhormonal cells or both,
remains unknown. The stem cell⁄progenitor cell hypothesis is
further supported by the ﬁnding that the SP cells spontaneously
make proliferating ‘spheres’ when kept in suspension culture (656)
and grow rapidly in monolayer culture (656) but not in a three-
dimensional cell culture system in which hormonal cells are present
(648). On the other hand, stem cell markers and early embryonic
markers may be phenotypic features of cells with trophic roles, as
is the case in embryonic tissue. According to this view, SP
cells⁄nestin-positive cells may play a role in local homeostasis and
tissue remodelling, particularly because their number increases in
response to various growth factors, such as leukaemia-inhibitory
factor (LIF), FGF-2 and EGF, and in response to activating the Notch
pathway (658), and as in aggregate cell culture nestin-positive
cells organise in a network with long cellular extensions (648).
Nestin-positive cells display a high mobility when plated on
collagen-coated plastic (656), suggesting their potential to migrate
to particular targets. Nestin-positive cells have their unique pheno-
type because nestin does not localise in ﬁbronectin-immunoreactive
cells (mesenchymal cells) or sporadic cells expressing a-smooth
muscle actin (656). However, nestin-positive cells often codistribute
with the latter cells, mostly around capillaries (656).
FS cells are the best characterised among nonhormonal
cells
The characterisation of FS cells has been considerably improved
since these cells can be identiﬁed on the basis of both cellular and
functional molecules. Most if not all FS cells express the S-100
protein (82). The functional marker of FS cells is uptake of the
ﬂuorescent dipeptide b-Ala-Lys-N-AMCA (659). Several FS cell
lines have been produced, such as TtT⁄GF (mouse) (660), Tpit⁄F1
(mouse) (661), FS⁄D1h (rat) (95) and PDFS cells (human) (662).
Recently, transgenic mice have been generated that express
green ﬂuorescent protein under the direction of the S-100 gene
promoter (663).
Micro-anatomical architecture of FS cells suggests a role of
FS cells in microcirculation of nutrients, ions and waste
products in the pituitary
FS cells form two microanatomical structures (Fig. 7), which may
have a large impact on pituitary cell physiology. In the centre of
the hormonal cell cord (lobule), they can arrange in clusters and
form follicles, usually of submicroscopic size in the rat but in
other species, including human, of a larger size (664, 665). In the
follicles, numerous microvilli protrude and some cilia are present.
Follicle-forming FS cells are polarised. At the apical pole, bordering
the follicle, they form tight junctions among each other, although
not always fully sealed (666), and, more laterally, junctions of the
‘zonula adhaerens’ type (desmosomes) (664). The basolateral side
makes contact with the hormonal cells and with other FS cells,
and extends processes that end on the basal membrane surround-
ing the cell cords (Fig. 7). A second group of FS cells extends
long cytoplasmic processes between the hormonal cell types
within each glandular cell cord (664). These processes form inter-
cellular junctions, mostly of the zonula adherens-type, amongst
each other (667–669), but they are also eletrotonically coupled
through gap junctions (665). Some FS cells make intimate foot
processes with the basal membrane of the extra-vascular spaces
at the periphery of the cell cords (664, 665). In some species FS
cells located in the periphery of the cell cords are juxtaposed in
a way that they form sinusoid-like spaces (670). Intercellular
lacunae are also often seen between hormonal cells (664).
Apparently, lacunae between hormonal cells, sinusoid-like spaces
surrounded by FS cells and peri-vascular spaces form a micro-
channel system within the pituitary, through which hormones,
paracrine factors, nutrients, ions and waste products can circulate.
Such a channel system is thought to play an important physio-
logical role, although the precise details and regulation of ﬂow
remain obscure.
Some functional importance can also be inferred from studies on
the development of FS cells and follicles. In infant rats (10 days of
life) the FS cell follicles are elongated and participating FS cells
have a columnar shape without cellular extensions and displaying
very little junctions. Later on (30 days), they separate into smaller
follicular units and start making extensions and junctions, especially
tight junctions (665). It appears therefore that the mico-channel
function is more related to the mature pituitary physiology than to
the development of the gland. In fact, before postnatal day 10, very
little S-100 is expressed in the pituitary, although this expression is
induced as soon as the pituitary cells of newborn rats are estab-
lished in aggregate cell culture (648; Pals and Genef, unpublished
observations).
In a series of elegant in vitro experiments, using a near-homog-
enous FS cell population from bovine anterior pituitary or pars
tuberalis, Ferrara and colleagues presented strong evidence that
FS cells can make tight and functionally polarised epithelia,
displaying the typical ion transport characteristics of such epithelia
(671, 672). Monolayers of these FS cells, grown on polycarbonate
ﬁlters and placed in Ussing chambers, show a transepithelial
potential difference of approximately 1.1 mV and a short-circuit
current, consistent with transepithelial ion transport. These conﬂu-
ent cultures also made domes, a typical feature of cultures of
transporting epithelia. The current was inhibited by ameloride
applied at the mucosal surface and further depressed by ouabain
applied at the serosal surface, indicating a current made by active
Na
+ absorption. Also, the domes collapsed after treatment
with ameloride (671). Interestingly, the current was increased by
b-adrenergic agonists, prostaglandin E2, bradykinin and lysine
vasopressin (671, 672).
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2+ waves from cell-to-cell suggest a role for
FS cells in co-ordinating cellular activity
Of utmost functional importance is that FS cells make gap junc-
tions, mostly with the adjacent FS cells (665) but also with a few
hormonal cells (673). Junctions among FS cells, however, are
incomplete and do not seal off compartments from diffusion of
biological molecules; intercellular spaces (between hormonal cells)
are also freely accessible for diffusing molecules (668, 669). FS cells
are excitable and electrotonically coupled through their gap junc-
tions, as shown by rapid transduction of Ca
2+ currents over long
distances in the gland (674). On this basis, they are thought to co-
ordinate activity of hormonal cells. Such co-ordinated activity has
been demonstrated at least for somatotrophs. Large clusters of GH
cells, visualised by labelling them transgenically with GFP driven
by the GH promoter, can display simultaneous intracellular Ca
2+
transients (675, 676).
Consistent with a function of FS cells in co-ordination of glandu-
lar cells is the observation in the mink, that the expression of the
gap junctional protein connexin-43 increases in parallel with
increased activity of the PRL cells in the breeding season (677).
Also in the rat, there is an obvious correlation between the
number of gap junctions and reproductive maturation (665). In the
immature pituitary, gap junctions are poorly developed, but there is
a steep rise at puberty. During the oestrous cycle, their number is
lowest at dioestrous. There is an increase at the end of pregnancy
and during lactation. GnRH and testosterone markedly increase the
number of gap junctions.
The role of follicles remains obscure but the structures are
thought to be involved in intercellular transport of metabolic
products and ions (82). FS cells also may have a role in phago-
cytosis as microscopic images showing phagocytised cell debris
are more conspicuous when certain hormonal cells regress after a
period of hyperplasia (82).
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Fig. 7. Tissue architecture of the anterior pituitary showing the epithelial cell cords with hormonal cells and folliculo-stellate (FS) cells, the capillaries (C) with
fenestrated endothelial cells (EC) and connective tissue (CT). The cell cords are a cluster of endocrine cells surrounding an aggregate of FS cells that make a
follicle (F). FS cells also make a meshwork between the hormonal cells, making junctions among each other (thick lines) and extending foot processes (f) end-
ing on the basal membrane (BM) in the periphery of the cord. The cords are surrounded by BM, which may have extensions between some cells. A second BM
surrounds the capillary vessels and between these two some connective tissue resides. Small and larger lacunae are present between hormonal cells. Paracrine
substances may circulate from cell-to-cell but also could be released in these lacunae and reach more remote places. FS cells make gap junctions mostly
among each other, but occasionally also with some hormonal cells. Hormonal cells can make interdigitations with FS cells (small arrows) to favour cell-to-cell
communication. Adapted from Vila-Porcile (664).
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to immune stress and inﬂammation (Fig. 8)
The anterior pituitary drives the response to inﬂammatory
stress
It has been well established that during immune and inﬂammatory
stress, such as induced by bacterial endotoxin (lipopolysaccharide;
LPS), secretion of ACTH (678) and of GH and PRL (679) is
enhanced whereas pulsatile release of LH (680) and TSH (681) is
inhibited. Although this response is initiated in hypophysiotrophic
areas in the hypothalamus, which in turn affects pituitary hor-
mone release via the hypothalamic-releasing⁄inhibiting hormones
(682), actions of LPS also occur directly at the pituitary level.
Deafferentation of the hypothalamus or surgical removal of the
medial hypothalamus does not abolish the activation of the HPA
axis by endotoxin (683, 684). Activation of the HPA axis by signals
from immune-activated lymphocytes was suggested by Besedovsky
in 1981 (59, 685), who observed that cultured immune cells,
stimulated with mitogens or antigens in vitro, released sub-
stance(s) in the supernatant capable of eliciting an adrenal
response after intraperitoneal injection. At that time the factor(s)
was called ‘glucocorticoid-increasing factor’. Several more recent
observations support the essential role of the pituitary itself in
driving, at least in part, its response to inﬂammation. After abol-
ishing the hypothalamic drive of the stress response by transgenic
elimination of the CRH-R1 in mice, the activation of HPA axis by
local inﬂammation with turpentine remained pronounced (567). In
the latter mice, basal ACTH secretion and the stress response is
mediated by AVP but the rise in ACTH and corticosteroid secretion
was preserved even after immunoneutralisation of AVP in the
latter CRH-R1-null mice (567). CRH knockout mice also retain the
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Fig. 8. Schematic representation of the paracrine loops thought to act between folliculo-stellate (FS) cells and hormonal cell types and of autocrine loops in
FS cells. Interrupted lines indicate hypothetical interactions proposed on the basis of the presence of the indicated factors in the cell and their pharmacological
effects on the same cell. ﬁ , Stimulatory effect; ^, inhibitory effect; ABC-A1, ATP binding cassette A1 transporter; ACTH, adrenocorticotrophic hormone; CRH,
corticotrophin-releasing hormone; GC, guanylate cyclase; FGF, ﬁbroblast growth factor; FS, folliculo-stellate; GH, growth hormone; GHRH, growth hormone-
releasing hormone; GnRH, gonadotophin-releasing hormone; IL, interleukin; iNOS, inducible nitric oxide synthase; LH, luteinising hormone; LIF, leukaemia-inhib-
itory factor; LPS, lipopolysaccharide; MIF, migration inhibitory protein; nNOS, neuronal nitric oxide synthase; NO, nitric oxide; PACAP, pituitary adenylate
cyclase-activating peptide; POMC, pro-opiomelanocortin; PRL, prolactin; TGF, transforming growth factor; TRH, thyroid-releasing hormone; VEGF, vascular endo-
thelial growth factor; VIP, vasoactive intestinal peptide.
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local inﬂammation but this no longer occurs after hypophy-
sectomy (686). Thus, it is clear that a direct effect at the pituitary
and⁄or adrenal level by molecules derived from immune cells or
microorganisms is essential.
FS cells belong to the dendritic cell meshwork of the body
FS cells have characteristics of immune cells. Part of the FS cells
expresses markers and functional molecules of monocytes and
dendritic cells of the immune system (650). FS cells are now
considered to be members of the dendritic cell meshwork
throughout the body, together with Langerhans cells in the skin
and lymphatic system, ‘veile’ cells, and lymphodendritic and
interdigitating cells in a number of tissues (687). All these cells
are antigen presenting cells and most of them express S-100,
CD1, CD45, CD54, F418, MHC class I and II antigens, Fc and
complement receptors (687).
FS cells are targets for inﬂammatory molecules
A potent stimulus for production of the pro-inﬂammatory cyto-
kines, IL-1, IL-6 and TNF-a by stimulated peripheral immune cells
is LPS (688). All these cytokines, including LPS itself, target FS
cells (95, 689). FS cells express CD14, which binds the LPS⁄LPS-
binding protein complex and Toll-like receptor type 4, which
transduces the LPS signal (689). LPS is known to rapidly activate
transcriptional activity of NF-jB, a transcription factor that regu-
lates the expression of many pro-inﬂammatory cytokines, and
this occurs in cells scattered throughout the anterior pituitary
(690). Through this action LPS induces expression of IL-1b, IL-1a
converting enzyme, IL-1 receptor antagonist and TNF-a (690,
691).
In pituitary monolayer cell cultures, IL-1 stimulates the release
of ACTH, LH, GH, and TSH, whereas it inhibits PRL release at con-
centrations within the range reported for IL-1 in serum (692,
693). However, except for ACTH and GH, the latter response is
not a replicate of what happens when LPS is administered in vivo.
Thus, there is an interplay between hypothalamic and pituitary
responses.
The anterior pituitary produces cytokines
Various pro- and anti-inﬂammatory cytokines are produced by the
anterior pituitary (e.g. by FS cells). The ﬁrst cytokine to be identi-
ﬁed in the pituitary was IL-6 (694, 695) and we have shown that
FS cells are the main cells producing this cytokine (696, 697).
Although IL-6 is released from the local inﬂammatory site (698)
and circulates in plasma, local IL-6 from FS cells is involved in
the activation of the HPA axis. Indeed, in CRH knockout mice that
are still capable of a partial HPA activation via AVP (567), an IL-6
immunoneutralising antibody abolishes this HPA activation (686,
699). An antibody blocking LPS action at CD14 abolished both
LPS-induced IL-6, as well as ACTH secretion in aggregate cultures,
and a neutralising anti-IL-6 antibody also blocked LPS-induced
ACTH secretion in pituitary cell aggregates (700). Interestingly, the
latter effect was not seen in monolayer cultures, indicating that
intimate intercellular contact is required as is the case in aggre-
gate cell cultures. IL-6 receptors are expressed in corticotrophs
and IL-6 can stimulate ACTH secretion directly at the pituitary
level (701). The production and release of IL-6 is stimulated by IL-
1 in rat anterior pituitary cells in vitro (702) and IL-1 and IL-6
act synergistically in stimulating ACTH secretion in vivo (703). Also
LPS directly stimulates IL-6 release from FS cells (701). Similar
local actions of FS cell cytokines appear to be involved as far as
the activation of pituitary POMC gene is concerned during inﬂam-
mation (704).
The paracrine action of IL-6 observed in vitro is relevant for the
in vivo situation because peripheral administration of a neutralising
IL-6 antibody or elimination of the IL-6 gene in transgenic mice
results in a signiﬁcant blunting of the plasma corticosterone
response to local inﬂammation (698). Furthermore, also in mice
infected with murine cytomegalovirus, IL-6 is mediating the activa-
tion of the HPA axis as shown by IL-6 immunoneutralisation in
mice in which the central drive of the HPA axis is abolished by
CRH gene deletion (686). Remarkably, in mice deﬁcient in either
CRH or IL-6, LPS activates the HPA axis less than in wild-type mice
but signiﬁcantly more than in mice deﬁcient in both CRH and IL-6
(705), suggesting the appearance of compensatory mechanisms
during severe depletion of stress mediators.
It should be noted that the action of IL-6 is downstream of IL-1,
as both induction of IL-6 and activation of HPA axis are inhibited
by transgenic inactivation of type I IL-1 receptor (698). Whether
this also is the case for the paracrine action of IL-6 in the pituitary
remains to be studied.
IL-10, an important anti-inﬂammatory cytokine, appears to be a
regulator in the activation of the HPA axis during immune stress.
IL-10 and its receptor are expressed in the anterior pituitary (706,
707). It stimulates ACTH production in vivo and in vitro (706, 708).
However, IL-10 knockout mice secrete more corticosterone during
immune stress than wild-type mice (709), suggesting negative con-
trol of the HPA axis by IL-10. In human and murine pituitary, IL-11
and IL-11-R mRNA expression has been demonstrated and, as far
as tested in corticotroph AtT-20 cells, IL-11 stimulates ACTH secre-
tion and POMC gene transcription (710). The exact pituitary action
of IL-10 and IL-11 and their site of production need to be explored
further.
Another important endotoxin-inducible cytokine in FS cells is LIF
(711). In vivo, LIF enhances POMC expression and ACTH secretion in
synergy with CRH. LIF is important in mediating the pituitary
response to inﬂammatory stress as transgenic disruption of the LIF
gene weakens ACTH secretion (712). However, although null muta-
tion of either CRH or LIF blunts the LPS-induced HPA activation,
mice in which both CRH and LIF genes were deleted show a normal
HPA axis response to LPS (713), showing that plasticity in the pitui-
tary can compensate for the lacking factors. The latter animals
show very high expression of TNF-a, IL-1b and IL-6 in the pituitary
(713).
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inhibits the HPG and HPT axis
Also, in this respect, FS cells are contributing. IL-6 from FS cells
stimulates the release of PRL and gonadotrophins in pituitary cell
cultures (714), although other studies found it to stimulate LH but
inhibit FSH secretion (701, 715). Bilezikjian and colleagues have
shown that LPS enhances expression of follistatin and activin B in
the pituitary in vivo (716), that FS cells are targets for IL-1 (95) and
that IL-1 augments the production of follistatin both in vivo and
in vitro, thereby attenuating FSH output in response to activins
(716). Noteworthy, the latter effects were not mimicked by LPS or
IL-6 in vitro, although they were in vivo. After LPS treatment, IL-1
appears in rat thyrotrophs (717). IL-1 inhibits TSH secretion (718).
FS cells also contain and release macrophage migration inhibitory
protein (MIF) and MIF release is enhanced by endotoxin and gluco-
corticoids (719). As far as has been tested in the FS cell line TtT⁄GF,
recombinant MIF did not affect basal IL-6 release but antagonised
the inhibition of IL-6 release by glucocorticoids, a pro-inﬂammatory
action typical for MIF on classical immune cells (719). MIF has a
synergistic effect on LPS.
FS cells express several GPCRs possibly modulating the FS
cell responses to immune stress
FS cells express b1 and b2-adrenergic receptors (720), acetylcholine
(599), VIP and PACAP receptors (721), angiotensin II receptor-1
(722), adenosine A1 and A2B receptors (723) and the TSH receptor
(724). Ligands of some of these receptors are known to modulate
the function of immune cells. For example, in macrophages, VIP
and PACAP prevent iNOS transcription by inhibiting NF-jB and IFN
regulatory factor 1 activation. Thus, these GPCRs may function in a
feedback scenario to avoid overactivation of the HPA axis, which
would lead to immunosuppression by corticosteroid. In FS cells, VIP,
PACAP and agents that stimulate cAMP accumulation increase IL-6
production (701). Also, calcitonin was recently found to induce IL-6
production in FS cells (725), representing a putative feedforward
mechanism.
Inﬂammatory stress may also implicate the pituitary
tachykinin system (e.g. substance P, neurokinin A and B)
LPS was reported to decrease neurokinin A concentration in parallel
with PRL secretion in the anterior pituitary (726). Since Substance P
may have a paracrine PRL-releasing action (727), the decrease of
neurokinin A by LPS may be a mechanism to attenuate excessive
PRL secretion during immune stress. It remains unknown where the
LPS-induced neurokinin A production is located. Since LPS targets
FS cells, they are candidates but, to our knowledge, no data are
available to support this hypothesis, the main cell types producing
tachykinins in the pituitary being somatotrophs and thyrotrophs
(728).
It should be noted that the anterior pituitary also shows vagal
innervation from nodose ganglion (729), the nerve endings showing
expression of Substance P and CGRP and making close contacts
with lactotrophs, somatotrophs, corticotrophs and thyrotrophs
(730–734), but not with FS cells (735). Whether these nerve ﬁbres
are activated by locally released cytokines and whether Substance P
and CGRP are involved in modulating these actions remains unex-
plored. The issue is important because a neural pathways exists in
the transmission of inﬂammatory signals to the brain via vagal
afferents activated by locally released IL-1 (736, 737).
The actions of cytokines at the pituitary level appear
important for the immune system itself
In a recent review (738), it was noted that GH, PRL and thyroid
hormones inﬂuence the functioning of the immune system but that
these hormones are not obligate for primary lymphopoiesis or for B
and T cell-mediated immune responses. Pituitary hormones most
likely have a protective action during chronic states of inﬂamma-
tion or other forms of natural prolonged stress. Under particular
circumstances, one or more of these hormones can stimulate
immune cell function. For example, during pregnancy and lactation,
which are physiological states of stress due to the many increased
metabolic demands, PRL, GH, thyroid hormones and glucocorticoids
are elevated. Glucocorticoids are needed to utilise more glucose
and to mobilise protein from mother to fetus. However, the
immune-suppressive effects of glucocorticoids might be detrimental
and it is thought that the rise of PRL output during pregnancy has
an adjuvant role in protecting the immune system from a too pro-
found suppression. Also, GH and thyroid hormone are found to be
protective during times of stress.
Direct feedback from pituitary hormones to FS cells?
In view of the fact that secretion of all pituitary hormones is
altered during immune stress, it has been explored whether FS cells
express receptors for pituitary hormones. The TtT⁄GF cell line indeed
expresses mRNA of GH-R, TSH-R and ACTH-R, but not of LH-R,
FSH-R and PRL-R (739). This would allow ultra-short feedback
actions of these hormones on FS cell signalling to the hormonal
cell types that are targeted during immune stress, although this
requires experimental veriﬁcation.
FS cells may exert scavenger functions through generation
of NO (Fig. 8)
Prolonged pituitary activation during immune and other stresses
should not lead to excess glucocorticoid hormone production,
because this would lead to inhibition of reproduction and to
immune suppression, which would predispose to infection or even
tumour progression. It is therefore a homeostatic imperative that
internal negative feedback loops exist to avoid these digressions. FS
cells appear to operate as an interface in these homeostatic reac-
tions as they appear to blunt many stimulated activities of hormonal
cells. By making a meshwork with junctional complexes, FS cells cre-
ate functional cell groups and compartments in the pituitary (665,
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of secreted material (668, 669). Scavenging by FS cells is based on
functional inhibition of hormonal cells by material released by them.
This was demonstrated by experiments in which hormonal cells were
mixed with cell populations enriched in FS cells. When a dispersed
cell preparation consisting of approximately 65% FS cells was coag-
gregated with a highly enriched populations of hormone-secreting
cells and the coaggregates, after 5 days in culture, were perifused
with various secretagogues, the stimulation of PRL release by TRH
or angiotensin II, of GH release by GHRH and adrenaline, and of LH
release by GnRH, was blunted, compared to aggregates consisting of
the hormonal cells only (94). Interestingly, addition of FS cells also
weakened the secretory response to inhibitory signals such as dopa-
mine and somatostatin on PRL and GH release, respectively (668).
Under what physiological or pathological conditions FS cells are
recruited to attenuate excesses in hormone responses remains to be
determined, but it is possible that cytokines, liberated during the
activation of the HPA, HPG and⁄or HPT axis during immune stress
may be such mediators or that the FS cells may exert a tonic inhibi-
tory tone. In support for this hypothesis are experiments with pitui-
tary cell aggregates treated with IFN-c and other cytokines.
Prolonged exposure of pituitary cell aggregates to IFN-c resulted in
an inhibition in the secretory response of ACTH, GH and PRL to vari-
ous secretagogues (740). Also TNF-a and IL-6, but not LPS or IL-1,
had an inhibitory action on CRH-induced ACTH release. This inhibi-
tion was only seen when FS cells were present in a sufﬁcient num-
ber (741). The factor mediating this apparent scavenger effect is, at
least in part, NO (742). nNOS is expressed in FS cells and iNOS can
be induced in FS cells (but also in some non-identiﬁed nonhormonal
cells) by IFN-c (743).
Also, TNF-a may recruit FS cells to blunt other hormonal responses
during immune stress. TNF-a is one of the ﬁrst molecules to appear
in blood during inﬂammation. It is also expressed in the anterior
pituitary (744), although the cell type of production remains
unknown. TNF-R1 and TNF-R2 mRNA are detectable in the FS cell-
derived TtT⁄GF cell line (745), suggesting that scavenging actions of
TNF-a are mediated by FS cells. Although TNF-a was found to stimu-
late basal ACTH, GH, and TSH, but not PRL secretion in hemipituitar-
ies and dispersed cells upon an acute exposure (746), prolonged
(> 4 h) treatment with TNF-a did not affect basal ACTH secretion
but depressed CRH- and AVP-stimulated ACTH production and abol-
ished the potentiation of CRH-induced ACTH release by AVP (747).
The protein also was ineffective on basal GH and LH secretion, but
did inhibit GHRH-stimulated GH and GnRH-stimulated LH release
(744, 747). TNF-a-induced inhibition of PRL secretion has been
shown to be mediated by NO (748). Of importance, TNF-a augmented
GHRH-stimulated GH release in sheep pituitary cell cultures, indicat-
ing that species-speciﬁc mechanism are to be examined (749).
FS cells mediate very rapid negative feedback of
glucocorticoids via annexin-1 (Fig. 8)
The latter function has been extensively studied by Buckingham
and colleagues. Annexin-1 (lipocortin 1) has originally been identi-
ﬁed as a glucocorticoid-induced protein that mediates the anti-
inﬂammatory action of the latter hormone in the immune system.
Glucocorticoids have a negative feedback on pituitary ACTH secre-
tion and production at the level of the hypothalamus and the pitui-
tary via classic genomic interactions. Glucocorticoids, however,
exert also a much faster negative feedback, detectable within 0.5–
1.0 h after a rise in plasma glucocorticoid during acute stress and
this action appears to be mediated by annexin-1 (750). Annexin-1
is expressed in FS cells and glucocorticoids appear to mobilise
annexin-1 to the external cell surface. Addition of annexin-1 to cul-
tured pituitary cells inhibits CRH-stimulated ACTH secretion,
whereas the early inhibitory effects of the steroid on secretagogue-
stimulated ACTH release in vitro and in vivo are prevented by block-
ing synthesis of annexin-1 with antisense oligodeoxynucleotides or
by blocking the activity of annexin-1 with anti-annexin-1 antise-
rum. Interestingly, annexin-1 also appears to inhibit the secretion
of PRL, GH, LH and TSH in vitro (750). It remains to be investigated
whether the scavenging action of FS cells that we have observed
previously in coaggregation experiments with enriched FS cells (see
earlier in this section) also recruites the annexin-1 system in addi-
tion to the NO system. It should be noticed, however, that the
latter studies examined long-term presence of FS cells, whereas
glucocorticoid-induced annexin-1 actions are examined over a short
time interval.
FS cells may have a role in pituitary plasticity
During postnatal development and during adaptive changes in pitu-
itary hormone secretions, such as during the oestrous cycle, preg-
nancy and lactation, the pituitary shows remarkable ﬂuctuations in
the expansion or involution of certain cell types or functional
subtypes. Several growth factors have been identiﬁed in FS cells,
such as FGF-2 (751), LIF (752), VEGF (44) and, as already mentioned,
various cytokines and follistatin. The production of these growth
factors is regulated, as indicated by data describing the effect of
TGF-b1 and TGF-b3 on VEGF (753) and FGF-2 content (372) and of
oestradiol on FGF-2 content (754). Also, PACAP and IL-6 stimulate
VEGF secretion whereas glucocorticoid is inhibitory (755). A func-
tional link between FGF-2 from FS cells and lactotroph cell prolifer-
ation has already been discussed above, as has the paracrine role
of follistatin in relation to the selective regulation of FSH output in
gonadotrophs. LIF appears to play an essential role in corticotroph
development during fetal life (756).
FS cells also appear to be permissive for the mitogenic effect of
oestradiol on lactotrophs and this is far more impressive in rats
showing high sensitivity for oestrogen-induced mitogenesis of lacto-
trophs (Fisher 344 rats) (372, 754). Fisher rats have a higher propor-
tion of FS cells than Sprague-Dawley (SD) rats. Oestradiol itself does
not affect the number of FS cells but, when pituitaries from SD rats
and Fisher rats are cotransplanted under the kidney capsule or when
FS cells derived from Fisher rats are cocultured with either SD or
Fisher 344-derived lactotrophs in vitro, FS cells from F344 rats
increase the mitogenic action of oestradiol, whereas SD-derived FS
cells do not (372, 754). FS cells exert their permissive action on
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the action itself) is enhanced by oestradiol to a higher extent in
Fisher 344-derived FS cells than in SD-derived FS cells (372, 754).
However, the lactotroph’s growth response to FGF-2 was similar in
both strains. Interestingly, in Fisher rats, but not SD rats, pituitary FS
cells show morphological signs of strong hyperactivity when treated
with oestrogen (they frequently contained phagosomes including
parts of secretory cells, mostly somatotrophs and lactotrophs) (757).
After gonadectomy, FS cells become more numerous and extend
cytoplasmic processes to gonadotrophs but, in thyroidectomised
rats, this was not observed for thyrotrophs (758), suggesting a par-
ticular relationship between gonadotrophs and FS cells. That associ-
ation is perhaps related to the production of follistatin by FS cells
that is well known to attenuate the autocrine action of activin on
FSH production. Of note, GH and PRL producing adenomas fre-
quently contain signiﬁcant numbers of FS cells (759). Furthermore,
during lactation FS cells become hypertrophic, displaying an abun-
dant cytoplasm, enlarged Golgi complex, and dilation of the follicles
(760). In mice with a genetically induced copper deﬁciency, the GH
axis is dysfunctional and this appears to be due in part to an
excessive phagocytic activity of FS cells (761).
Taken together, all these data support a trophic action of FS cells
during phases of cell population adaptation to endocrine needs.
FS cells may be important for glutamate and GABA
signalling (Fig. 9)
Rat FS cells have been found to express glutamine synthase, a
key enzyme for glutamate metabolism in the central and periph-
eral nervous system (762). As in other systems, the enzyme is
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Fig. 9. Schematic representation of cholinergic and GABA-ergic paracrine loops thought to act between hormonal cell types and their relationship with
nonhormonal cells and adrenergic signals. ﬁ , Stimulatory effect; ^, inhibitory effect; A, B, C, GABAA, GABAB and GABAC receptor subtypes, respectively; 2,
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Paracrinicity 39
ª 2008 The Author. Journal Compilation ª 2008 Blackwell Publishing Ltd, Journal of Neuroendocrinology, 20, 1–70glucocorticoid-dependent (762). As assessed by immunostaining,
FS cells also contain high levels of glutamine (763). Expression
of glutamine synthase is dramatically age-dependent. Whereas, at
30 days of age, only a small portion of the FS cells is positive
for the enzyme, 25% are positive at 60 days and 74% are
expressing at 2 years. In the brain, the role of glutamine
synthase is to convert glutamate + NH3 into glutamine, and is
thought to be a protective mechanism against excessive excita-
tion by the neurotransmitter glutamate (764). Glutamate appears
to be an intercellular messenger in the pituitary as well. Gluta-
mate or certain aspartate analogues have been found to stimu-
late PRL, GH and LH release and rat anterior pituitary cells
express mRNA of glutamate receptors GluR1, GluR2, GluR3,
GluR4, GluR5, GluR6, GluR7, KA1 and KA2 subunits (765). It is
therefore feasible that FS cells have a role in preserving optimal
levels of glutamate in the microenvironment as is the case for
glial cells in the brain. In brain and liver, glutamine synthase is
also important for detoxiﬁcation of ammonium (766).
Putative control of glutamate availability by FS cells may also have
consequences for the availability of GABA in the pituitary. GABA is
delivered to the pituitary via nerve endings (intermediate lobe) and
portal blood, but GABA is also synthesised in rat and human somato-
trophs by the enzyme glutamate decarboxylase that uses glutamate
as substrate (767, 768). Human, rat and monkey somatotrophs
express the GABA transporter and GABAA, GABAB and GABAC recep-
tors are present in the anterior pituitary (769–771). GABA stimulates
GH production via a GABAB receptor, whereas blocking GABAB recep-
tors with phaclofen decreased GH levels in pituitary cell cultures,
demonstrating endogenous autocrine or paracrine GABA-ergic mod-
ulation of GH production (770). On the other hand, GABA inhibits
PRL secretion via GABAA receptor but stimulates it via a GABAC
receptor (768). Moreover, endogenous GABA exerts both an excitatory
and an inhibitory tone on basal PRL release as shown by the ﬁnding
that the GABAC receptor antagonist, (1,2,5,6-tetrahydropyridin-4-yl)
methylphosphinic acid, and the GABAA receptor antagonist, bicucul-
line, suppressed and enhanced basal PRL secretion, respectively (768).
The GABAB agonist baclofen also inhibited basal and TRH-stimulated
PRL secretion in anterior pituitary cells from pro-oestrous rats.
Baclofen caused inhibition of GnRH-stimulated LH release in anterior
pituitary cell cultures from immature rats (772). GABA also inhibits
TRH-stimulated TSH release, probably via the GABAA receptor (773).
The importance of GABAB receptors in the HPG and PRL axis is clearly
shown in the GABAB receptor-1 knockout mouse (774).
On the basis of all these data, FS cells likely have a local role in
glutamate and GABA homeostasis and the latter transmitters exert
delicate and balanced paracrine⁄autocrine effects on GH, PRL and
LH secretion, possibly related to basal and immune-stress homeo-
static mechanisms.
FS cells may also be linked to cholinergic and adrenergic
signalling in the anterior pituitary
FS cells express muscarinic and b-adrenergic receptors. As already
mentioned, acetylcholine is a paracrine factor stimulating GH and
PRL release but it becomes inhibitory in the presence of glucocor-
ticoids, an effect possibly mediated through a paracrine inhibitory
action of NO released from FS cells by acetylcholine. On the other
hand, we have shown that adrenaline stimulates GH release in
pituitary cell aggregates through b2- and a1-adrenergic receptors
and that this effect is dependent on glucocorticoids (775, 776).
Interestingly, the action of glucocorticoids is not a direct one but is
mediated by small cells of low density, as demonstrated by cocul-
ture experiments of enriched somatotrophs with low density cells
obtained after separation by sedimentation at unit gravity (775).
The latter cells are probably not gonadotrophs, corticotrophs or thy-
rotrophs but may be immature lactotrophs or nonhormonal cells or
even a subpopulation FS cells that expresses b2-adrenergic recep-
tors. It is tempting to consider that FS cells integrate a network
of glutamate, GABA, acetylcholine and adrenergic signals in the
anterior pituitary.
Can FS cells signal through agmatine?
As already discussed, FS cells express nNOS and iNOS, enzymes
converting arginine into NO. In neurones and glia, arginine can also
be converted to the diamine agmatine by mitochondrial arginine
decarboxylase and this substance fulﬁlls most criteria to be a neu-
rotransmitter⁄neuromodulator (777). Agmatine can be released into
the synaptic space, where it can block several ligand-gated ion
channels (including NMDA, nicotinic acetylcholine or 5-HT3 recep-
tors, all expressed in the anterior pituitary), or bind to either I1 imi-
dazoline binding sites or a2-adrenoceptors. Agmatine inhibits all
isoforms of NOS by inhibiting catalytic activity, and reduces expres-
sion of iNOS in astrocytes (777). The agmatine system is widely but
unevenly distributed among tissues and tissue cell types (778).
Agmatine is present at a high level in the hypothalamus (779) and
has recently been detected in the anterior pituitary as well (780).
Since FS cells already have the machinery to use arginine for NO
signalling, it would be worthwhile to investigate whether FS cells
are also the site for agmatine formation in the anterior pituitary
and whether agmatine has effects on hormone secretion or cellular
differentiation, either directly or via its effects on the NO system.
FS cells can generate retinoic acid
Retinoic acid (RA) plays a critical role in stem cell differentiation
and development and is also a regulatory factor in the anterior pitu-
itary. The expression of the RA receptor isoform RXRc is develop-
mentally regulated in the pituitary and RA is known to activate the
GH gene through a RA-responsive element in the GH promoter and
in the Pit-1 promoter (781, 782) but to repress the THSb gene (783).
Moreover, RA converts somatotroph progenitor cells into GH-pro-
ducing cells in vitro (784). RA is synthesised from retinoids through
retinaldehyde dehydrogenases (RALDH). Recently, it was reported
that RALDH2 and RALDH3 are highly expressed in the embryonic rat
anterior pituitary (785). Expression was seen already at E12.5,
showed peak values at E15.5–17.5 and declined steeply thereafter to
disappear after postnatal day 5. The NIL only expresses RALDH3 and
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cells) (785). In the adult gland, RALDH1 is the expressed isoform
(786). By in situ hybridisation, RALDH1 mRNA was localised in a
subpopulation of lactotrophs, in FS cells and in some marginal cells
of the cleft. The cell type localisation in the embryonic pituitary was
not analysed but since expression was already found at E12.5 when
no hormones are expressed yet and in situ hybridisation signals
were punctuate, it has been proposed that RA is generated in
stem⁄progenitor cells. Taken together, RA from FS cells may be
involved in the development of cell lineages in the anterior pituitary.
Are FS cells related to stem cells?
An old proposal that FS cells are stem cells in the anterior pituitary
has still been supported by some investigators on the basis of indi-
rect evidence. Some information discussed in the previous sections,
when taken together, may prompt to reexamine that hypothesis.
First, FS cells have many characteristics in common with marginal
cells facing the pituitary cleft (664, 665). Second, marginal cells are
remnant cells of Rathke’s pouch, in which proliferation of progenitor
cells occurs during embryonic development (787). Third, most
recently, expression of retinoic acid forming enzymes has been iden-
tiﬁed in embryonic rat pituitary progenitor cells and in adult FS cells
but also in some marginal cells (785, 786); retinoic acid is important
in differentiation of GH progenitor cells (784). Fourth, the ﬁrst FS
cells seem to develop in the postero-lateral region near the marginal
layer of the cleft (665). Fifth, cells ultrastructurally identiﬁed as FS
cells in 10-day-old rats are junction-poor columnar cells making
elongated follicles (intragladular extensions of the cleft?) that grad-
ually convert into the normal adult cellular architecture around
40 days of life (665). Sixth, the adult pituitary contains a small and
heterogeneous population of nonhormonal cells (side-population
cells), not expressing S-100 but showing morphological features
(stellate shape, agranular) common to FS cells, which express several
genes typical for stem⁄progenitor cells in other tissues (656, 657);
some of these cells also occur in the marginal zone of the cleft.
As already said above, a scenario uniting all proposed concepts
concerning the nature of ‘stellate’ cells in the pituitary, is that there
is a cell pool in the pituitary that remains primitive and of which
part can develop into hormonal cells during postnatal development
and part into FS cells. The remainder of these cells may play
primarily a trophic paracrine role in basal tissue homeostasis, a role
that could be extended to that of being effective progenitor cells
when the needs for hormonal output rise to a level that cannot be
met by increased cellular activity and cell proliferation alone.
Whether such needs exist under normal physiological conditions or
whether they arise only under pathological pressure, such as after
gonadectomy, adrenalectomy, oestrogen treatment or during
tumour development, remains to be seen.
What do FS cell lines teach us about FS cells?
Because of the extreme heterogeneity of the nonhormonal cell pop-
ulation in the anterior pituitary, signiﬁcant efforts have been
devoted to generate FS cell lines. These are now available, such as
TtT⁄GF (mouse) (660), Tpit⁄F1 (mouse) (661), FS⁄D1 h (rat) (95) and
PDFS (human) (662). Similar to authentic FS cells, the TtT⁄GF cells
contain many lysosomes and intermediate ﬁlaments in the cyto-
plasm, display phagocytic activity, form follicles, and express GFAP
and S-100 (660). The cell line also expresses TGF-b1, TGF-b recep-
tor, IL-6, leptin, leptin receptor, PACAP and PACAP receptors (788).
TtT⁄GF cells express the same regulatory molecules as normal FS
cells, obtained by laser-capture microdissection (788). Like normal
FS cells, Tpit⁄F1 cells express nNOS and FGF-2 and respond to
PACAP (blunting of IL-6 secretion) and glucocorticoids stimulate
glutamine synthase expression (661). Interestingly, ATP stimulates
nNOS expression in the FS cell line via P2Y2-purinoceptors (661).
Since ATP is cosecreted with hormones, this cotransmitter may
provide a paracrine feedback from hormonal cells, activated during
immune stress, on FS cells, that, in turn, will dampen the activity of
hormone-secreting cells via NO (661).
FS cell lines have so far been studied in monolayer cultures and
data obtained in the latter in vitro condition may predict what nor-
mal FS cells do in monolayer culture. It should be reminded, how-
ever, that FS cells in monolayer culture rapidly proliferate (671, 672,
789), while in vivo or in a three-dimensional culture system they
do not. Thus, the monolayer conﬁguration is artefactual for FS cells.
Moreover, it has been observed that, in monolayer cultures, various
biological responses in which FS cells might be involved do not
occur or are opposite of what is found in reaggregate cell cultures.
In the latter, dispersed cells reassociate into a three-dimensional
tissue-like structure with a typical FS cell distribution in a mesh-
work (668). It has been observed that ciliary neurotropic factor and
IL-11 have no effect on PRL and GH secretion in monolayer cell
cultures, but stimulate these secretions in aggregate cell culture
(790). The stimulation of ACTH secretion by LPS is also dependent
on a compact cellular organisation. Although LPS stimulates IL-6
secretion in monolayer as well as in mouse pituitary cell aggre-
gates, LPS can stimulate ACTH secretion only in aggregates (700).
Another example of differential responses in aggregate or whole
pituitary was made in studies on the effect of PACAP on PRL
release. In monolayers or in a reverse haemolytic plaque assay sys-
tem, PACAP inhibits PRL release and has no effect on GH release
but PACAP stimulates both GH and PRL release in pituitary tissue
blocks and in aggregates as well as in vivo in rats with hypotha-
lamic lesions (in which hypothalamic-releasing hormone inﬂuence
is abolished) (207). Since FS cells organise in an extensive network
in vivo and have intimate associations with glandular cells, and
since FS cells have been shown to co-ordinate cellular activities
throughout the pituitary, it is clear that such associations are much
better reformed in vitro when the cells are allowed to associate in
a three-dimensional space. The above experiments therefore clearly
suggest that cytokine actions during immune stress can be strongly
affected by intimate cell–cell contact between FS cells among each
other and with the hormonal cells. Thus, in designing studies on
paracrine and autocrine communication in in vitro models, the
three-dimensional conﬁguration of the tested cells is of utmost
importance.
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cells and pericytes
As is the case for all other tissues, the pituitary contains connective
tissue cells and a vascular system. As in other endocrine organs,
the vascular system is richly developed. Vessels consist of endothe-
lial cells embedded in the basal membrane and associated with
each other by tight junctions. In addition, there are mural cells ana-
tomically and functionally associated with the endothelial cell⁄vas-
cular tube layer, called pericytes. Pericytes display long cytoplasmic
processes embracing the endothelial tube, an ideal position for
paracrine signalling (791). In addition, larger vessels are surrounded
by smooth muscle cells. The pericyte has a phenotype between
vascular smooth muscle cells and ﬁbroblasts with the capacity to
differentiate into a myoﬁbroblast.
Peculiarities of anterior pituitary vessels
The portal vessels of the pituitary lack smooth muscle ﬁbres, but
are associated with many pericytes showing highly ramifying pro-
cesses. Importantly, as in all endocrine organs, the endothelium has
many fenestrations and channels, ensuring high permeability for
molecules traveling from the interstitial ﬂuid to the blood and vice
versa (792). Thus, portal vessels are capillary sinusoids with
pericytes rather than typical portal veins. Another peculiarity of
pituitary vessels is the lack of von Willebrand factor. We detected
cells expressing CD31, a general marker of endothelial cells, in the
anterior pituitary of the adult rat, but we found no cells positive
for von Willebrand factor, consistent with the sinusoidal nature of
the pituitary portal vessels (656). Von Willebrand factor is promi-
nent in veins, but largely absent from sinusoidal endothelial cells
(793).
Plasticity in the anterior pituitary requires tight control of
angiogenesis
Once developed, the vascular system is quiescent but new vessels
can be made from existing ones by sprouting or intussusception,
either during certain physiological conditions where a higher
demand for blood supply is required or in pathological states such
as during tissue repair after injury or inﬂammation and tumouri-
genesis. Angiogenesis starts with basement membrane degradation
by activated endothelial cells, then the latter migrate and prolifer-
ate, which leads to the formation of endothelial cell sprouts. Subse-
quently, vascular loops and capillary tubes are formed with tight
junctions and, ﬁnally, there is new basement membrane deposition
(794).
In the pituitary gland, which is highly protected from injury due
to its location in the skull underneath the brain, neovascularisation
for tissue repair is probably of less importance. However, the pitui-
tary is a plastic tissue capable of remodelling blood supply accord-
ing to needs, such as during pregnancy and lactation when the
gland expands considerably. Thus, tight control of angiogenesis is
essential in the adult pituitary. Moreover, the pituitary is prone to
develop adenomas and, hence, angiogenesis may be most relevant
to their progression.
An important new mechanism recently advanced is that angio-
genesis and tissue growth go hand in hand. It appears that neuro-
nal guidance can be mediated by similar factors as vessel guidance
(795). Thus, growth factors that are involved in angiogenesis in the
pituitary may be relevant to pituitary plasticity as well.
Pro- and anti-angiogenic factors in the anterior pituitary
In general, angiogenesis depends on the balance of pro-angiogenic
and anti-angiogenic growth factors, which are produced by endo-
thelial and tissue cord cells, as well as on remodelling of the extra-
cellular matrix (ECM) to allow endothelial migration. The most
important pro-angiogenic factors are VEGF (and different VEGF-like
molecules), angiopoietins, FGFs, TGF-a, proliferin, platelet-derived
growth factor, IL-8, TGF-b1, and placenta growth factor (796, 797).
Anti-angiogenic factors are thrombospondin-1 (a matrix glycopro-
tein), angiostatin (a cleaved product of plasminogen), endostatin (a
cleaved part of collagen XVIII), cleaved PRL and GH fragments, and
cleaved perlecan (796). Some angiogenesis inhibitors are intrinsic to
endothelial cells such as soluble VEGFR-1, vascular endothelial
growth inhibitor (VEGI) and vasoinhibins (798). In addition, many
other substances have been found to exert angiogenic (erythropoie-
tin, angiotensin II, ETs, adrenomedullin, proadrenomedullin N-termi-
nal 20 peptide, urotensin II, leptin, adiponectin, resistin, NPY, VIP,
PACAP, and Substance P) and anti-angiogenic (somatostatin, natri-
uretic peptides and neurokinin B) activity (799, 800).
Many of the known angiogenic and anti-angiogenic substances
have been localised in the anterior pituitary, but their actual effec-
tiveness on vascularity and permeability in the gland has only been
documented for part of them.
FGF
Historically, FGF-1 and FGF-2 were the ﬁrst characterised angio-
genic factors, but among the more than 20 members of the FGF
family, several other FGFs are angiogenic. FGFs are pleiotrophic:
they stimulate endothelial cell proliferation and migration, the plas-
min–plasminogen activator system, matrix metalloproteinase (MMP)
shedding, integrin and cadherin receptor expression, and intercellu-
lar gap-junction communication (801). MMPs degrade ECM and
release several growth factors sequestered in the ECM. FGFs partici-
pate in vessel assembly, sprouting and vessel branching. The pecu-
liarity of FGFs is that they interact with several binding partners,
either located on the endothelial cell surface, or in the ECM, or in
the extracellular space as freely moving molecules (801). These
molecules strongly affect the angiogenic potential of FGFs. Some of
the strongest partners are heparan sulfate proteoglycans (HSPGs),
without which FGFs are not active (802–804).
The association of FGF-2 with basal membrane in the anterior
pituitary has been clearly demonstrated. In the adult rat pituitary,
FGF-2 has been located mainly in FS cells and in a subpopulation
of marginal cells of the intermediate lobe facing the pituitary cleft
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localised within all cells of the pituitary (805). Interestingly, FGF
from gonadotrophs appears to play a signiﬁcant role. In 15–20-
day-old rat fetuses, dense foci of extracellular FGF were observed
at sites of capillary penetration, in the vicinity of partially disrupted
gonadotrophs (805). Also, in the adult pituitary, disrupted gonado-
trophs containing FGF-2 have been detected, particularly in the
postero-lateral zone, closely located near the meningeal mem-
branes, which could represent a site for invading vessels (see
below).
VEGF
This growth factor was originally identiﬁed in FS cell-conditioned
medium (44). It is a potent endothelial cell mitogen, stimulates
endothelial cell migration and increases fenestration of endothelial
cells and, in this way, capillary permeability. VEGF is also found in
all hormonal cell types of the pituitary, particularly GH and POMC
cells, as well as in various cell lines derived from these cell types
(806). The VEGF isoforms, VEGF164 and VEGF120, are expressed in
the anterior and neural lobes but not in the intermediate lobe
(807). The VEGF receptors ﬂt-1, ﬂk-1 and neuropilin-1 are also
expressed in the pituitary (806). Flt-1 was detected in endocrine
cells, whereas ﬂk-1 and neuropilin-1 were found to be exclusively
expressed in endothelial cells (808).
It is remarkable that VEGF is probably not involved in the initial
development of the portal blood vessels to the pituitary, since the
formation of portal vessels begins at E13.5, which is 2 days earlier
that the ﬁrst appearance of VEGF-A mRNA in the pars tuberalis
and the rostral region of the pars distalis (809). The appearance of
VEFG mRNA coincides with the penetration of portal vessels into
the pars distalis to connect with the secondary capillary plexus
there. In the pars tuberalis, VEGF is located in TSH and FS cells
whereas, in the pars distalis, VEGF is located initially in ACTH cells
and later also in subpopulations of all cell types (809).
Whereas hypoxia is a strong stimulus for VEGF up-regulation in
many tissues, in order to cope with hypoxia and ischemia, it
remains to be seen whether this stimulus is also operative in the
pituitary. The question seems relevant because the tissue is fed by
a portal system that is already less saturated with oxygen.
Oestrogens
Oestrogens strongly up-regulate VEGF expression in the anterior
pituitary (807). VEGF has therefore been studied in relation to neo-
vascularisation in oestrogen-induced pituitary tumourigenesis and
in human pituitary adenomas (807, 810). Oestrogen-induced rat
pituitary tumours and GH3 pituitary tumour cells express VEGF164
and coreceptor, neuropilin-1. VEGF164 and neuropilin-1 mRNA and
protein levels are signiﬁcantly higher in tumours and in GH3
tumour cell line (807). VEGF and its receptor Flk-1 are expressed at
much higher levels than normal in human nonfunctioning pituitary
tumours (808). Also, FGF-2 expression is increased by oestrogen, at
least in rats susceptible to develop prolactinomas (e.g. Fisher 344
rats) (811). In the latter rats, oestrogen treatment rapidly leads to
lactotroph hyperplasia and causes high FGF-2 expression in the
cytosol of gonadotrophs, located in the postero-lateral zone near
the intermediate lobe, close to the meningeal blood vessels. The
postero-lateral zone is known to be home to many gonadotrophs
and lactotrophs and is also the area in which FS cells start to
develop during postnatal development (665). Oestrogen treatment
leads to neovascularisation growing into the anterior pituitary from
these meningeal vessels bordering the postero-lateral zone. ECM-
associated FGF was also revealed in foci at the postero-lateral edge.
These data clearly demonstrate FGF- and VEGF-mediated angiogen-
esis in oestrogen-induced tumourigenesis in rats predisposed to
tumour development.
EG-VEGF
An exciting question is whether the pituitary expresses the endo-
crine gland-derived vascular endothelial growth factors (EG-VEGF or
prokineticin), as has recently been discovered in steroid-producing
endocrine glands, the brain, gastrointestinal system and even
immune cells (812). These peptides have a wide range of functions
but stimulate the endothelial cells in various endocrine glands par-
ticularly well (813). However, no data are as yet available for sub-
stantial pituitary expression. EG-VEGF cooperates with VEGF in the
formation of capillary fenestrations, which, as in other endocrine
tissues, are well developed in the pituitary (814).
Angiopoietins
The anterior pituitary also expresses angiopoietins (Ang) and their
receptor Tie2 (815). These peptides act either as agonist (Ang-1
and Ang-4) or antagonist (Ang-3) in vascular expansion and sur-
vival. Ang-2 can stimulate or inhibit angiogenesis depending on
contexts. Ang-1 promotes endothelial cell survival (protection from
apoptosis) through the Akt pathway and stimulates endothelial
cell migration, sprouting and tube formation. The cells that pro-
duce Ang-1 and Ang-2 in the anterior pituitary are the gonado-
trophs, which is in striking contrast with the neural lobe where
strong expression is seen in endothelial cells (816). It is remark-
able that, in addition to angiopoietins, gonadotrophs produce
FGF-2 and VEGF, which may be relevant to the neovascularisation
from meningeal vessels into the postero-lateral zone of the ante-
rior pituitary, known to be rich in gonadotrophs and lactotrophs
(see earlier in this section).
Pituitary tumour transforming gene (PTTG)
PTTG, an oncogene of which the gene product is a cytoplasmic
and nuclear protein (806). It is expressed in low level in many tis-
sues but is strongly up-regulated in many tumours, including
pituitary adenomas. It displays a powerful angiogenic effect.
Important targets of PTTG are FGF-2 and VEGF, which are both
up-regulated. PTTG itself is up-regulated by FGF-2 and oestrogen
(817).
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TGF-b1 is inhibitory or stimulatory on angiogenesis, depending on
the receptor types expressed on endothelial cells. TGF-b up-regu-
lates VEGF production in the pituitary (753).
Trombospondin-1 (TSP-1)
The anti-angiogenic factor trombospondin-1 (TSP-1) has been
detected in anterior pituitary endothelial cells. Levels go down
after oestrogen treatment in vivo and in puriﬁed pituitary endo-
thelial cells in culture (818). TSP-1 depresses proliferation and
migration of pituitary-derived endothelial cells in primary cultures.
These data suggest that oestrogen-induced tumour growth may
be promoted by down-regulation of locally produced anti-angio-
genic TSP-1.
Cleaved PRL and GH
Endothelial cells have been shown to produce PRL and GH that
exert an autocrine⁄paracrine angiogenic effects, although this
remains to be studied in the pituitary. Most interestingly, PRL and
GH can be cleaved by various proteases to smaller fragments of
14–17 kDa (819). Recently, still another cleaved derivative of PRL
and GH has been discovered that is speciﬁcally processed by the
metalloprotease bone morphogenetic protein-1 (BMP-1). The latter
cleaves PRL between Ala-159 and Asp-160, turning the molecule
from an angiogenic into an anti-angiogenic substance (820). The
latter PRL fragment is distinct from the cleaved PRL that we previ-
ously identiﬁed in the pituitary and is mitogenic for gonadotrophs
and thyrotrophs (see above).
Role of basement membrane and ECM
The basement membrane (BM) is a thin sheet consisting of a mesh-
work of type IV collagen, laminin, nidogen and HSPG, to which epi-
thelial, endothelial cells or stromal cells are attached. BM therefore
provides structural support for cells and makes a barrier between
different tissue compartments. Collagen type IV confers structural
stability, whereas HSPGs cross-link the collagen type IV and lami-
nins. Many isoforms of the different families that compose the BM
exist, so that BM can vary substantially from one tissue to another.
In addition, there are several minor components, such as osteonec-
tin, ﬁbulins, collagen types VIII, XV and XVIII, and thrombospondin-
1 and -2 (821).
In the rat pituitary, laminin, the HSPG perlecan, and type IV col-
lagen. are found inside nonhormonal cells whereas laminin and, to
a lesser extent, type IV collagen are found in hormonal cells, sug-
gesting that hormonal cells participate to the elaboration of BM
(822). Laminin is detected in gonadotrophs, thyrotrophs and corti-
cotrophs, little is found in lactotrophs but it is absent in somato-
trophs, suggesting differential production according to cell type.
Laminin is found in Golgi and secretory vesicles, indicating export
of the protein. The pituitary expresses high levels of perlecan,
particularly in the subendothelial region of sinusoidal vessels (823)
and also shows sequestration of FGF-2 in BM (811, 824).
Increasing evidence suggests that BM has also an important
functional role in cell physiology, differentiation and homeostasis.
BM laminin can signal to cell surface adhesion receptors, such as
integrins, which can also function in concert with growth factors
(821). The highly glycosylated nature of BM and the heparin-bind-
ing feature of HSPGs make BM a high-afﬁnity and high-capacity
binding place of growth factors, like VEGF and FGF-2 (821). Lami-
nins are the functionally active components, with different iso-
forms generating different signals in different tissues (821). In the
pituitary, laminin affects PRL and gonadotrophin secretion and
collagen IV has been reported to affect the release of prolactin
(825).
Assuming that the BM signals to the cord cells, it is clear
that regulatory mechanisms must exist that modulate this signal-
ling, particularly when the tissue has to remodel. MMP isoforms
play an essential role in remodelling BM. This is particularly
prominent in pituitary adenomas in which very high levels of
active MMP-2 and MMP-9 and low levels of tissue inhibitor of
metalloproteinases-1 have been reported (825). It has also been
shown that MMPs can release growth factors sequestered in the
ECM, that, in turn, stimulate pituitary cell proliferation and hor-
mone secretion (825). Another relevant proteases is BMP-1 (820).
It plays an important role in the deposition of ﬁbrous ECM.
Moreover, it processes perlecan to produce a potent anti-angio-
genic factor. BMP-1 activates growth factors such as TGF-b1.
BMP1 mRNA is one of the most highly elevated transcripts in
endothelial cells of tumours.
ECM and MMPs and their inhibitors play also an important role in
angiogenesis (826), which again is prominent in pituitary tumours. In
aggressive prolactinomas, expression of the polysialylated neural cell
adhesion molecule is up-regulated whereas that of the E-cadherin⁄
catenin complex is reduced (826), indicating altered cell adhesion and
cell migration. Chronic oestrogen treatment increases gelatinase
(pro-MMP-9) levels in the pituitary of tumour-susceptible Fischer 344
rats.
Another important protein expressed in the anterior pituitary
with a potential role in modifying paracrinicity by interaction
with the ECM is connective tissue growth factor (CTGF) (827). It
is a secreted protein with a main function of promoting cell
adhesion through an integrin binding domain, the type of inter-
acting integrin being tissue-speciﬁc. Importantly, cell surface
HSPG is a necessary coreceptor, interacting with the carboxyl-
terminal domain. The latter domain also promotes ﬁbroblast
proliferation. A von Willebrand factor domain located more
N-terminally interacts with TGF-b and in this way assists in pre-
senting TGF-b to the TGF-b type II receptor. Thus, CTGF seems
to exert context- and cell-speciﬁc effects. As shown by gene
deletion studies, the molecule is essential in the development of
mesenchymal cell lineages, but it plays also an important role in
the adult, where it is expressed in endothelia and the cerebral
cortex, consistent with a role in promoting angiogenesis and
tissue integrity (828).
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and paracrine systems
Perhaps the most difﬁcult aspects of autocrine and paracrine
systems are the spatial dimension over which autocrine and para-
crine factors work and the dynamics of the receptor–ligand inter-
actions. These aspects are very difﬁcult to study as ligand and
receptor densities cannot directly be altered by the investigator,
since it is the cell itself that determines them. In the case that
the ligand of a receptor is a hormone or a drug, traveling to its
target via the bloodstream, receptor-ligand dynamics follow
Michaelis–Menten kinetics. By contrast, when the ligand is an
autocrine substance that is released by the cell in the vicinity of
the surface receptors, only the molecules present in a ‘thin secre-
tion layer’ surrounding the cell, are relevant for the dynamics of
the receptor interaction, because all other molecules that diffuse
further are indeﬁnitely diluted and lost for receptor interaction
(829). One has to consider competition between the ligand cap-
ture avidity of the receptor and the diffuse rate into the bulk
environment to determine the efﬁcacy of signalling, rather than
the KD of the receptor and ligand concentration. A situation lead-
ing to equilibrium between a receptor and its ligand solubilised in
the bulk environment, as is the case for pharmacological interac-
tions, is not existing in autocrine interactions, and, hence, the
kinetic model used to describe the interaction quantitatively must
be different. For the TGF-a–EGF-R autocrine system it has been
demonstrated by biocomputing modelling that the dynamics of
cellular responses are directly proportional to the ratio of the rate
of ligand production and the rate of receptor production (386).
Surprisingly, with a ratio of <0.2, no ligand was found free in
the medium, but up to 20% of the EGF-Rs were occupied. Thus,
an EGF autocrine system functions by immediately capturing the
released ligand and hence the ligand does not reach neighbouring
cells and is often undetectable in the culture medium. When this
ratio was experimentally increased, the ligand could be found in
the medium. It was found, however, that various EGF autocrine
systems operate at a ratio of ligand : receptor production rates
much smaller than 0.2 (388), indicating that EGF-R autocrine
systems are regulated primarily through ligand availability and
capture and not through regulation of receptor number. The latter
is in clear contrast with what usually happens in classical hor-
monal or pharmacological systems.
Signalling in autocrine systems appears to be strongly inﬂu-
enced by extracellular molecules that bind the released ligand. The
TGF-a–EGF-R loop, for example, was found to only transiently
stimulate the intracellular transduction pathway when TGF-a was
released and allowed to be bound by certain molecules in the
microenvironment, whereas the pathway was activated over a
prolonged period when EGF-R could recapture the released TGF-a
(830). Furthermore, if several ligands compete for binding to the
receptor, the type of ligand will be important for the magnitude
and duration of the response. For example, heparin-binding EGF
(HB-EGF) and TGF-a are both agonists at the EGF-R, but the for-
mer and not the latter binds to HSPG present in the extracellular
microenvironment; consequently, the dynamics of the same cell
through the same EGF-R will be different when stimulated with
TGF-a than with HB-EGF, even when both are shed at the same
rate.
Another important consequence of the peculiar dynamics of
autocrine systems is the fact that neutralisation of the ligand-
receptor signalling by the use of extracellular compounds
requires unexpectedly high doses of blocking agent of up to
eight orders of magnitude greater than the KD for ligand binding
to the receptors) (831) and that the efﬁcacy of signalling disrup-
tion is much higher when compounds are used that bind the
receptor than when substances are used that bind the ligand
(831, 832). Complete annihilation of the autocrine response is
not obtainable until all bulk ligand has been bound by the
administered compound. Moreover, annihilation can only occur
when the association rate constant of the compound for binding
the ligand is much higher than the association rate constant of
the autocrine ligand for its cellular receptor (831). The latter
observations are of paramount importance for setting-up experi-
ments as well as strategies aimed to target autocrine systems in
the treatment of disease.
In a regular experimental set-up, it is very difﬁcult to distin-
guish between a pure autocrine effect of a signal on a receptor
expressed on the same cell and a paracrine effect on similar
receptors on neighbouring cells. Neither is it possible to evaluate
whether both mechanisms are operating and what the conse-
quences are for cell physiology. As an autocrine agent, a signal
has an advantage compared with its action as paracrine signal:
it has a spatial proximity advantage (i.e. when examined in a
temporal sequence, the autocrine effects occur before the para-
crine effects due to a shorter distance between site of release
and site of primary action in case of the autocrine situation). In
addition, there is a concentration gradient from the autocrine
compartment (high concentration) towards the paracrine com-
partment (low concentration), which is important to consider if
exogenous molecules can interfere with this gradient. Recently, a
mathematical model was proposed that allowed to distinctions to
be made between auto- and paracrine actions by registering the
effect of increasing the volume distribution, in which the
secreted signal diffuses, on the auto⁄paracrine action under
study (a macrophage cholesterol efﬂux model in monolayer)
(833). It was found that only the paracrine contribution was
affected by an increase in distribution volume, presumably
because the autocrine action occurs too closely to the cell sur-
face and cannot be affected by increasing the bulk volume sur-
rounding the cells. Thus, the relative importance of autocrine
and paracrine mediation depends on the size of the local distri-
bution volume. These considerations have never been made in
the pituitary ﬁeld and may have great repercussions on inter-
preting data obtained with monolayer cultures versus data
obtained with aggregate cell cultures. The above ﬁndings also
predict that tissue architecture, ECM elements and size of inter-
cellular spaces and lacunas may profoundly affect cell physiology
based on autocrine and paracrine mediators.
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When the ﬁrst hypothalamic-releasing and inhibiting hormones
were discovered and their structure identiﬁed some 30 years ago,
no one realised that the hierarchy of one releasing hormone–one
pituitary hormone–one pituitary cell type was an over-simpliﬁcation
of the hypothalamic hypophysiotrophic hormonal system. Although
the rigid boundaries between endocrine systems and neural systems
were already fading due to the growing impact of neuroendocrinol-
ogy, it was not realised that the correct release of each hormone is
an integrative phenomenon in which a plethora of signals partici-
pates. Many hormones from the hypothalamus, endocrine feedback
glands, fat tissue, the immune system and metabolic tissues have
been discovered to signal to the pituitary. An astonishing discovery
was the masses of regulatory signals that are generated within the
pituitary itself, inﬂuencing pituitary function either in an indepen-
dent fashion or by modulating the action of other intra- and extra-
pituitary signals.
Several autocrine loops have been discovered that operate in a
particular cell type. The best studied autocrine systems are: (i) the
stimulatory VIP and galanin, and the inhibitory ET and PRL loops in
the lactotrophs; (ii) the stimulatory activin and inhibitory inhibin
loops in gonadotrophs; (iii) the inhibitory NMB loop in thyrotrophs;
and (iv) cytokine loops in FS cells. Ghrelin in somatotrophs, and
CRH and urocortin II in corticotrophs may also form stimulatory
autocrine loops. Well explored paracrine systems are: (i) the
gonadotroph–lactotroph axis, of which the mediators remain
incompletely deﬁned but could be in part angiotensin II, PACAP,
N-POMC and calcitonin; (ii) the gonadotroph–somatotroph axis,
which is particularly well developed in ﬁsh; (ii) a cholinergic system
in corticotrophs targeting somatotrophs, lactotrophs and FS cells;
(iii) a GABA-ergic system in somatotrophs; (iv) several inhibitory
systems targeting gonadotrophs (e.g. galanin and PRL from lacto-
trophs and b-endorphin from corticotrophs); and (v) several cyto-
kines, such as IL-6, LIF, MIF, follistatin and NO, produced in FS cells
and targeting several cell types, and annexin-1 from FS cells medi-
ating the rapid negative feedback of glucocorticoid on ACTH secre-
tion. Many other autocrine and paracrine interactions may exist on
the basis of the presence and pharmacology of bioactive substances
in particular cell types, but these still need to be characterised.
It is clear that the response to these different signals is not sim-
ply the sum of them but that there is integration of hypothalamic,
peripheral and local signals that can differ highly according to con-
text. Autocrine and paracrine systems associate in networks that
are recruited to establish functional changes. One of these networks
consists of VIP–galanin–TGF-b1–TGF-b3–bFGF that is activated by
oestrogen to establish its action on PRL release and lactotroph
expansion. Networking ensures the positive feedforwarding neces-
sary to elicit the required functional activity. Another integrative
system is based on EGF-R transactivation by various GPCR-medi-
ated signals. FS cells have their own cytokine network but can also
interact with other networks, such as with the paracrine cholinergic
and GABA-ergic systems and the endocrine adrenergic system. FS
cells also come in interplay with the oestrogen-dependent autocrine
systems in lactotrophs. Many examples demonstrate that autocrine
and paracrine systems enable context-dependent signalling and bio-
computational models have been presented (830). Responses seen
in the presence of adrenal steroids can reverse in the absence of
the latter, such as the GH response to acetylcholine and angioten-
sin II and the PRL response to acetylcholine. Other responses
depend on the presence of thyroid hormone, such as the PRL
response to acetylcholine. Still other responses, such as responses
to galanin, VIP, calcitonin, oxytocin and gastrin-releasing peptide,
require the presence of oestrogens. The direction of a response
(stimulation or inhibition) may depend on the concentration of oes-
trogen such as the response of lactotrophs to ETs. Certain receptor
subtypes mediate an inhibitory response to GABA, whereas others
mediate a stimulatory one.
Integration of signalling in the pituitary is also illustrated by the
fact that almost all autocrine and paracrine activities are up- or
down-regulated during the physiological change that has an impact
on the hormone output during that change, either by changing the
expression level of the ligand or by changing the expression level
of the receptors, or both. Moreover, the same paracrine factor can
be expressed in different cell types, but the change in its expression
occurs only in the cell type that is relevant for supporting the
changing pituitary function. An example is leptin, which is
expressed in all cell types except lactotrophs, but the change in
expression that occurs at pro-oestrous is only seen in somato-
trophs, consistent with the surge in GH release at that time. Also,
gender differences in hormone output are often based on gender
differences in the activity of the underlying paracrine system, such
as is the case of the galanin system in lactotrophs.
The multiplicity of paracrine factors can be viewed as a biological
system aimed at preserving stability in a complex integrating tissue
such as the pituitary. Maintaining a certain level of basal hormone
release, particularly in somatotrophs and lactotrophs, which are
both under substantial hypothalamic inhibitory tone, may also
proﬁt from underlying paracrine mechanisms. However, the pitui-
tary is also a plastic tissue that needs to adapt to many life-essen-
tial changes such as during the reproductive cycle, stress, metabolic
needs, day–night rhythm and changes in energy stores and needs.
Changes in hormone output are imposed by the hypothalamic and
peripheral hormone signals but are executed in the pituitary. A cor-
rect response needs a microenvironment that is well stabilised
under basal conditions but can adapt and ﬁne-tune activity when
necessary. The latter can occur when the system disposes of auto-
crine loops that together create a positive feedforward mechanism
as well as negative feedbacks.
Nevertheless, despite enormous progress, many questions remain
open. For example, although AVP is synthesised in corticotrophs
and the potentiation of the ACTH response to CRH by AVP has
been extensively studied, it is not known whether AVP from the
hypothalamus is the player here or whether it is (also) AVP from
corticotrophs. The pituitary displays the highest expression level of
various putative paracrine⁄autocrine factors such as NMU and CNP,
yet the function of these peptides in the pituitary remains elusive.
Certain peptides, such as the bombesin-like peptide gastrin-releas-
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dicted by their pharmacology (183). There are many pituitary pep-
tides that show various effects when added to test systems but for
which the endogenous action has not been convincingly demon-
strated yet, such as neurotensin, prodynorphin-derived peptides,
enkephalin, adrenomedullin, CGRP, NPY, natriuretic peptides, leptin,
neuropeptide B and W, calcitonin-receptor stimulating peptide,
orexins, and adipokines. Also, the role of local classical releas-
ing⁄inhibiting hormones TRH, GnRH, GHRH and somatostatin made
within the pituitary remains to be speciﬁed. Peptides for which an
autocrine role has been shown may also function as paracrine
factors because receptors for these peptides are not only expressed
by the cell of origin, but also by other cell types, although whether
this also occurs remains unexplored. In gonadotrophs, NPY, CNP,
PACAP and leptin are putative autocrine factors but such a role
remains to be demonstrated by direct experimental evidence.
The ultimate question is whether paracrinicity can lead to
pathology, particularly with respect to pituitary tumourigenesis. To
date, there is no evidence for a primary causal role of disturbed
paracrinicity in the pathogenesis of pituitary adenoma but there is
indirect evidence for a role in the progression of these tumours.
Pituitary adenomas may over-express certain growth factors or
their receptors such as FGF-2, EGF, TGF-a, EGF-R, Notch-3, FGF-R1,
and VEGF (834–838). Other growth factors, known to be antiprolif-
erative, are down-regulated, such as sonic hedgehog (839) and GFG
protein, which is encoded by a bFGF antisense gene (840). The clini-
cal observation of paradoxical hormone secretory responses may
also be explained by abnormal expression levels of certain peptide
receptors in the tumours (834). It therefore appears that pituitary
adenomas may be growing faster by both increased growth factor
stimulation and the decreased availability of endogenous antiprolif-
erative protection mechanisms.
It is hoped that the story of 30 years of cellular pituitary cross-
talk will inspire future approaches for medical treatment by realis-
ing that the basis of disease, and of medically altering its course, is
made by a multiplicity of agents and not by solitary or protagonist
factors alone. Biophilosophically spoken at least, we have learned
that cells determine their fate themselves by recruiting many
resources in the microenvironment rather than by obeying only
gods acting from remote places.
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